U.S. patent application number 16/886276 was filed with the patent office on 2020-11-19 for indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity.
The applicant listed for this patent is Vernalis (R&D) Ltd.. Invention is credited to Simon Bedford, Martin Drysdale, Andrea Fiumana, Nicolas Foloppe, Stephen Stokes, Paul Webb.
Application Number | 20200361905 16/886276 |
Document ID | / |
Family ID | 1000004993378 |
Filed Date | 2020-11-19 |
United States Patent
Application |
20200361905 |
Kind Code |
A1 |
Stokes; Stephen ; et
al. |
November 19, 2020 |
Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory
Activity
Abstract
A method of treating a mammal suffering from a cancer responsive
to inhibition of protein kinase activity, by administering to the
mammal an amount of a compound of formula (I), or a
pharmaceutically acceptable salt thereof, effective to inhibit
protein kinase activity, wherein the compound of formula (I) is:
##STR00001##
Inventors: |
Stokes; Stephen; (Great
Abington, GB) ; Foloppe; Nicolas; (Great Abington,
GB) ; Fiumana; Andrea; (Great Abington, GB) ;
Drysdale; Martin; (Great Abington, GB) ; Bedford;
Simon; (Great Abington, GB) ; Webb; Paul;
(Great Abington, GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Vernalis (R&D) Ltd. |
Great Abington |
|
GB |
|
|
Family ID: |
1000004993378 |
Appl. No.: |
16/886276 |
Filed: |
May 28, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15962306 |
Apr 25, 2018 |
10696652 |
|
|
16886276 |
|
|
|
|
15427457 |
Feb 8, 2017 |
|
|
|
15962306 |
|
|
|
|
14536764 |
Nov 10, 2014 |
9604975 |
|
|
15427457 |
|
|
|
|
12812791 |
Sep 23, 2010 |
8916591 |
|
|
PCT/GB2009/000149 |
Jan 20, 2009 |
|
|
|
14536764 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 401/14 20130101;
A61K 31/4439 20130101; A61K 31/496 20130101; A61K 31/5377 20130101;
A61K 31/4545 20130101; C07D 413/14 20130101 |
International
Class: |
C07D 401/14 20060101
C07D401/14; C07D 413/14 20060101 C07D413/14; A61K 31/4439 20060101
A61K031/4439; A61K 31/4545 20060101 A61K031/4545; A61K 31/496
20060101 A61K031/496; A61K 31/5377 20060101 A61K031/5377 |
Foreign Application Data
Date |
Code |
Application Number |
Jan 22, 2008 |
GB |
0801090.2 |
Oct 11, 2008 |
GB |
0818695.9 |
Claims
1. (canceled)
2. A process for preparation of a compound of formula (I) or a
pharmaceutically acceptable salt thereof ##STR00215## comprising
removing the Boc group and SEM group from the compound of formula
(II) to form a compound of formula (I) ##STR00216## wherein
R.sub.1, R.sub.2, R.sub.5 and R.sub.6 are each independently
selected from hydrogen, hydroxy, methyl, trifluoromethyl,
hydroxymethyl, methoxy, trifluoromethoxy, methylamino, and
dimethylamino; R.sub.3, and R.sub.4 are independently selected from
hydrogen, hydroxy, C.sub.1-C.sub.3 alkyl,
fluoro-(C.sub.1-C.sub.3)-alkyl, hydroxy-(C.sub.1-C.sub.3)-alkyl,
C.sub.1-C.sub.3 alkoxy, fluoro-(C.sub.1-C.sub.3)-alkoxy,
hydroxy-(C.sub.1-C.sub.3)-alkoxy, --N(R.sub.11)--R.sub.12,
-Alk-N(R.sub.11)--R.sub.12, --O-Alk-N(R.sub.11)--R.sub.12,
--C(.dbd.O)OH, carboxy-(C.sub.1-C.sub.3)-alkyl, or
--C(.dbd.O)--NH--R.sub.13; Alk is a straight or branched chain
divalent C.sub.1-C.sub.6 alkylene radical; R.sub.7 and R.sub.8 are
independently selected from hydrogen, hydroxy, or C.sub.1-C.sub.3
alkoxy; X is a straight chain divalent C.sub.1-C.sub.3 alkylene
radical, optionally substituted on one or more carbons by R.sub.9
and/or R.sub.10; R.sub.9 and R.sub.10 are independently selected
from methyl, hydroxy, or fluoro; R.sub.11 is hydrogen,
C.sub.1-C.sub.3 alkyl, or fluoro-(C.sub.1-C.sub.3)-alkyl, and
R.sub.12 is C.sub.1-C.sub.3 alkyl or
hydroxy-(C.sub.1-C.sub.6)-alkyl, either of which may be optionally
substituted on the alkyl portion by phenyl, C.sub.1-C.sub.3
alkoxy-(C.sub.1-C.sub.3)-alkyl-, halo-(C.sub.1-C.sub.4)-alkyl,
C.sub.3-C.sub.6 cycloalkyl, methylsulfonyl-(C.sub.1-C.sub.3)-alkyl,
or --N(R.sub.18)--R.sub.19; R.sub.13 is hydrogen, C.sub.1-C.sub.3
alkyl, fluoro-(C.sub.1-C.sub.3)-alkyl, or a radical of formula
-Alk-N(R.sub.14)--R.sub.15; R.sub.14 and R.sub.15 are independently
selected from hydrogen, C.sub.1-C.sub.3 alkyl, or
fluoro-(C.sub.1-C.sub.3)-alkyl; or R.sub.11 and R.sub.12, or
R.sub.14 and R.sub.15, together with the nitrogen atom to which
they are respectively attached, form an optionally substituted, 4-
to 6-membered, monocyclic heterocyclic ring having no more than
three additional heteroatoms independently selected from oxygen,
sulphur and nitrogen; W is selected from
--C(.dbd.O)--N(--R.sub.16)-- or --N(--R.sub.17)--C(.dbd.O)--;
R.sub.16 or R.sub.17 is selected from hydrogen, C.sub.1-C.sub.3
alkyl, or fluoro-(C.sub.1-C.sub.3)-alkyl; R.sub.18 and R.sub.19 are
selected from hydrogen, C.sub.1-C.sub.3 alkyl, or
fluoro-(C.sub.1-C.sub.3)-alkyl or R.sub.18 and R.sub.19 together
with the nitrogen atom to which they are respectively attached,
form an optionally substituted, 4- to 6-membered, monocyclic
heterocyclic ring having no more than three additional heteroatoms
independently selected from oxygen, sulphur, and nitrogen; Y is
hydrogen, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy, or halo;
and Q is selected from optionally substituted phenyl, optionally
substituted cyclohexyl, or an optionally substituted 6-membered
monocyclic heteroaryl ring.
3. The process as claimed in claim 2, wherein the compound of
formula (II) is a compound of formula (II'), ##STR00217## and
wherein the compound of formula (II') is formed by reacting a
compound of formula (III) with a compound of formula (IV)
##STR00218## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5,
R.sub.6, R.sub.7, R.sub.8, Q, Y, and X are as defined in claim
1.
4. The process as claimed in claim 3, wherein the preparation of
the compound of formula (II') is carried out in
dichloromethane.
5. The process as claimed in claim 3, wherein the preparation of
the compound of formula (II') is carried out in the presence of
trimethylamine.
6. The process as claimed in claim 2, wherein the compound of
formula (II) is a compound of formula (II''), ##STR00219## and
wherein the compound of formula (II'') is formed by reacting a
compound of formula (V) with a compound of formula (VI)
##STR00220## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5,
R.sub.6, R.sub.7, R.sub.8, Q, Y, and X are as defined in claim
1.
7. The process as claimed in claim 6, wherein the preparation of
the compound of formula (II'') is carried out in
dichloromethane.
8. The process as claimed in claim 6, wherein the preparation of
the compound of formula (II'') is carried out in the presence of
trimethylamine.
9. The process as claimed in claim 3, wherein the compound of
formula (III) is formed by reacting a compound of formula (VII)
with a compound of formula (VIII) under Suzuki coupling conditions
to form the compound of formula (IX) ##STR00221## and then the
nitro group of the compound of formula (IX) is reduced to
--NH.sub.2 to form the compound of formula (III); wherein R.sub.1,
R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, Q,
Y, and X are as defined in claim 1; and A is independently selected
from hydrogen or C.sub.1-3 alkyl, or both A groups may be taken
together with the oxygen atom to which they are joined and the
associated boron atom, to form a C.sub.2 to C.sub.6 cyclic boronic
ester.
10. A process as claimed in claim 9, wherein the compound of
formula (VII) is formed by reacting the compound of formula (XIII)
with a strong base and then boronic acid ##STR00222## wherein
R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 are as defined in claim
1.
11. The process as claimed in claim 6, wherein the compound of
formula (V) is formed by reacting a compound of formula (VII) with
a compound of formula (X) under Suzuki coupling conditions to form
the compound of formula (XII) ##STR00223## and then the ester of
the compound of formula (XII) is hydrolysed to form the compound of
formula (V); wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5,
R.sub.6, R.sub.7, R.sub.8, Q, Y, and X are as defined in claim 1; V
is ethyl or methyl; and A is independently selected from hydrogen
or a C.sub.1-3 alkyl, or both A groups may be taken together with
the oxygen atom to which they are joined and the associated boron
atom, to form a C.sub.2 to C.sub.6 cyclic boronic ester.
12. A process as claimed in claim 11, wherein the compound of
formula (VII) is formed by reacting the compound of formula (XIII)
with a strong base and then boronic acid ##STR00224## wherein
R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 are as defined in claim
1.
13. The process as claimed in claim 2, wherein R.sub.3 or R.sub.4
is selected from --N(R.sub.11)--R.sub.12,
-Alk-N(R.sub.11)--R.sub.12, or --O-Alk-N(R.sub.11)--R.sub.12,
wherein R.sub.11 and R.sub.12 together with the nitrogen atom to
which they are attached form an optionally substituted, 5- to
6-membered, monocyclic heterocyclic ring having no more than three
additional heteroatoms independently selected from oxygen, sulphur
and nitrogen.
14. The process as claimed in claim 2, wherein R.sub.11 and
R.sub.12 together with the nitrogen atom to which they are attached
form a piperidine, morpholine, or piperazine ring, optionally
substituted by C.sub.1-C.sub.3 alkyl, hydroxy-(C.sub.1-C.sub.3
alkyl)- or fluoro.
15. The process as claimed in claim 2, wherein R.sub.11 and
R.sub.12 together with the nitrogen atom to which they are attached
form piperidin-1-yl, morpholin-4-yl, piperazin-1-yl,
1-methyl-piperidin-4-yl, 1-methyl-piperazin-4-yl, or
1-fluoro-piperidin-4-yl.
16. The process as claimed in claim 2, wherein R.sub.3 or R.sub.4
is selected from --N(R.sub.11)--R.sub.12,
-Alk-N(R.sub.11)--R.sub.12, or --O-Alk-N(R.sub.11)--R.sub.12,
wherein R.sub.11 and R.sub.12 are independently selected from
methyl and ethyl, or R.sub.11 is methyl or ethyl and R.sub.12 is
--N(R.sub.18)--R.sub.19 wherein R.sub.18 and R.sub.19 are
independently selected from methyl and ethyl.
17. The process as claimed in claim 2, wherein Alk is --CH.sub.2--,
--CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2--
--CH.sub.2C(CH.sub.3).sub.2CH.sub.2-- or is a divalent radical of
formula (II): ##STR00225##
18. The process as claimed in claim 2, wherein R.sub.1, R.sub.2,
R.sub.5 and R.sub.6 are each hydrogen.
19. The process as claimed in claim 2, wherein R.sub.1, R.sub.2,
R.sub.4, R.sub.5 and R.sub.6 are each hydrogen.
20. The process as claimed in claim 2, wherein Y is hydrogen or
methyl.
21. The process as claimed in claim 2, wherein W is
--NH--C(.dbd.O)-- wherein the carbonyl group is linked to the
pyrazole ring.
22. The process as claimed in claim 2, wherein R.sub.7 and R.sub.8
are both hydrogen.
23. The process as claimed in claim 2, wherein X is --CH.sub.2--,
--CH(CH.sub.3)-- or --C(CH.sub.3).sub.2--.
24. The process as claimed in claim 2, wherein Q is optionally
substituted phenyl.
25. The process as claimed in claim 2, wherein the substituent or
substituents on the phenyl ring is/are selected from methyl,
trifluoromethyl, methoxy, fluoro, chloro, or cyano.
26. The process as claimed in claim 2, wherein Q is
2-methyl-phenyl, 3-methyl-phenyl, 4-methyl-phenyl,
3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl,
4-methoxy-phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl,
4-fluoro-phenyl, 3-chloro-phenyl, 4-chloro-phenyl, 3-cyano-phenyl,
4-cyano-phenyl, 3,4-difluoro-phenyl, 3,5-difluoro-phenyl, or
3-fluoro-4-methyl-phenyl.
27. The process as claimed in claim 2, wherein Q is cyclohexyl or
pyrid-3-yl.
28. The process as claimed in claim 2, wherein: R.sub.1, R.sub.2,
R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are each hydrogen; Y
is hydrogen or methyl; W is --NH--C(.dbd.O)-- wherein the carbonyl
group is linked to the pyrazole ring; R.sub.3 is
--N(R.sub.11)--R.sub.12, -Alk-N(R.sub.11)--R.sub.12, or
--O-Alk-N(R.sub.11)--R.sub.12; R.sub.11 and R.sub.12 together with
the nitrogen atom to which they are attached form an optionally
substituted, 5- to 6-membered, monocyclic heterocyclic ring having
no more than three additional heteroatoms independently selected
from oxygen, sulphur and nitrogen; or R.sub.11 and R.sub.12 are
independently selected from methyl and ethyl; or R.sub.1 is methyl
or ethyl and R.sub.12 is --N(R.sub.18)--R.sub.19 wherein R.sub.18
and R.sub.19 are independently selected from methyl and ethyl; Alk
is --CH.sub.2--, --CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2--, --CH.sub.2C(CH.sub.3).sub.2CH.sub.2--
or is a divalent radical of formula (II): ##STR00226## X is
--CH.sub.2--, --CH(CH.sub.3)-- or --C(CH.sub.3).sub.2--; and Q is
phenyl, optionally substituted by one or two substituents selected
from C.sub.1-C.sub.3 alkyl, fluoro-(C.sub.1-C.sub.3)alkyl,
C.sub.1-C.sub.3 alkoxy, fluoro-(C.sub.1-C.sub.3) alkoxy, halo, and
cyano.
29. The process as claimed in claim 2, wherein R.sub.1 and R.sub.12
together with the nitrogen atom to which they are attached form a
piperidine, morpholine, or piperazine ring, optionally substituted
by C.sub.1-C.sub.3 alkyl or fluoro.
30. The process as claimed in claim 2, wherein the compound of
formula (I) is selected from the group consisting of:
1-Benzyl-1H-pyrazole-4-carboxylic acid
[5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide,
1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic acid
[6-oxo-5-(5-piperidin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridin-3-yl]-
-amide, 1-Benzyl-1H-pyrazole-4-carboxylic acid
{5-[5-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide, 1-Benzyl-1H-pyrazole-4-carboxylic acid
[6-oxo-5-(5-piperidin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridin-3-yl]-
-amide, 1-Benzyl-1H-pyrazole-4-carboxylic acid
{5-[5-(cis-2,6-dimethyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-di-
hydro-pyridin-3-yl}-amide, 1-Benzyl-1H-pyrazole-4-carboxylic acid
{5-[5-(4-methyl-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide, 1-(1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic acid
{5-[5-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide, 1-Benzyl-1H-pyrazole-4-carboxylic acid
{5-[5-(3-dimethylamino-2,2-dimethyl-propoxy)-1H-indol-2-yl]-6-oxo-1,6-dih-
ydro-pyridin-3-yl}-amide,
1-((R)-1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic acid
{5-[5-(cis-2,6-dimethyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-6-oxo-1-
,6-dihydro-pyridin-3-yl}-amide, 1-Benzyl-1H-pyrazole-4-carboxylic
acid
{5-[5-((S)-2-methyl-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydr-
o-pyridin-3-yl}-amide, 1-Benzyl-1H-pyrazole-4-carboxylic acid
{5-[5-((R)-2-methyl-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydr-
o-pyridin-3-yl}-amide, 1-Benzyl-1H-pyrazole-4-carboxylic acid
[5-(5-{[(3-dimethylamino-2,2-dimethyl-propyl)-ethyl-amino]-methyl}-1H-ind-
ol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide,
1-Benzyl-1H-pyrazole-4-carboxylic acid
{5-[5-(cis-2,6-dimethyl-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-di-
hydro-pyridin-3-yl}-amide, 1-Benzyl-1H-pyrazole-4-carboxylic acid
{5-[5-(3-diethylamino-2,2-dimethyl-propoxy)-1H-indol-2-yl]-6-oxo-1,6-dihy-
dro-pyridin-3-yl}-amide, 1-Benzyl-1H-pyrazole-4-carboxylic acid
{5-[5-(2-dimethylamino-1,1-dimethyl-ethoxy)-1H-indol-2-yl]-6-oxo-1,6-dihy-
dro-pyridin-3-yl}-amide, 1-Benzyl-1H-pyrazole-4-carboxylic acid
{5-[5-(2,2-dimethyl-3-pyrrolidin-1-yl-propoxy)-1H-indol-2-yl]-6-oxo-1,6-d-
ihydro-pyridin-3-yl}-amide, 1-Benzyl-1H-pyrazole-4-carboxylic acid
{5-[5-(2,2-dimethyl-3-piperidin-1-yl-propoxy)-1H-indol-2-yl]-6-oxo-1,6-di-
hydro-pyridin-3-yl}-amide, 1-Benzyl-1H-pyrazole-4-carboxylic acid
{5-[5-(1-diethylaminomethyl-cyclopropylmethoxy)-1H-indol-2-yl]-6-oxo-1,6--
dihydro-pyridin-3-yl}-amide, and pharmaceutically acceptable salts
thereof.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation application of U.S.
application Ser. No. 15/962,306, filed Apr. 25, 2018, which is a
divisional application of U.S. application Ser. No. 15/427,457
filed Feb. 8, 2017, which is a continuation application of U.S.
application Ser. No. 14/536,764 filed Nov. 10, 2014, now U.S. Pat.
No. 9,604,975, which is a divisional application of U.S.
application Ser. No. 12/812,791 filed Sep. 23, 2010, now U.S. Pat.
No. 8,916,591, which is a National Stage application of PCT
application PCT/GB2009/000149 filed Jan. 20, 2009, which claims the
benefit of Great Britain application number 0801090.2 filed Jan.
22, 2008 and Great Britain application number 0818695.9 filed Oct.
11, 2008. These applications are incorporated herein by reference
in their entireties.
FIELD OF THE INVENTION
[0002] This invention relates to indolyl-pyridone derivatives
having checkpoint kinase 1 (CHK1) inhibitory activity, to the use
of such compounds in medicine, particularly in relation to the
treatment of cancer, via the inhibition of aberrant cell
proliferation, and to pharmaceutical compositions containing such
compounds.
BACKGROUND OF THE INVENTION
[0003] Many standard cancer chemotherapeutic agents act primarily
through their ability to induce DNA damage causing tumor growth
inhibition. However, these agents cause cell cycle arrest by
induction of checkpoints at either S-phase or G2-M boundary. The G2
arrest allows the cell time to repair the damaged DNA before
entering mitosis. CHK1 and an unrelated serine/threonine kinase,
CHK2, play a central role in arresting the cell cycle at the G2-M
boundary (O'Connell et al EMBO J (1997) vol 16 p 545-554). CHK1/2
induce this checkpoint by phosphorylating serine 216 of the CDC25
phosphatase, inhibiting the removal of two inactivating phosphates
on cyclin dependent kinases (CDKs) (Zheng et al Nature (1998) vol
395 p 507-510). Another overlapping pathway mediated by p53 also
elicits cycle arrest in response to DNA-damage. However, p53 is
mutationally inactivated in many cancers, resulting in a partial
deficiency in their ability to initiate a DNA-repair response. If
CHK1 activity is also inhibited in p53-negative cancers, all
ability to arrest and repair DNA in response to DNA-damage is
removed resulting in mitotic catastrophe and enhancing the effect
of the DNA damaging agents (Konarias et al Oncogene (2001) vol 20 p
7453-7463, Bunch and Eastman Clin. Can. Res. (1996) vol 2 p
791-797, Tenzer and Pruschy Curr. Med Chem (2003) vol 3 p 35-46).
In contrast, normal cells would be relatively unaffected due to
retention of a competent p53-mediated cell-cycle arrest pathway.
The inhibition of DNA damage checkpoints is therefore expected to
sensitise aberrantly proliferating cells to DNA damaging agents.
Such sensitization is in turn expected to increase the therapeutic
index of such chemotherapeutic agents or ionizing radiation.
(Clary, D. O. Inhibition of Chk kinases in a leukemia model
abrogates DNA damage checkpoints and promotes mitotic catastrophe.
Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 5385) Therefore it
is expected that efficacious inhibitors of CHK1 will lead to a
corresponding Improvement in the efficacy of current DNA-damage
inducing chemotherapeutic regimens (Sausville et al, J. Clinical
Oncology (2001) vol 19 p 2319-2333). A number of putative CHK1
inhibitors are currently in phase I clinical trials including
XL-844 (a dual CHK1/CHK2 inhibitor for the treatment of lymphoma
and solid tumours), PF 00477736 (Phase I Study of PF-00477736 with
gemcitabine in patients with advanced solid malignancies) &
AZD7762 (Phase I open label multi center dose escalation study to
assess safety tolerability and pharmacokinetics of AZD7762
administered as a single intravenous agent and in combo with weekly
standard dose gemcitabine in patients with advanced solid
malignancies). Thus, there remains an unmet medical need for low
molecular weight CHK1 inhibitors with pharmacokinetic and
pharmacodynamic properties making them suitable for use as
pharmaceutical agents. The object of the present invention is to
provide such pharmaceutical agents and treatments.
[0004] It has now been found that certain indolyl-pyridone
derivatives show efficacy as CHK1 inhibitors.
BRIEF DESCRIPTION OF THE INVENTION
[0005] The present invention relates to a class of substituted
indolyl-pyridone compounds useful as CHK1 inhibitors, for example,
for the treatment of cancer. A core indolyl-pyridone template, with
substitution on the pyridone portion by a substituted-pyrazolyl
amido-linked group are principle characterising features of the
compounds with which the invention is concerned.
BRIEF DESCRIPTION OF THE DRAWING
[0006] FIG. 1 shows the In vivo potentiation results of the
compound of Example 20 in combination with gemcitabine.
DETAILED DESCRIPTION OF THE INVENTION
[0007] According to the present invention, there is provided a
compound of formula (I) or a pharmaceutically acceptable salt
thereof:
##STR00002##
[0008] wherein
[0009] R.sub.1, R.sub.2, R.sub.5 and R.sub.6 are independently
selected from hydrogen, hydroxy, methyl, trifluoromethyl,
hydroxymethyl, methoxy, trifluoromethoxy, methylamino and
dimethylamino;
[0010] R.sub.3 and R.sub.4, are independently selected from
hydrogen, hydroxy, C.sub.1-C.sub.3 alkyl,
fluoro-(C.sub.1-C.sub.3)-alkyl, hydroxy-(C.sub.1-C.sub.3)-alkyl,
C.sub.1-C.sub.3 alkoxy, fluoro-(C.sub.1-C.sub.3)-alkoxy,
hydroxy-(C.sub.1-C.sub.3)-alkoxy, --N(R.sub.11)--R.sub.12,
-Alk-N(R.sub.11)--R.sub.12, --O-Alk-N(R.sub.11)--R.sub.12,
--C(.dbd.O)OH, carboxy-(C.sub.1-C.sub.3)-alkyl, or
--C(.dbd.O)--NH--R.sub.13;
[0011] Alk is a straight or branched chain divalent C.sub.1-C.sub.6
alkylene radical;
[0012] R.sub.7 and R.sub.8 are independently selected from
hydrogen, hydroxy, or C.sub.1-C.sub.3 alkoxy;
[0013] X is a straight chain divalent C.sub.1-C.sub.3 alkylene
radical, optionally substituted on one or more carbons by R.sub.9
and/or R.sub.10;
[0014] R.sub.9 and R.sub.10 are independently selected from methyl,
hydroxy, or fluoro;
[0015] R is hydrogen, C.sub.1-C.sub.3 alkyl, or
fluoro-(C.sub.1-C.sub.3)-alkyl, and
[0016] R.sub.12 is C.sub.1-C.sub.3 alkyl or
hydroxy-(C.sub.1-C.sub.6)-alkyl, either of which may be optionally
substituted on the alkyl portion by phenyl, C.sub.1-C.sub.3
alkoxy-(C.sub.1-C.sub.3)-alkyl, halo-(C.sub.1-C.sub.4)-alkyl,
C.sub.3-C.sub.6 cycloalkyl, methylsulfonyl-(C.sub.1-C.sub.3)-alkyl
or --N(R.sub.18)--R.sub.19;
[0017] R.sub.13 is hydrogen, C.sub.1-C.sub.3 alkyl,
fluoro-(C.sub.1-C.sub.3)-alkyl, or a radical of formula
-Alk-N(R.sub.14)--R.sub.15;
[0018] R.sub.14 and R.sub.15 are independently selected from
hydrogen, C.sub.1-C.sub.3 alkyl, or
fluoro-(C.sub.1-C.sub.3)-alkyl;
[0019] or R and R.sub.12, or R.sub.14 and R.sub.15, together with
the nitrogen atom to which they are respectively attached, form an
optionally substituted, 4- to 6-membered, monocyclic heterocyclic
ring having no more than three additional heteroatoms independently
selected from oxygen, sulphur and nitrogen;
[0020] W is selected from --C(.dbd.O)--N(--R.sub.16)-- or
--N(--R.sub.17)--C(.dbd.O)--;
[0021] R.sub.16 or R.sub.17 is selected from hydrogen,
C.sub.1-C.sub.3 alkyl, or fluoro-(C.sub.1-C.sub.3)-alkyl;
[0022] R.sub.18 and R.sub.19 are selected from hydrogen,
C.sub.1-C.sub.3 alkyl, or fluoro-(C.sub.1-C.sub.3)-alkyl, or
R.sub.18 and R.sub.19 together with the nitrogen atom to which they
are respectively attached, form an optionally substituted, 4- to
6-membered, monocyclic heterocyclic ring having no more than three
additional heteroatoms independently selected from oxygen, sulphur
and nitrogen;
[0023] Y is hydrogen, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3
alkoxy, or halo; and
[0024] Q is selected from optionally substituted phenyl, optionally
substituted cyclohexyl, or an optionally substituted 6-membered
monocyclic heteroaryl ring.
[0025] The active compounds of formula (I) are inhibitors of CHK1,
and are useful for the treatment, prevention and suppression of a
proliferative disease such as cancer in combination with
radiotherapy or chemotherapy.
[0026] According to a further embodiment of the present invention
there is provided the use of a compound of formula (I), or a
pharmaceutically acceptable salt thereof, in the manufacture of a
medicament for enhancing a therapeutic effect of radiation or
chemotherapy in the treatment of cancer.
[0027] According to a further embodiment of the present invention
there is provided a method of treatment of cancer comprising
administration to a subject in need of such treatment an effective
dose of the compound of formula (I), or a pharmaceutically
acceptable salt thereof. According to a further embodiment of the
present invention there is provided a pharmaceutical composition
comprising a compound of formula (I), or a pharmaceutically
acceptable salt thereof, and a pharmaceutically acceptable
carrier.
Terminology
[0028] As used herein, the term "(C.sub.a-C.sub.b)alkyl" wherein a
and b are integers refers to a straight or branched chain alkyl
radical having from a to b carbon atoms. Thus when a is 1 and b is
6, for example, the term includes methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and
n-hexyl.
[0029] As used herein the term "divalent (C.sub.a-C.sub.b)alkylene
radical" wherein a and b are integers refers to a saturated
hydrocarbon chain having from a to b carbon atoms and two
unsatisfied valences, such as --CH.sub.2--, --CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2--, --CH.sub.2CH(CH.sub.3)CH.sub.2-- and
--CH.sub.2C(CH.sub.3).sub.2CH.sub.2--. For the avoidance of doubt,
it is to be understood that a divalent branched chain
(C.sub.a-C.sub.b)alkylene radical includes those wherein one of the
carbons of the hydrocarbon chain is a ring carbon of a cycloalkyl
ring (ie is a spiro centre), such as those of formulae (II):
##STR00003##
[0030] As used herein, the term "fluoro-(C.sub.a-C.sub.b)-alkyl"
wherein a and b are integers refers to a straight or branched chain
alkyl radical having from a to b carbon atoms substituted by one or
more fluoro atoms. The term includes, for example, fluoromethyl,
difluoromethyl and trifluoromethyl.
[0031] As used herein the term "cycloalkyl" refers to a saturated
carbocyclic radical having from 3-8 carbon atoms and includes, for
example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl and cyclooctyl.
[0032] As used herein the term "carbocyclic" refers to a mono- or
bi-cyclic radical whose ring atoms are all carbon, and includes
monocyclic aryl, cycloalkyl, and cycloalkenyl radicals, provided
that no single ring present has more than 8 ring members. A
"carbocyclic" group includes a mono-bridged or multiply-bridged
cyclic alkyl group.
[0033] As used herein the term "aryl" refers to a mono-, bi- or
tri-cyclic carbocyclic aromatic radical. Illustrative of such
radicals are phenyl, biphenyl and napthyl.
[0034] As used herein the term "heteroaryl" refers to a mono-, bi-
or tri-cyclic aromatic radical containing one or more heteroatoms
selected from S, N and O. Illustrative of such radicals are
thienyl, benzthienyl, furyl, benzfuryl, pyrrolyl, imidazolyl,
benzimidazolyl, thiazolyl, benzthiazolyl, isothiazolyl,
benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl,
benzisoxazolyl, isothiazolyl, triazolyl, benztriazolyl,
thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl,
pyrazinyl, triazinyl, indolyl and indazolyl.
[0035] As used herein the unqualified term "heterocyclyl" or
"heterocyclic" includes "heteroaryl" as defined above, and in
particular refers to a mono-, bi- or tri-cyclic non-aromatic
radical containing one or more heteroatoms selected from S, N and
O, to groups consisting of a monocyclic non-aromatic radical
containing one or more such heteroatoms which is covalently linked
to another such radical or to a monocyclic carbocyclic radical, and
to a mono-, bi- or tri-cyclic non-aromatic radical containing one
or more heteroatoms selected from S, N and O which is mono-bridged
or multiply-bridged. Illustrative of such radicals are pyrrolyl,
furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl,
thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl,
pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl,
benzfuranyl, pyranyl, isoxazolyl, benzimidazolyl,
methylenedioxyphenyl, ethylenedioxyphenyl, maleimido and
succinimido groups.
[0036] Unless otherwise specified in the context in which it
occurs, the term "substituted" as applied to any moiety herein
means substituted with at least one substituent, for example
selected from (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy,
hydroxy, hydroxy(C.sub.1-C.sub.6)alkyl, mercapto,
mercapto(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkylthio, halo
(including fluoro and chloro), trifluoromethyl, trifluoromethoxy,
nitro, nitrile (--CN), oxo, phenyl, --COOH, --COOR.sup.A,
--COR.sup.A, SO.sub.2R.sup.A, --CONH.sub.2, --SO.sub.2NH.sub.2,
--CONHR.sup.A, SO.sub.2NHR.sup.A, CONR.sup.AR.sup.B,
SO.sub.2NR.sup.AR.sup.B, --NH.sub.2, --NHR.sup.A,
--NR.sup.AR.sup.B, --OCONH.sub.2, --OCONHR.sup.A,
--OCONR.sup.AR.sup.B, --NHCOR.sup.A, --NHCOOR.sup.A,
--NR.sup.BCOOR.sup.A, --NHSO.sub.2OR.sup.A,
--NR.sup.BSO.sub.2OR.sup.A, --NHCONH.sub.2, --NR.sup.ACONH.sub.2,
--NHCONHR.sup.B, --NR.sup.ACONHR.sup.B, --NHCONR.sup.AR.sup.B, or
--NR.sup.ACONR.sup.AR.sup.B wherein R.sup.A and R.sup.B are
independently a (C.sub.1-C.sub.6)alkyl group, or R.sup.A and
R.sup.B when attached to the same nitrogen may form acyclic amino
ring such as a morpholinyl, piperidinyl or piperazinyl ring. An
"optional substituent" or "substituent" may be one of the foregoing
substituent groups.
[0037] As used herein the term "salt" includes base addition, acid
addition and quaternary salts. Compounds of the invention which are
acidic can form salts, including pharmaceutically or veterinarily
acceptable salts, with bases such as alkali metal hydroxides, e.g.
sodium and potassium hydroxides, alkaline earth metal hydroxides
e.g. calcium, barium and magnesium hydroxides, with organic bases
e.g. N-ethyl piperidine, dibenzylamine and the like. Those
compounds (1) which are basic can form salts, including
pharmaceutically or veterinarily acceptable salts with inorganic
acids, e.g. with hydrohalic acids such as hydrochloric or
hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid
and the like, and with organic acids e.g. with acetic, tartaric,
succinic, fumaric, maleic, malic, salicylic, citric,
methanesulphonic and p-toluene sulphonic acids and the like.
[0038] For a review on suitable salts, see Handbook of
Pharmaceutical Salts: Properties, Selection, and Use by Stahl and
Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
[0039] Compounds of the invention are expected to be isolatable as
hydrates and solvates. The term `solvate` is used herein to
describe a molecular complex comprising the compound of the
invention and a stoichiometric amount of one or more
pharmaceutically acceptable solvent molecules, for example,
ethanol. The term `hydrate` is employed when said solvent is water.
Any reference herein to a compound of formula (I) is to be
understood as including such hydrates and solvates.
[0040] Compounds with which the invention is concerned which may
exist in one or more stereoisomeric form, because of the presence
of asymmetric atoms or rotational restrictions, can exist as a
number of stereoisomers with R or S stereochemistry at each chiral
centre or as atropisomeres with R or S stereochemistry at each
chiral axis. The invention includes all such enantiomers and
diastereoisomers and mixtures thereof.
[0041] So-called `pro-drugs` of the compounds of formula (I) are
also within the scope of the invention. Thus certain derivatives of
compounds of formula (I) which may have little or no
pharmacological activity themselves can, when administered into or
onto the body, be converted into compounds of formula (I) having
the desired activity, for example, by hydrolytic cleavage. Such
derivatives are referred to as `prodrugs`. Further information on
the use of prodrugs may be found in Pro-drugs as Novel Delivery
Systems, Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella)
and Bioreversible Carriers in Drug Design, Pergamon Press, 1987
(ed. E. B. Roche, American Pharmaceutical Association).
[0042] Prodrugs in accordance with the invention can, for example,
be produced by replacing appropriate functionalities present in the
compounds of formula (I) with certain moieties known to those
skilled in the art as `pro-moieties` as described, for example, in
Design of Prodrugs by H. Bundgaard (Elsevier, 1985).
[0043] Also included within the scope of the invention are
metabolites of compounds of formula (I), that is, compounds formed
in vivo upon administration of the drug. Some examples of
metabolites include
[0044] (i) where the compound of formula (I) contains a methyl
group, an hydroxymethyl derivative thereof
(--CH.sub.3->--CH.sub.2OH):
[0045] (ii) where the compound of formula (I) contains an alkoxy
group, an hydroxy derivative thereof (--OR->--OH),
[0046] (iii) where the compound of formula (I) contains a tertiary
amino group, a secondary amino derivative thereof
(--NR.sup.1R.sub.2->--NHR.sup.1 or --NHR.sup.2),
[0047] (iv) where the compound of formula (I) contains a secondary
amino group, a primary derivative thereof
(--NHR.sup.1->--NH.sub.2),
[0048] (v) where the compound of formula (I) contains a phenyl
moiety, a phenol derivative thereof (-Ph->-PhOH), and
[0049] (vi) where the compound of formula (I) contains an amide
group, a carboxylic acid derivative thereof
(--CONH.sub.2->COOH).
[0050] Variable substituents present in compounds (1) will now be
further described. It is to be understood in the further
description that any disclosed substituent or substituent class may
be present in any combination with any of the other disclosed
substituent classes. Specific examples of the variable substituents
include those present in the compounds of the Examples herein.
[0051] The Groups R.sub.1, R.sub.2, R.sub.5 and R.sub.6
[0052] R.sub.1, R.sub.2, R.sub.5 and R.sub.6 are independently
selected from hydrogen, or small substituents such as hydroxy,
methyl, trifluoromethyl, hydroxymethyl, methoxy, trifluoromethoxy,
methylamino and dimethylamino. Currently it is preferred that
R.sub.1, R.sub.2, R.sub.5 and R.sub.6 are each hydrogen.
[0053] The Groups R.sub.3 and R.sub.4
[0054] R.sub.3 and R.sub.4 are hydrogen, hydroxy, C.sub.1-C.sub.3
alkyl, fluoro-(C.sub.1-C.sub.3)-alkyl,
hydroxy-(C.sub.1-C.sub.3)-alkyl, C.sub.1-C.sub.3 alkoxy,
fluoro-(C.sub.1-C.sub.3)-alkoxy, hydroxy-(C.sub.1-C.sub.3)-alkoxy,
--N(R.sub.11)--R.sub.12, -Alk-N(R.sub.11)--R.sub.12,
--O-Alk-N(R.sub.11)--R.sub.12, --C(.dbd.O)OH,
carboxy-(C.sub.1-C.sub.3)-alkyl, or --C(.dbd.O)--NH--R.sub.13.
[0055] In some embodiments of the invention, one of R.sub.3 and
R.sub.4 is hydrogen and the other is selected from
--N(R.sub.11)--R.sub.12, -Alk-N(R.sub.11)--R.sub.12, and
--O-Alk-N(R.sub.11)--R.sub.12, especially the latter two. Currently
it is preferred that R.sub.4 be hydrogen. R and R.sub.12 together
with the nitrogen atom to which they are attached, may form an
optionally substituted, 4- to 6-membered, monocyclic heterocyclic
ring having no more than three additional heteroatoms independently
selected from oxygen, sulphur and nitrogen. Preferred structures
include those wherein R and R.sub.12 together with the nitrogen
atom to which they are attached form an azetidine, pyrrolidine,
piperidine, morpholine, or piperazine ring, optionally substituted
by C.sub.1-C.sub.3 alkyl, hydroxy-(C.sub.1-C.sub.3)-alkyl, fluoro,
or hydroxy. Particularly preferred are those compounds wherein R
and R.sub.12 together with the nitrogen atom to which they are
attached form 1-hydroxy-azetidin-3-yl, pyrrolidin-1-yl,
piperidin-1-yl, morpholin-4-yl, piperazin-1-yl,
1-methyl-piperidin-4-yl, 1-fluoro-piperidin-4-yl,
1-hydroxy-piperidin-4-yl, 1-(hydroxymethyl)-piperidin-4-yl, or
1-methyl-piperazin-4-yl. In this subclass Alk may be, for example
C.sub.1-C.sub.6 alkylene, preferably methylene, or ethylene. In
this subclass Alk may be, for example --CH.sub.2--,
--CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2-- or
--CH.sub.2CH(CH.sub.3)CH.sub.2-- or a divalent branched chain
alkylene radical --CH.sub.2C(CH.sub.3).sub.2CH.sub.2-- or of
formula (II):
##STR00004##
[0056] In other embodiments of the invention, one of R.sub.3 and
R.sub.4 is hydrogen and the other is selected from
--N(R.sub.11)--R.sub.12, -Alk-N(R.sub.11)--R.sub.12, and
--O-Alk-N(R.sub.11)--R.sub.12, especially the latter two, wherein R
and R.sub.12 are independently selected from C.sub.1-C.sub.3 alkyl,
for example methyl and ethyl, or R is C.sub.1-C.sub.3 alkyl, for
example methyl or ethyl and R.sub.12 is --N(R.sub.18)--R.sub.19
wherein R.sub.18 and R.sub.19 are independently selected from
C.sub.1-C.sub.3 alkyl, for example methyl and ethyl. In this
subclass also Alk may be, for example --CH.sub.2--,
--CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2-- or
--CH.sub.2CH(CH.sub.3)CH.sub.2-- or preferably a divalent branched
chain alkylene radical --CH.sub.2C(CH.sub.3).sub.2CH.sub.2-- or of
formula (II):
##STR00005##
[0057] In other embodiments of the invention, one of R.sub.3 and
R.sub.4 is hydrogen and the other is selected from
--N(R.sub.11)--R.sub.12, -Alk-N(R.sub.11)--R.sub.12, or
--O-Alk-N(R.sub.11)--R.sub.12, wherein R is hydrogen or
C.sub.1-C.sub.3 alkyl, particularly methyl or ethyl, and R.sub.12
is hydroxy-(C.sub.1-C.sub.6)-alkyl, such as 2-hydroxy-ethyl. In
this subclass also Alk may be, for example --CH.sub.2--,
--CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2-- or
--CH.sub.2CH(CH.sub.3)CH.sub.2-- or preferably a divalent branched
chain alkylene radical --CH.sub.2C(CH.sub.3).sub.2CH.sub.2-- or of
formula (II):
##STR00006##
[0058] The Group Y
[0059] Y is hydrogen, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3
alkoxy, or halo. Presently, it is preferred that Y is hydrogen,
methyl, methoxy, or halo. Particularly preferred are those
compounds wherein Y is hydrogen or methyl.
[0060] The Group W
[0061] W is selected from --C(.dbd.O)--N(--R.sub.16)-- or
--N(--R.sub.17)--C(.dbd.O)--. R.sub.16 and R.sub.17 are selected
from hydrogen C.sub.1-C.sub.3 alkyl such as methyl and
fluoro-(C.sub.1-C.sub.3)-alkyl such as trifluoromethyl.
[0062] Preferred structures include those wherein W is
[0063] --C(.dbd.O)--NH-- (ie where the nitrogen is linked to the
pyrazole ring, or
[0064] --NH--C(.dbd.O)-- (ie where the carbonyl group is linked to
the pyrazole ring), particularly the latter.
The Radicals R.sub.7 and R.sub.8
[0065] R.sub.7 and R.sub.8 are independently selected from
hydrogen, hydroxy, or C.sub.1-C.sub.3 alkoxy. Preferred structures
include those wherein R.sub.7 and R.sub.8 are independently
selected from hydrogen, hydroxy, or methoxy. Particularly preferred
cases are wherein one or both of R.sub.7 and R.sub.8 is/are
hydrogen.
[0066] The Divalent Radical X
[0067] X is a straight chain divalent C.sub.1-C.sub.3 alkylene
radical, optionally substituted on one or more carbons by R.sub.9
and/or R.sub.10. R.sub.9 and R.sub.10 are independently selected
from methyl, hydroxy, or fluoro. Currently, it is preferred that
both R.sub.9 and R.sub.10 when present are methyl. For example, X
may be --CH.sub.2--, --CH(CH.sub.3)-- or --C(CH.sub.3).sub.2--.
[0068] The Group Q
[0069] Q is selected from optionally substituted phenyl, optionally
substituted cyclohexyl, or an optionally substituted 6-membered
monocyclic heteroaryl ring.
[0070] In a subclass of compounds with which the invention is
concerned, Q is unsubstituted or substituted phenyl. Unsubstituted
phenyl is currently preferred, but when substituents are present
the phenyl ring may be substituted by no more than two substituents
independently selected from C.sub.1-C.sub.3 alkyl,
halo-(C.sub.1-C.sub.3)alkyl, C.sub.1-C.sub.3 alkoxy, halo, or
cyano. Preferred substituents are methyl, trifluoromethyl, methoxy,
fluoro, chloro, or cyano. Preferred structures include those
wherein Q is 2-methyl-phenyl, 3-methyl-phenyl, 4-methyl-phenyl,
3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl,
4-methoxy-phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl,
4-fluoro-phenyl, 3-chloro-phenyl, 4-chloro-phenyl, 3-cyano-phenyl,
4-cyano-phenyl, 3,4-difluoro-phenyl, 3,5-difluoro-phenyl, or
3-fluoro-4-methyl-phenyl.
[0071] In another subclass of compounds with which the invention is
concerned, Q is optionally substituted cyclohexyl.
[0072] In yet a further subclass of compounds with which the
invention is concerned, Q is an optionally substituted 6-membered
monocyclic heteroaryl ring, preferably pyridyl, particularly
pyrid-3-yl or pyrid-4-yl.
[0073] Currently, it is preferred that Q is phenyl,
3-methyl-phenyl, 4-methyl-phenyl, 3-trifluoromethyl-phenyl,
3-fluoro-phenyl, 4-fluoro-phenyl, 3-chloro-phenyl, 4-chloro-phenyl,
3,4-difluoro-phenyl, or 3,5-difluoro-phenyl, particularly phenyl,
4-methyl-phenyl, or 4-chloro-phenyl.
[0074] In a currently preferred subclass of compounds of formula
(I) of the invention, R.sub.1, R.sub.2, R.sub.4, R.sub.5, R.sub.6,
R.sub.7 and R.sub.8 are each hydrogen; Y is hydrogen or methyl; W
is --NH--C(.dbd.O)-- wherein the carbonyl group is linked to the
pyrazole ring; R.sub.3 is --N(R.sub.11)--R.sub.12,
-Alk-N(R.sub.11)--R.sub.12, or --O-Alk-N(R.sub.11)--R.sub.12; R and
R.sub.12 together with the nitrogen atom to which they are attached
form an optionally substituted, 5- to 6-membered, monocyclic
heterocyclic ring having no more than three additional heteroatoms
independently selected from oxygen, sulphur and nitrogen. or R and
R.sub.12 are independently selected from methyl and ethyl; Alk is
--CH.sub.2--, --CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2-- or
--CH.sub.2C(CH.sub.3).sub.2CH.sub.2--; X is --CH.sub.2--,
--CH(CH.sub.3)-- or --C(CH.sub.3).sub.2--; and Q is phenyl,
optionally substituted by one or two substituents selected from
C.sub.1-C.sub.3 alkyl, fluoro-(C.sub.1-C.sub.3)alkyl,
C.sub.1-C.sub.3 alkoxy, fluoro-(C.sub.1-C.sub.3) alkoxy, halo, and
cyano. In this preferred subclass, R and R.sub.12 together with the
nitrogen atom to which they are attached may form a piperidine,
morpholine, or piperazine ring, optionally substituted by
C.sub.1-C.sub.3 alkyl or fluoro. Furthermore, in this preferred
subclass Q may be unsubstituted phenyl.
[0075] Specific compounds of the invention include those of the
Examples herein, and their pharmaceutically acceptable salts.
[0076] Utility
[0077] The present invention may be employed in respect of a human
or animal subject, more preferably a mammal, more preferably a
human subject.
[0078] Compounds of the invention may be used alone in the
treatment of cancers and autoimmune disorders such as organ
transplant rejection, lupus, multiple sclerosis, rheumatoid
arthritis and osteoarthritis. However, as explained above in the
background to the present invention, the main utility of inhibitors
of CHK1 is considered to be their ability to improve the efficacy
of current DNA-damage inducing radiotherapy or chemotherapeutic
regimens for cancer treatment. The compound of formula (I) is
therefore preferably used in combination for the treatment of
cancer with radiation therapy or one or more cytotoxic or
cytostatic drugs, or drugs which induce cytotoxicity or cytostasis.
The compound of the invention and the other component may be in the
same pharmaceutical formulation or in separate formulations for
administration simultaneously or sequentially.
[0079] Non-limiting examples of chemotherapeutic agents,
radiotherapeutic agents and other active and ancillary agents are
set forth below.
[0080] (i) Alkylating agents.
[0081] (ii) Nitrogen mustards such as
TABLE-US-00001 chlorambucil cyclophosphamide ifosfamide
mechlorethamine melphalan
[0082] (iii) Nitrosoureas such as
TABLE-US-00002 carmustine (BCNU) lomustine (CCNU) semustine
(methyl-CCNU)
[0083] (iv) Ethylenimine/Methyl-melamine such as
TABLE-US-00003 hexamethylmelamine (HMM/altetamine)
thriethylenemelamine (TEM) trethylene thiophosphoramide
(thiotepa)
[0084] (v) Alkyl sulphonates such as busulphan.
[0085] (vi) Triazines such as dacarbazine (DTIC).
[0086] (vii) Antimetabolites such as the Folic acid analogues such
as
TABLE-US-00004 Methoxtrexate pemetrexed (multi-targeted antifolate)
Trimetrexate
[0087] (viii) Pyrimidine analogues such as
TABLE-US-00005 2,2'-difluorodeoxy-cytidine 5-azacytidine
5-fluorouracil cytosine arabinoside (araC/cytarabine)
Fluorodeoxyuridine Gemcitabine
[0088] (ix) Purine analogues such as
TABLE-US-00006 2-chlorodeoxyadenosine (cladribine/2-CdA)
2'-deoxycoformycin (pentostatin) 6-Mercaptopurine 6-thioguanine
Azathioprine erthyrohydroxynonyl-adenine (EHNA) fludarabine
phosphate
[0089] (x) Type I Topoisomerase Inhibitors such as
TABLE-US-00007 camptothecin irinotecan topotecan
[0090] (xi) Biological response modifiers such as G-CSF and
GM-CSF.
[0091] (xii) Differentiation agents such as retinoic acid
derivatives.
[0092] (xiii) Hormones and antagonists.
[0093] (xiv) Adrenocorticosteroids/antagonists such as
TABLE-US-00008 ainoglutethimide dexamethasone prednisone and
equivalents
[0094] (xv) Progestins such as
TABLE-US-00009 hydroxyprogesterone caproate medroxyprogesterone
acetate megestrol acetate
[0095] (xvi) Estrogens such as
TABLE-US-00010 diethylstilbestrol ethynyl estradiol/equivalents
[0096] (xvii) Antiestrogens such as tamoxifen.
[0097] (xviii) Andogens such as
TABLE-US-00011 testosterone propionate
fluoxymesterone/equivalents
[0098] (xix) Anti-androgens such as
TABLE-US-00012 Flutimide gonadotropin-releasing hormone analogues
Leuprolide
[0099] (xx) Nonsteroidal antiandrogens.
[0100] (xxi) Natural products.
[0101] (xxii) Antimitotic drugs.
[0102] (xxiii) Taxanes such as
TABLE-US-00013 docetaxel (Taxotere) estramustine/estramustine
phosphate Paclitaxel vinblastine (VLB) vinca alkaloids Vincristine
Vinorelbine
[0103] (xxiv) Epipodophylotoxins such as etoposide or
teniposide.
[0104] (xxv) Antibiotics such as
TABLE-US-00014 actimomycin D aphidicolin Bleomycin Dactinomycin
daunomycin (rubidomycin) doxorubicin (adriamycin) mitomycin C
Mitroxantroneidarubicin splicamycin (mithramycin)
[0105] (xxvi) Enzymes such as L-asparaginase and L-arginase.
[0106] (xxvii) Radiosensitizers such as
TABLE-US-00015 5-bromodeozyuridine 5-idoddeoxyuridine
Bromodeoxycytidine Desmethylmisonidazole EO9 Etanidazole
Metronidazole Misonidazole Nicotinamide Nimorazole Pimonidazole RB
6145 RSU 1069 SR4233
[0107] (xxviii) Platinum coordination complexes such as
TABLE-US-00016 Anthracenedione Carboplatin Cisplatin Mitoxantrone
oxaliplatin
[0108] (xxix) Substituted ureas such as hydroxyurea.
[0109] (xxx) Methyhydrazine derivatives such as N-methylhyrazine
(MIH) and procarbazine.
[0110] (xxxi) Adrenocortical suppressant mitocane (o,p'-DDD)
ainoglutethimide.
[0111] (xxxii) Cytokines such as interferon (.alpha., .beta.,
.gamma.) and interleukin-2.
[0112] (xxxiii) Photosensitisers such as
TABLE-US-00017 bacteriochlorophyll-a benzoporphyrin derivatives
hematoporphyrin derivatives napthalocyanines Npe6 pheboride-a
photofrin phthalocyanines tin etioporphyrin (SnET2) zinc
phthalocyanines
[0113] (xxxiv) Radiation such as
TABLE-US-00018 gamma radiation infrared radiation microwave
radiation ultraviolet light visible light X-ray
[0114] It will be understood that the specific dose level for any
particular patient will depend upon a variety of factors including
the activity of the specific compound employed, the age, body
weight, general health, sex, diet, time of administration, route of
administration, rate of excretion, drug combination and the
causative mechanism and severity of the particular disease
undergoing therapy. In general, a suitable dose for orally
administrable formulations will usually be in the range of 0.1 to
3000 mg, once, twice or three times per day, or the equivalent
daily amount administered by infusion or other routes. However,
optimum dose levels and frequency of dosing will be determined by
clinical trials as is conventional in the art.
[0115] The compounds with which the invention is concerned may be
prepared for administration by any route consistent with their
pharmacokinetic properties. The orally administrable compositions
may be in the form of tablets, capsules, powders, granules,
lozenges, liquid or gel preparations, such as oral, topical, or
sterile parenteral solutions or suspensions. Tablets and capsules
for oral administration may be in unit dose presentation form, and
may contain conventional excipients such as binding agents, for
example syrup, acacia, gelatin, sorbitol, tragacanth, or
polyvinyl-pyrrolidone, fillers for example lactose, sugar,
maize-starch, calcium phosphate, sorbitol or glycine, tabletting
lubricant, for example magnesium stearate, talc, polyethylene
glycol or silica, disintegrants for example potato starch, or
acceptable wetting agents such as sodium lauryl sulphate. The
tablets may be coated according to methods well known in normal
pharmaceutical practice. Oral liquid preparations may be in the
form of, for example, aqueous or oily suspensions, solutions,
emulsions, syrups or elixirs, or may be presented as a dry product
for reconstitution with water or other suitable vehicle before use.
Such liquid preparations may contain conventional additives such as
suspending agents, for example sorbitol, syrup, methyl cellulose,
glucose syrup, gelatin hydrogenated edible fats, emulsifying
agents, for example lecithin, sorbitan monooleate, or acacia,
non-aqueous vehicles (which may include edible oils), for example
almond oil, fractionated coconut oil, oily esters such as
glycerine, propylene glycol, or ethyl alcohol, preservatives, for
example methyl or propyl p-hydroxybenzoate or sorbic acid, and if
desired conventional flavouring or colouring agents.
[0116] For topical application to the skin, the drug may be made up
into a cream, lotion or ointment. Cream or ointment formulations
which may be used for the drug are conventional formulations well
known in the art, for example as described in standard textbooks of
pharmaceutics such as the British Pharmacopoeia.
[0117] The active ingredient may also be administered parenterally
in a sterile medium. Depending on the vehicle and concentration
used, the drug can either be suspended or dissolved in the vehicle.
Advantageously, adjuvants such as a local anaesthetic, preservative
and buffering agents can be dissolved in the vehicle.
[0118] There are multiple synthetic strategies for the synthesis of
the compounds (1) with which the present invention is concerned,
but all rely on known chemistry, known to the synthetic organic
chemist. Thus, compounds according to formula (I) can be
synthesised according to procedures described in the standard
literature and are well-known to the one skilled in the art.
Typical literature sources are "Advanced organic chemistry",
4.sup.th Edition (Wiley), J March, "Comprehensive Organic
Transformation", 2.sup.nd Edition (Wiley), R. C. Larock, "Handbook
of Heterocyclic Chemistry", 2.sup.nd Edition (Pergamon), A. R.
Katritzky), review articles such as found in "Synthesis", "Acc.
Chem. Res.", "Chem. Rev", or primary literature sources identified
by standard literature searches online or from secondary sources
such as "Chemical Abstracts" or "Beilstein". Such literature
methods include those of the preparative Examples herein, and
methods analogous thereto.
[0119] Examples of methods known in the art of organic chemistry in
general, by which the compounds of the present invention may be
prepared, are included in the following reaction schemes and
procedures.
##STR00007##
##STR00008##
##STR00009## ##STR00010##
##STR00011##
##STR00012## ##STR00013##
##STR00014## ##STR00015## ##STR00016##
##STR00017## ##STR00018##
##STR00019## ##STR00020##
##STR00021## ##STR00022##
##STR00023## ##STR00024##
##STR00025## ##STR00026##
EXAMPLES
[0120] The following examples illustrate the preparation of
specific compounds of the invention and are not intended to be
limiting of the full scope of the invention.
Example 1:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
(1-benzyl-1H-pyrazol-4-yl)-amide
##STR00027##
[0122] The title compound was prepared according to the route
outlined in Scheme 1.
Step 1: Preparation of
5-Iodo-6-(2-trimethylsilanyl-ethoxy)-nicotinic acid methyl ester
(1a)
[0123] 6-Hydroxy-5-iodo-nicotinic acid methyl ester (2.0 g, 7.17
mmol) was stirred in anhydrous 1,2-dimethoxyethane (60 mL) at
ambient temperature, with potassium fluoride (4.17 g, 71.7 mmol).
2-(Trimethylsilyl)ethoxymethyl chloride (1.20 g, 1.27 mL, 7.17
mmol) was added drop wise and the reaction stirred at ambient
temperature for 3 hours. The reaction mixture was filtered through
celite, and the filter cake washed with methanol (2.times.25 mL).
The filtrate and the washings were combined and concentrated in
vacuo. The residue was partitioned between water and
dichloromethane, and the organic layer was separated. The aqueous
was extracted with a further portion of dichloromethane and the
combined dichloromethane layers were dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. The resultant crude product was purified by
flash chromatography on SiO.sub.2 eluting first with 20% ethyl
acetate/hexane and then 66% ethyl acetate/hexane to firstly afford
the undesired oxygen substituted compound and then the desired
title compound as an off-white solid, 2.28 g, 78%.
Step 2: Preparation of
2-[5-Methoxycarbonyl-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydr-
o-pyridin-3-yl]-indole-1-carboxylic Acid tert-butyl ester (1b)
[0124] Intermediate (1a),
5-iodo-6-(2-trimethylsilanyl-ethoxy)-nicotinic acid methyl ester
(1.14 g, 2.79 mmol), 1-(tert-butoxycarbonyl) indole-2-boronic acid
(1.09 g, 4.18 mmol), bis(triphenylphosphine) palladium(II)
dichloride (0.1 g, 0.143 mmol), potassium acetate (0.82 g, 8.37
mmol) and anhydrous N,N-dimethylformamide (15 mL) were combined in
a 20 mL microwave vial. The contents of the vial were degassed and
then were heated at 60.degree. C. for 20 minutes under microwave
irradiation. The reaction mixture was concentrated in vacuo. The
residue was partitioned between water and dichloromethane, and the
organic layer was separated. The aqueous was extracted with a
further portion of dichloromethane and the combined dichloromethane
layers were dried (Na.sub.2SO.sub.4) and concentrated in vacuo. The
resultant crude product was purified by flash chromatography on
SiO.sub.2 eluting with 20% ethyl acetate/hexane to afford the
desired title compound as an oil 1.39 g, 100%.
Step 3: Preparation of
2-[5-Carboxy-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridi-
n-3-yl]-indole-1-carboxylic acid tert-butyl ester (1c)
[0125] Intermediate (1b),
2-[5-methoxycarbonyl-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydr-
o-pyridin-3-yl]-indole-1-carboxylic acid tert-butyl ester (2.88 g,
5.78 mmol) was stirred in a mixture of tetrahydrofuran (40 mL) and
water (20 mL). Lithium hydroxide (0.469 g, 11.2 mmol) was added and
the reaction stirred at reflux for 2 hours. After cooling the
reaction mixture was concentrated in vacuo, and the residue was
taken up in water and the pH adjusted to 5 with the careful
addition of an aqueous 2M hydrochloric acid solution. This aqueous
solution was extracted with dichloromethane (.times.3), and the
combined extracts were washed with brine, dried (Na.sub.2SO.sub.4)
and concentrated in vacuo to afford the desired title compound as a
yellow solid 2.30 g, 85%.
Step 4: Preparation of
2-[5-(1-Benzyl-1H-pyrazol-4-ylcarbamoyl)-2-oxo-1-(2-trimethylsilanyl-etho-
xymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic Acid
tert-butyl ester (1d)
[0126] Intermediate (1c),
2-[5-carboxy-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridi-
n-3-yl]-indole-1-carboxylic acid tert-butyl ester (300 mg, 0.62
mmol), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
(357 mg, 1.86 mmol), 1-hydroxybenzotriazole hydrate (251 mg, 1.86
mmol), N,N-diisopropylethylamine (320 mg, 0.431 mL, 2.48 mmol),
1-benzyl-1H-pyrazol-4-ylamine (322 mg, 1.86 mmol) and
tetrahydrofuran (12 mL) were combined in a 20 mL microwave vial.
The contents of the vial were heated at 90.degree. C. for 30
minutes under microwave irradiation. The reaction mixture was
concentrated in vacuo. The residue was partitioned between water
and dichloromethane, and the organic layer was separated. The
aqueous was extracted with a further portion of dichloromethane and
the combined dichloromethane layers were dried (Na.sub.2SO.sub.4)
and concentrated in vacuo. The resultant crude product was purified
by flash chromatography on SiO.sub.2 eluting with 20% ethyl
acetate/hexane and then 2% methanol/dichloromethane to afford the
desired title compound as a solid, 315 mg, 80%.
Step 5: Preparation of Title compound:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
(1-benzyl-1H-pyrazol-4-yl)-amide
[0127] Intermediate (1d),
2-[5-(1-benzyl-1H-pyrazol-4-ylcarbamoyl)-2-oxo-1-(2-trimethylsilanyl-etho-
xymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic acid
tert-butyl ester (315 mg, 0.492 mmol) was stirred in
tetrahydrofuran (15 mL) and 1,2-diaminoethane (89 mg, 98 ul, 1.48
mmol) was added followed by tetrabutylammonium fluoride solution
1.0M in tetrahydrofuran (2.46 mL, 2.46 mmol). The reaction mixture
was heated at reflux for 18 hours, and cooled to ambient
temperature. The reaction mixture was concentrated in vacuo. The
residue was partitioned between water and dichloromethane, and the
organic layer was separated. The aqueous was extracted with a
further portion of dichloromethane and the combined dichloromethane
layers were washed with water (.times.3) dried (Na.sub.2SO.sub.4)
and concentrated in vacuo. The resultant crude product was purified
by flash chromatography on SiO.sub.2 eluting with
dichloromethane-8% methanol/dichloromethane (gradient) to afford a
solid. This solid was triturated with diethyl ether to afford the
desired title compound as a yellow solid, 41 mg, 20%.
[0128] LC/MS: RT=2.33 Min (270 nm), m/z=410, 411 [M+H]. Total run
time 3.75 min (short pos).
[0129] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.33 (s, 2H), 6.97-7.01
(m, 1H), 7.07-7.11 (m, 1H), 7.24-7.38 (m, 6H), 7.49 (d, 1H), 7.55
(d, 1H), 7.61 (s, 1H), 8.10 (s, 1H), 8.11 (d, 1H), 8.56 (d, 1H),
10.30 (s, 1H), 11.50 (s, 1H), 12.30 (s, 1H).
Example 2:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
[1-(4-methoxy-benzyl)-1H-pyrazol-4-yl]-amide
##STR00028##
[0131] The title compound was prepared according to the route
outlined in Scheme 1.
Step 1: Preparation of 4-Nitro-1H-pyrazole (1e)
[0132] Pyrazole (16 g, 235 mmol) was added in portions to sulfuric
acid, 98%, (100 mL) keeping the temperature below 40.degree. C. To
this solution was added nitric acid, 70%, (16 mL) maintaining the
temperature below 55.degree. C. After addition the reaction was
heated at 55.degree. C. for 3 hours, and then cooled to 0.degree.
C., before carefully adding to ice/water (400 mL) with stirring.
This mixture was neutralized by the careful addition of aqueous 50%
sodium hydroxide solution using external cooling and efficient
stirring. The resultant solution was extracted with ethyl acetate
(3.times.300 mL), and the combined extracts were washed with brine
(2.times.250 mL) dried (Na.sub.2SO.sub.4) and concentrated in vacuo
to yield a white solid, which was used without further
purification, 24.74 g, 93%.
Step 2: Preparation of 1-(4-Methoxy-benzyl)-4-nitro-1H-pyrazole
[0133] 4-Nitro-1H-pyrazole (565 mg, 5 mmol) was stirred in
acetonitrile (15 mL) with potassium carbonate (829 mg, 6 mmol) for
5 minutes and then 4-methoxybenzyl chloride (861 mg, 0.746 mL, 5.5
mmol) was added. The reaction was stirred at ambient temperature
for 18 hours, and then partitioned between ethyl acetate and an
aqueous 2M hydrochloric acid solution. The organic layer was
separated and the aqueous was extracted with a further portion of
ethyl acetate. The combined ethyl acetate layers were dried
(Na.sub.2SO.sub.4) and concentrated in vacuo. The resultant crude
product was purified by flash chromatography on SiO.sub.2 eluting
with 20% ethyl acetate/hexane and then 50% ethyl
acetate/dichloromethane to afford the desired title compound as an
oil, 1.08 g, 93%.
Step 3: Preparation of
1-(4-Methoxy-benzyl)-1H-pyrazol-4-ylamine
[0134] 1-(4-Methoxy-benzyl)-4-nitro-1H-pyrazole (240 mg, 1.03 mmol)
was stirred in ethanol (10 mL) and the flask was evacuated and then
flushed with nitrogen. Platinum, sulfided, 5 wt. % on carbon,
reduced, dry (10 mg, catalytic amount) was added and after two
vacuum/H.sub.2 cycles to replace the nitrogen inside with hydrogen,
the mixture was shaken for 18 hours under ordinary hydrogen
pressure (1 atm). The reaction mixture was filtered and the
filtrate was concentrated in vacuo to yield a red oil, which was
used without further purification, 168 mg, 81%.
Step 4: Preparation of
2-[5-[1-(4-Methoxy-benzyl)-1H-pyrazol-4-ylcarbamoyl]-2-oxo-1-(2-trimethyl-
silanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic
Acid tert-butyl ester
[0135] The title compound was prepared according to the
experimental used in Example 1, Step 4 using intermediate (1c) and
1-(4-methoxy-benzyl)-1H-pyrazol-4-ylamine.
[0136] After the usual aqueous work up, the resultant crude product
was purified by flash chromatography on SiO.sub.2 eluting with
hexane-50% ethyl acetate/hexane. This afforded the title compound
as a pink solid, 180 mg, 50%.
Step 5: Preparation of Title Compound:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
[1-(4-methoxy-benzyl)-1H-pyrazol-4-yl]-amide
[0137] The title compound was prepared according to the
experimental used in Example 1, Step 5 with
2-[5-[1-(4-methoxy-benzyl)-1H-pyrazol-4-ylcarbamoyl]-2-oxo-1-(2-trimethyl-
silanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic
acid tert-butyl ester.
[0138] After the usual aqueous work up the resultant crude product
was purified by flash chromatography on SiO.sub.2 eluting with 50%
ethyl acetate/dichloromethane and then 5% methanol/dichloromethane
to afford a solid which was further purified via preparative HPLC
at pH9, to furnish the title compound as a yellow solid, 40 mg,
36%.
[0139] LC/MS: RT=2.29 Min (270 nm), m/z=440 [M+H]. Total run time
3.75 min (short pos).
[0140] .sup.1H NMR (d.sub.6 DMSO): .delta. 3.75 (s, 3H), 5.25 (s,
2H), 6.91-6.95 (m, 2H), 6.98-7.03 (m, 1H), 7.09-7.13 (m, 1H),
7.23-7.28 (m, 3H), 7.51 (d, 1H), 7.56 (d, 1H), 7.6 (d, 1H), 8.06
(s, 1H), 8.12 (d, 1H), 8.57 (d, 1H), 10.3 (s, 1H), 11.51 (br s,
1H), 12.5 (br s, 1H).
Example 3:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
[1-(2-methyl-benzyl)-1H-pyrazol-4-yl]-amide
##STR00029##
[0142] The title compound was prepared according to the route
outlined in Scheme 2.
Step 1: Preparation of 1H-Pyrazol-4-ylamine (2f)
[0143] Intermediate (1e), 4-nitro-1H-pyrazole (2.8 g, 24.8 mmol),
was stirred in ethanol (200 mL) and the flask was evacuated and
then flushed with nitrogen. Palladium, 10 wt. % on activated carbon
(300 mg, catalytic amount) was added and after two vacuum/H.sub.2
cycles to replace the nitrogen inside with hydrogen, the mixture
was shaken for 18 hours under ordinary hydrogen pressure (1 atm).
Palladium, 10 wt. % on activated carbon (300 mg) was added and
after two vacuum/H.sub.2 cycles to replace the nitrogen inside with
hydrogen, the mixture was shaken for a further 4 hours. The
reaction mixture was filtered through celite and the filter cake
was washed through with ethanol (2.times.50 mL). The combined
washings and the filtrate were concentrated in vacuo. The residue
obtained was triturated with ethyl acetate to yield a light pink
solid, 1.48 g, 72%. The filtrate subsequently obtained was
concentrated in vacuo to yield another batch of sufficiently pure
material, 0.54 g, 26%, as a dark pink solid.
Step 2: Preparation of
2-[2-Oxo-5-(1H-pyrazol-4-ylcarbamoyl)-1-(2-trimethylsilanyl-ethoxymethyl)-
-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic Acid tert-butyl
ester (2d)
[0144] To a solution of intermediate (1c),
2-[5-carboxy-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridi-
n-3-yl]-indole-1-carboxylic acid tert-butyl ester, (3 g, 6.2 mmol)
in tetrahydrofuran (100 mL) was added intermediate (2f),
1H-pyrazol-4-ylamine (0.62 g, 7.46 mmol), 1-hydroxybenzotriazole
hydrate (1.09 g, 8.07 mmol), N,N-diisopropylethylamine (2.4 g, 3.24
mL, 18.6 mmol) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide
hydrochloride (1.55 g, 8.07 mmol). The reaction mixture was heated
at 40.degree. C. for 2 hours. The reaction mixture was cooled and
partitioned between ethyl acetate and aqueous saturated sodium
hydrogen bicarbonate solution. The ethyl acetate layer was
separated and washed with brine, dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. The resultant crude product was purified by
flash chromatography on SiO.sub.2 eluting with hexane-66% ethyl
acetate/hexane (gradient) to afford the desired title compound as a
yellow solid, 1.36 g, 40%.
Step 3:
2-[5-[1-(2-Methyl-benzyl)-1H-pyrazol-4-ylcarbamoyl]-2-oxo-1-(2-tri-
methylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic
Acid tert-butyl ester (2e)
[0145] Intermediate (2d),
2-[2-oxo-5-(1H-pyrazol-4-ylcarbamoyl)-1-(2-trimethylsilanyl-ethoxymethyl)-
-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic Acid tert-butyl
ester (50 mg, 0.091 mmol), Cs.sub.2CO.sub.3 (45 mg, 0.136 mmol) and
2-methylbenzyl bromide (21 mg, 15 ul, 0.11 mmol) were stirred in
N,N-dimethylformamide (5 mL) at ambient temperature for 48 hours.
The inorganics were separated via filtration and the filtrate was
concentrated in vacuo. The resultant crude product was purified by
flash chromatography on SiO.sub.2 eluting with hexane-50% ethyl
acetate/hexane (gradient) to afford the desired title compound as a
solid, 55 mg, 93%.
Step 4: Preparation of Title Compound:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
[1-(2-methyl-benzyl)-1H-pyrazol-4-yl]-amide
[0146] The title compound was prepared according to the
experimental used in Example 1, Step 5 with intermediate (2e),
2-[5-[1-(2-methyl-benzyl)-1H-pyrazol-4-ylcarbamoyl]-2-oxo-1-(2-trimethyls-
ilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic
acid tert-butyl ester. After the usual aqueous work up, the
resultant crude product was purified by trituration with
acetonitrile. This afforded the title compound as a yellow solid,
30 mg, 84%.
[0147] LC/MS: RT=2.41 Min (270 nm), m/z=424 [M+H]. Total run time
3.75 min (short pos).
[0148] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.29 (s, 3H), 5.33 (s,
2H), 6.98 (br t, 2H), 7.08 (br t, 1H), 7.17 (m, 4H), 7.29 (s, 1H),
7.47 (d, 1H), 7.54 (d, 1H), 7.69 (br s, 1H), 8.00 (s, 1H), 8.12 (br
s, 1H), 8.74 (br m, 1H), 10.50 (br s, 1H), 11.57 (br s, 1H)
Example 4:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic
Acid[1-(3-methyl-benzyl)-1H-pyrazol-4-yl]-amide
##STR00030##
[0150] The title compound was prepared by the route outlined in
Scheme 2, following the same procedures as for Example 3.
[0151] LC/MS: RT=2.41 Min (270 nm), m/z=424 [M+H]. Total run time
3.75 min (short pos).
[0152] .sup.1H NMR (d.sub.4 MeOD): .delta. 2.30 (s, 3H), 5.28 (s,
2H), 7.05 (m, 5H), 7.15 (s, 1H), 7.22 (t, 1H), 7.42 (d, 1H), 7.54
(t, 1H), 7.68 (s, 1H), 8.07 (m, 2H), 8.61 (d, 1H), NHs not
seen.
Example 5:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic
Acid[1-(4-methyl-benzyl)-1H-pyrazol-4-yl]-amide
##STR00031##
[0154] The title compound was prepared by the route outlined in
Scheme 2, following the same procedures as for Example 3.
[0155] LC/MS: RT=2.31 Min (270 nm), m/z=424 [M+H]. Total run time
3.75 min (short pos).
[0156] .sup.1H NMR (d.sub.6 DMSO): .delta. 3.31 (s, 3H), 5.26 (s,
2H), 6.98 (td, 1H), 7.09 (td, 1H), 7.15 (br s, 4H), 7.24 (d, 1H),
7.48 (dd, 1H), 7.54 (d, 1H), 7.58 (d, 1H), 8.05 (s, 1H), 8.01 (br
s, 1H), 8.55 (d, 1H) 10.27 (s, 1H), 11.49 (br s, 1H), 12.46 (br s,
1H)
Example 6:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
[1-(3-cyano-benzyl)-1H-pyrazol-4-yl]-amide
##STR00032##
[0158] The title compound was prepared by the route outlined in
Scheme 2, following the same procedures as for Example 3.
[0159] LC/MS: RT=2.12 Min (270 nm), m/z=435 [M+H]. Total run time
3.75 min (short pos).
[0160] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.41 (s, 2H), 6.98 (t,
1H), 7.08 (t, 1H), 7.24 (s, 1H), 7.49 (d, 1H), 7.55 (m, 3H), 7.63
(s, 1H), 7.69 (s, 1H), 7.78 (dt, 1H.), 8.11 (d, 1H), 8.19 (s, 1H),
8.55 (d, 1H), 10.35 (s, 1H), 11.52 (s, 1H), 12.42 (br s, 1H)
Example 7:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
[1-(4-cyano-benzyl)-1H-pyrazol-4-yl]-amide
##STR00033##
[0162] The title compound was prepared by the route outlined in
Scheme 2, following the same procedures as for Example 3.
[0163] LC/MS: RT=2.15 Min (270 nm), m/z=435 [M+H]. Total run time
3.75 min (short pos).
[0164] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.41 (s, 2H), 6.99 (t,
1H), 7.09 (t, 1H), 7.25 (s, 1H), 7.36 (d, 2H), 7.49 (d, 1H), 7.54
(d, 1H), 7.64 (s, 1H), 7.83 (d, 2H), 8.12 (br m, 1H), 8.19 (s, 1H),
8.55 (d, 1H), 10.33 (s, 1H), 11.50 (s, 1H), 12.47 (br s, 1H)
Example 8:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
[1-(2-fluoro-benzyl)-1H-pyrazol-4-yl]-amide
##STR00034##
[0166] The title compound was prepared by the route outlined in
Scheme 2, following the same procedures as for Example 3.
[0167] LC/MS: RT=2.24 Min (270 nm), m/z=428 [M+H]. Total run time
3.75 min (short pos).
[0168] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.39 (s, 2H), 6.98 (td,
1H), 7.11 (td, 1H), 7.21 (m, 4H), 7.37 (m, 1H), 7.48 (d, 1H), 7.54
(d, 1H), 7.61 (d, 1H), 8.11 (m, 2H), 8.55 (d, 1H), 10.30 (s, 1H),
11.49 (br s, 1H), 12.47 (br s, 1H)
Example 9:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
[1-(3-fluoro-benzyl)-1H-pyrazol-4-yl]-amide
##STR00035##
[0170] The title compound was prepared by the route outlined in
Scheme 2, following the same procedures as for Example 3.
[0171] LC/MS: RT=2.24 Min (270 nm), m/z=428 [M+H]. Total run time
3.75 min (short pos).
[0172] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.35 (s, 2H), 6.98 (t,
1H), 7.04 (m, 5H), 7.24 (br s, 1H), 7.40 (qd, 1H), 7.48 (d, 1H),
7.54 (d, 1H), 7.62 (s, 1H), 8.11 (d, 1H), 8.14 (s, 1H), 8.55 (d,
1H), 10.30 (br s, 1H), 11.53 (br s, 1H)
Example 10:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
[1-(4-fluoro-benzyl)-1H-pyrazol-4-yl]-amide
##STR00036##
[0174] The title compound was prepared by simple modifications of
the protocol described for Example 3, but still using the route
outlined in Scheme 2.
[0175] The principal modification was for Step 3, and this is
described below
2-[2-Oxo-5-(1H-pyrazol-4-ylcarbamoyl)-1-(2-trimethylsilanyl-ethoxym-
ethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic acid
tert-butyl ester, (2d), (100 mg, 0.182 mmol) was stirred in acetone
(5 mL) with potassium carbonate (126 mg, 0.91 mmol) and
4-fluorobenzyl bromide (41 mg, 27 ul, 0.218 mmol) was added. The
reaction mixture was heated at 50.degree. C. for 8 hours, and then
cooled to ambient temperature. The inorganics were separated via
filtration, and the filter cake was washed through with ethyl
acetate (2.times.5 mL). The combined washings and the filtrate were
concentrated in vacuo, and the residue obtained was purified by
flash chromatography on SiO.sub.2 eluting with 20% ethyl
acetate/hexane to afford the desired compound as an oil, 87 mg,
72%.
[0176] The title compound was isolated as a yellow solid.
[0177] LC/MS: RT=2.29 Min (270 nm), m/z=428 [M+H]. Total run time
3.75 min (short pos).
[0178] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.35 (s, 2H), 6.98-7.03
(m, 1H), 7.09-7.14 (m, 1H), 7.18-7.24 (m, 2H), 7.27 (d, 1H),
7.31-7.36 (m, 2H), 7.51 (d, 1H), 7.57 (d, 1H), 7.63 (d, 1H),
8.12-8.15 (m, 2H), 8.58 (d, 1H), 10.34 (s, 1H), 11.54 (br s, 1H),
12.1 (br s, 1H).
Example 11:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
[1-(3,4-difluoro-benzyl)-1H-pyrazol-4-yl]-amide
##STR00037##
[0180] The title compound was prepared by the route outlined in
Scheme 2, following the same procedures as for Example 10.
[0181] LC/MS: RT=1.21 Min (270 nm), m/z=446 [M+H]. Total run time
1.9 min (super short pos).
[0182] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.35 (s, 2H), 7.00 (t,
1H), 7.10 (t, 1H), 7.30 (br s, 1H), 7.35 (m, 1H), 7.45 (q, 1H),
7.55 (d, 1H), 7.60 (d, 1H), 7.70 (s, 1H) 8.15 (d, 1H), 8.20 (s,
1H), 8.60 (d, 1H), 10.35 (s, 1H), NH (.times.3) not seen.
Example 12:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
[1-(4-chloro-benzyl)-1H-pyrazol-4-yl]-amide
##STR00038##
[0184] The title compound was prepared by the route outlined in
Scheme 2, following the same procedures as for Example 10.
[0185] LC/MS: RT=1.24 Min (270 nm), m/z=444 [M+H]. Total run time
1.9 min (super short pos).
[0186] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.40 (d, 2H), 7.05 (t,
1H), 7.15 (t, 1H), 7.35 (d, 2H), 7.50 (d, 2H), 7.55 (d, 1H), 7.65
(d, 1H), 7.70 (s, 1H) 8.20 (d, 1H), 8.25 (s, 1H), 8.65 (d, 1H),
10.45 (s, 1H), NH (.times.3) not seen.
Example 13:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
[1-(3,5-difluoro-benzyl)-1H-pyrazol-4-yl]-amide
##STR00039##
[0188] The title compound was prepared by the route outlined in
Scheme 2, following the same procedures as for Example 10.
[0189] LC/MS: RT=1.22 Min (270 nm), m/z=446 [M+H]. Total run time
1.9 min (super short pos).
[0190] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.40 (s, 2H), 7.00 (m,
2H), 7.05 (t, 1H), 7.15 (t, 1H), 7.25 (m, 1H), 7.30 (d, 1H), 7.55
(d, 1H), 7.60 (d, 1H), 7.70 (s, 1H) 8.15 (d, 1H), 8.25 (s, 1H),
8.60 (d, 1H), 10.40 (s, 1H), NH (.times.2) not seen.
Example 14:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
[1-(3-fluoro-4-methyl-benzyl)-1H-pyrazol-4-yl]-amide
##STR00040##
[0192] The title compound was prepared by the route outlined in
Scheme 2, following the same procedures as for Example 10.
[0193] LC/MS: RT=1.25 Min (270 nm), m/z=442 [M+H]. Total run time
1.9 min (super short pos).
[0194] .sup.1H NMR (d.sub.6 DMSO): .delta. Q 2.25 (s, 3H), 5.30 (s,
2H), 7.00 (m, 3H), 7.10 (t, 1H), 7.30 (m, 2H), 7.50 (d, 1H), 7.60
(d, 1H), 7.70 (s, 1H) 8.15 (m, 2H), 8.55 (d, 1H), 10.35 (s, 1H),
NHs not seen.
Example 15:
5-[5-(4-Methyl-piperazine-1-carbonyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridine-3-carboxylic Acid (1-benzyl-1H-pyrazol-4-yl)-amide
##STR00041##
[0196] The title compound was prepared by the route outlined in
Scheme 3.
Step 1: Preparation of 1H-Indole-5-carboxylic Acid benzyl ester
(3a)
[0197] To a solution of indole-5-carboxylic Acid (2.63 g, 16.34
mmol) in N,N-dimethylformamide (50 mL) was added sodium bicarbonate
(8.24 g, 98.04 mmol) and benzyl bromide (11.66 mL, 98.04 mmol). The
reaction was stirred for 48 hours at ambient temperature under
nitrogen.
[0198] The reaction was then partitioned between ethyl acetate and
water. The organic layer was separated and the aqueous extracted
with a further portion of ethyl acetate. The combined organic
layers were dried (MgSO.sub.4) and evaporated in vacuo. The
resultant crude product was purified by flash chromatography on
SiO.sub.2, eluting with 20% ethyl acetate/hexane followed by 50%
ethyl acetate/hexane to afford the title compound as an oil, 4.82
g, quantitative.
Step 2: Preparation of Indole-1,5-dicarboxylic Acid 5-benzyl ester
1-tert-butyl ester (3b)
[0199] To a solution of intermediate (3a), 1H-indole-5-carboxylic
acid benzyl ester, (4.8 g, 16.34 mmol) in acetonitrile (100 mL) was
added di-tert-butyl dicarbonate (3.92 g, 17.97 mmol) and
4-dimethylaminopyridine (0.2 g, 1.63 mmol). The reaction was
stirred at ambient temperature under nitrogen for 12 hours. The
reaction was concentrated in vacuo and the resultant crude product
was purified by flash chromatography on SiO.sub.2, eluting with 20%
ethyl acetate/hexane to afford the title compound as an off white
solid, 5.04 g, 88%.
Step 3: Preparation of Indole-2-boronic Acid-1,5-dicarboxylic Acid
5-benzyl ester 1-tert-butyl ester (3c)
[0200] To a solution of intermediate (3b), indole-1,5-dicarboxylic
acid 5-benzyl ester 1-tert-butyl ester, (5.04 g, 14.36 mmol) in
tetrahydrofuran (50 mL) at 0.degree. C. was added triisopropyl
borate (5 mL, 21.54 mmol). Freshly prepared lithium
diisopropylamide solution (18.67 mmol) in tetrahydrofuran (10 mL)
was then added drop wise at 0.degree. C. and the reaction was
stirred at 0.degree. C. for 2 hours under nitrogen. The pH of the
reaction mixture was adjusted to pH7 by the careful addition of an
aqueous 2M hydrochloric acid solution and stirred at ambient
temperature for a further 30 minutes. The organics were separated,
dried (Na.sub.2SO.sub.4) and concentrated in vacuo. This afforded
the title compound, which was used without further purification,
5.05 g, quantitative.
Step 4: Preparation of
2-[5-Methoxycarbonyl-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydr-
o-pyridin-3-yl]-indole-1,5-dicarboxylic Acid 5-benzyl ester
1-tert-butyl ester (3d)
[0201] To a solution of intermediate (1a),
5-iodo-6-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,6-dihydro-pyridine-3-c-
arboxylic acid ester, (2.94 g, 7.18 mmol) in N,N-dimethylformamide
(16 mL) was added intermediate (3c), indole-2-boronic
acid-1,5-dicarboxylic acid 5-benzyl ester 1-tert-butyl ester, (5.05
g, 14.36 mmol) and potassium acetate (2.11 g, 21.54 mmol). The
reaction mixture was degassed for 10 minutes after which
bis(triphenylphosphine)palladium(II) dichloride (0.25 g, 0.359
mmol) was added and the reaction mixture degassed for a further 10
minutes. The reaction mixture was then heated to 60.degree. C. in
the microwave for 20 mins. The reaction mixture was concentrated in
vacuo, and the residue partitioned between dichloromethane and
water. The organic layer was separated and the aqueous extracted
with a further portion of dichloromethane. The combined organics
were dried (MgSO.sub.4) and evaporated in vacuo. The resultant
crude product was purified by flash chromatography on SiO.sub.2,
eluting with 20% ethyl acetate/hexane to afford the title compound
as a yellow oil, 2.07 g, 46%.
Step 5: Preparation of
2-[5-Methoxycarbonyl-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydr-
o-pyridin-3-yl]-indole-1,5-dicarboxylic Acid 1-tert-butyl ester
(3e)
[0202] To a degassed solution of intermediate (3d),
2-[5-methoxycarbonyl-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydr-
o-pyridin-3-yl]-indole-1,5-dicarboxylic acid 5-benzyl ester
1-tert-butyl ester, (2.07 g, 3.27 mmol) in methanol (30 mL) was
added palladium, 10 wt. % on activated carbon (50 mg) and the
reaction further degassed. The reaction was heated to 30.degree. C.
for 72 hours under a hydrogen atmosphere. The reaction mixture was
then filtered through a celite pad and the pad rinsed with hot
methanol (20 mL). The combined filtrate and washings were
concentrated in vacuo and poured onto 4.times.10 g PE-AX columns.
The columns were then flushed with methanol and eluted with 20%
acetic acid/methanol. The combined organics were concentrated in
vacuo. To the residue was added ether and this was concentrated in
vacuo. This process was repeated twice more and furnished the
desired title compound as a brown solid, 627 mg, 35%.
Step 6: Preparation of
2-[5-Methoxycarbonyl-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydr-
o-pyridin-3-yl]-5-(4-methyl-piperazine-1-carbonyl)-indole-1-carboxylic
Acid tert-butyl ester (3f)
[0203] The title compound was prepared according to the
experimental used in Example 3, Step 2 with intermediate (3e),
2-[5-methoxycarbonyl-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydr-
o-pyridin-3-yl]-indole-1,5-dicarboxylic acid 1-tert-butyl ester.
After the usual aqueous work up, the crude product was purified by
flash chromatography on SiO.sub.2, eluting with 6%
methanol/dichloromethane to afford the title compound as a yellow
gum, 219 mg, 95%.
Step 7: Preparation of
2-[5-Carboxy-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridi-
n-3-yl]-5-(4-methyl-piperazine-1-carbonyl)-indole-1-carboxylic Acid
tert-butyl ester (3 g)
[0204] The title compound was prepared according to the
experimental used in Example 1, Step 3 with intermediate (3f),
2-[5-methoxycarbonyl-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydr-
o-pyridin-3-yl]-5-(4-methyl-piperazine-1-carbonyl)-indole-1-carboxylic
acid tert-butyl ester. After the usual work up, the desired title
compound was isolated as a yellow solid, 142 mg, 66%.
Step 8: Preparation of
2-[5-(1-Benzyl-1H-pyrazol-4-ylcarbamoyl)-2-oxo-1-(2-trimethylsilanyl-etho-
xymethyl)-1,2-dihydro-pyridin-3-yl]-5-(4-methylpiperazine-1-carbonyl)-indo-
le-1-carboxylic Acid tert-butyl ester (3h)
[0205] The title compound was prepared according to the
experimental used in Example 1, Step 4 with intermediate (3 g),
2-[5-carboxy-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridi-
n-3-yl]-5-(4-methyl-piperazine-1-carbonyl)-indole-1-carboxylic acid
tert-butyl ester. After the usual work up, the crude product was
purified by flash chromatography on SiO.sub.2, eluting with 5%
methanol/dichloromethane to afford the title compound as a brown
foam, 178 mg, quantitative.
Step 9: Preparation of title compound
5-[5-(4-Methyl-piperazine-1-carbonyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridine-3-carboxylic Acid (1-benzyl-1H-pyrazol-4-yl)-amide
[0206] The title compound was prepared according to the
experimental used in Example 1, Step 5 with intermediate (3h),
2-[5-(1-benzyl-1H-pyrazol-4-ylcarbamoyl)-2-oxo-1-(2-trimethylsilanyl-etho-
xymethyl)-1,2-dihydro-pyridin-3-yl]-5-(4-methylpiperazine-1-carbonyl)-indo-
le-1-carboxylic acid tert-butyl ester. After the usual work up the
crude product was taken up in methanol (1 mL) and loaded onto a 5 g
SCX column. The column was flushed with methanol and then eluted
with ammonia solution 7N in methanol. The eluent was concentrated
in vacuo and the residue further purified by preparative HPLC at pH
4 to afford the title compound as a brown solid, 13 mg, 10%.
[0207] LC/MS RT=1.52 Min (270 nm), m/z=536 [M+H]. Total run time
3.75 min (short pos).
[0208] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.21 (s, 3H), 2.33 (br
m, 4H), 3.53-3.56 (br m, 4H) 0.33 (s, 2H), 7.13 (dd, 1H), 7.31 (m,
6H), 7.53 (d, 1H), 7.61 (s, 2H), 8.10 (s, 1H), 8.14 (d, 1H), 8.58
(d, 1H), 10.31 (s, 1H), 11.72 (s, 1H), 12.5 (s, 1H).
Example 16:
6-Oxo-5-(5-piperazin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridine-3-car-
boxylic Acid (1-benzyl-1H-pyrazol-4-yl)-amide
##STR00042##
[0210] The title compound was prepared by the route outlined in
Scheme 4.
Step 1: Preparation of Indole-2-boronic
Acid-5-(4-tert-butoxycarbonyl-piperazin-1-ylmethyl)-indole-1-carboxylic
Acid tert-butyl ester (4a)
[0211] To a stirred solution of indole-5-carboxaldehyde (2 g, 13.8
mmol) in toluene (10 mL) was added 4-dimethylaminopyridine (1 mol
%, 10 mg) and di-tert-butyl dicarbonate (3.14 g, 14.5 mmol) and the
mixture stirred at ambient temperature for 30 minutes. After this
time, tert-butyl piperazine-1-carboxylate (2.56 g, 13.8 mmol) was
added followed by sodium triacetoxyborohydride (4.44 g, 20.7 mmol)
in portions. After stirring for 90 minutes, a 2.5% v/v solution of
acetic acid in water (10 mL) was added, stirred briefly and the
organic layer separated. This layer was washed with water (50 mL)
and concentrated to near dryness. Methanol (50 mL) was added and
the reaction concentrated to dryness. The residue was triturated
with toluene and the liquors concentrated to dryness to yield the
protected indole. This residue was dissolved in anhydrous
tetrahydrofuran (6 mL).
[0212] This solution was added via syringe into a nitrogen-purged
flask and cooled to 5.degree. C. Triisopropyl borate (4.77 mL, 20.7
mmol) was added, followed by slow addition of lithium
diisopropylamide solution 2M in tetrahydrofuran (8.95 mL, 17.9
mmol), ensuring the temperature remained between 0 and 5.degree. C.
The mixture was stirred at 5.degree. C. for one hour then quenched
by the addition of an aqueous 2M hydrochloric acid solution (2 mL).
The pH was adjusted to 7 with aqueous ammonia solution, the ice
bath removed and the resultant biphasic mixture stirred at ambient
temperature for 30 minutes. The organic layer was separated, dried
(MgSO.sub.4) and concentrated in vacuo to afford the title
compound, 6.34 g, quantitative.
Step 2: Preparation of
5-(4-tert-Butoxycarbonyl-piperazin-1-ylmethyl)-2-[5-methoxycarbonyl-2-oxo-
-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-ca-
rboxylic Acid tert-butyl ester (4b)
[0213] Intermediate (4a), indole-2-boronic
acid-5-(4-tert-butoxycarbonyl-piperazin-1-ylmethyl)-indole-1-carboxylic
acid tert-butyl ester (6.34 g, 13.8 mmol), potassium acetate (2.59
g, 26.4 mmol) and intermediate (1a),
5-iodo-6-(2-trimethylsilanyl-ethoxy)-nicotinic acid methyl ester
(3.51 g, 8.6 mmol) were dissolved in N,N-dimethylformamide (70 mL).
The reaction was degassed three times using alternating cycles of
vacuum and dry nitrogen and then
bis(triphenylphosphine)palladium(II) dichloride (0.45 g, 0.64 mmol)
was added. The mixture was again degassed then heated under a
nitrogen atmosphere at 60.degree. C. for one hour. The mixture was
cooled, concentrated to dryness and the residue was partitioned
between water and ethyl acetate. The organic layer was separated
and the aqueous was extracted with a further portion of ethyl
acetate. The combined ethyl acetate layers were dried
(Na.sub.2SO.sub.4) and concentrated in vacuo. The resultant crude
product was purified by flash chromatography on SiO.sub.2 eluting
with hexane-20% ethyl acetate/hexane (gradient) to afford the
desired title compound as a copper coloured solid, 2.4 g, 40%.
Step 3: Preparation of
5-(4-tert-Butoxycarbonyl-piperazin-1-ylmethyl)-2-[5-carboxy-2-oxo-1-(2-tr-
imethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic
Acid tert-butyl ester (4c)
[0214] The title compound was prepared according to the
experimental used in Example 1, Step 3 with intermediate (4b),
5-(4-tert-butoxycarbonyl-piperazin-1-ylmethyl)-2-[5-methoxycarbonyl-2-oxo-
-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-ca-
rboxylic acid tert-butyl ester. After the usual work up, the title
compound was isolated as a brown foam, 2.35 g, quantitative.
Step 4: Preparation of
2-[5-(1-Benzyl-1H-pyrazol-4-ylcarbamoyl)-2-oxo-1-(2-trimethylsilanyl-etho-
xymethyl)-1,2-dihydro-pyridin-3-yl]-5-(4-tert-butoxycarbonyl-piperazin-1-y-
lmethyl)-indole-1-carboxylic Acid tert-butyl ester (4d)
[0215] Intermediate (4c),
5-(4-tert-butoxycarbonyl-piperazin-1-ylmethyl)-2-[5-carboxy-2-oxo-1-(2-tr-
imethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic
acid tert-butyl ester, (1 g, 1.46 mmol), benzyl-1H-pyrazole-4-yl
amine (0.75 g, 4.39 mmol), 1-hydroxybenzotriazole hydrate (0.59 g,
4.39 mmol) and tetrahydrofuran (15 mL) were placed in a microwave
vial. To this solution was added N,N-diisopropylethylamine (0.58 g,
0.78 mL, 4.49 mmol) and
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.84
g, 4.39 mmol), the vial capped and heated in the microwave at
90.degree. C. for 30 minutes. After cooling, the mixture was
concentrated in vacuo and the residue partitioned between water and
dichloromethane. The organic layer was separated and the aqueous
was extracted with a further portion of dichloromethane. The
combined dichloromethane layers were dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. The resultant crude product was purified by
flash chromatography on SiO.sub.2 eluting with dichloromethane-15%
methanol/dichloromethane (gradient) to afford the desired title
compound as a yellow foam, 1.0 g, 82%.
Step 5: Preparation of Title Compound
6-Oxo-5-(5-piperazin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridine-3-car-
boxylic Acid (1-benzyl-1H-pyrazol-4-yl)-amide
[0216] To a solution of intermediate (4d),
2-[5-(1-benzyl-1H-pyrazol-4-ylcarbamoyl)-2-oxo-1-(2-trimethylsilanyl-etho-
xymethyl)-1,2-dihydro-pyridin-3-yl]-5-(4-tert-butoxycarbonyl-piperazin-1-y-
lmethyl)-indole-1-carboxylic acid tert-butyl ester, 120 mg, 0.14
mmol) in methanol (4 mL) was added hydrochloric acid, 37% (0.75
mL). The mixture was heated at 90.degree. C. for 3 hours. The
reaction was allowed to attain ambient temperature and the pH
adjusted to 7 by the careful addition of ammonia solution 7N in
methanol. The mixture was concentrated in vacuo and the resultant
crude residue was purified via preparative HPLC at pH9, to furnish
the title compound as a yellow solid, 1.83 mg, 3%.
[0217] LC/MS: RT=1.59 Min (270 nm), m/z=508 [M+H]+. Total run time
3.75 min (short pos).
[0218] .sup.1H NMR (d.sub.4 MeOD): .delta. 2.71 (br t, 4H), 3.18
(t, 4H), 3.70 (s, 2H), 5.32 (s, 2H), 7.13 (m, 2H), 7.29 (m, 5H),
7.41 (d, 1H), 7.50 (br s, 1H), 7.68 (s, 1H), 8.07 (s, 2H), 8.45 (s,
1H), 8.57 (d, 1H), NHs not seen.
Example 17:
5-(1H-Indol-2-yl)-2-methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic
Acid (1-benzyl-1H-pyrazol-4-yl)-amide
##STR00043##
[0220] The title compound was prepared by the route outlined in
Scheme 5.
Step 1: Preparation of
(E)-4-[1-Amino-eth-(Z)-ylidene]-pent-2-enedioic Acid diethyl ester
(5a)
[0221] Ethyl propiolate (39.2 g, 41 mL, 400 mmol) was added to
ethyl 3-aminocrotonate (51.75 g, 400 mmol) and the mixture heated
at 90.degree. C. for 90 minutes to give a dark red oil. The mixture
was allowed to cool, to give the product as a dark orange solid,
87.0 g (96%).
Step 2: Preparation of
2-Methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid ethyl ester
(5b)
[0222] A solution of intermediate (5a),
(E)-4-[1-amino-eth-(Z)-ylidene]-pent-2-enedioic acid diethyl ester
(51 g, 225 mmol) in N,N-dimethylformamide (250 mL) was heated at
175.degree. C. for 24 hours to give a dark brown solution. The
resulting solution was allowed to cool and a pale brown precipitate
slowly formed. The precipitate was removed by filtration and the
solids washed with dichloromethane (75 mL) and hexane (100 mL) to
give a pale yellow powder. The solids were dried in vacuo
(60.degree. C.) to give the title compound as a pale yellow powder,
14.45 g (36%)
Step 3: Preparation of
5-Iodo-2-methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid ethyl
ester (5c)
[0223] N-Iodosuccinimide (40 g, 180 mmol) was added to a suspension
of intermediate (5b),
2-methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid ethyl ester
(18.1 g, 100 mmol) in acetonitrile (400 mL), under a nitrogen
atmosphere. The resulting suspension was heated at 95.degree. C.
for 5 hours to give an initial orange solution. An off-white
precipitate slowly formed. The resulting suspension was allowed to
cool and was poured into water (1200 mL) to give an off-white
precipitate. The separated by filtration and the solids washed with
water (500 mL) to give an off-white powder. The solids were dried
in vacuo (60.degree. C.) to give the product as an off-white
powder, 28.3 g (92%)
Step 4: Preparation of
5-Iodo-2-methyl-6-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,6-dihydro-pyr-
idine-3-carboxylic Acid ethyl ester (5d)
[0224] The title compound was prepared according to the
experimental used in Example 1, Step 1 using intermediate (5c),
5-iodo-2-methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid ethyl
ester. After the usual work up, the resultant crude product was
purified by flash chromatography on SiO.sub.2 eluting with 20%
ethyl acetate/hexane, to give the product as a yellow/green oil,
30.5 g (76%)
Step 5: Preparation of
2-Methyl-5-(1-methyl-1H-indol-2-yl)-6-oxo-1-(2-trimethylsilanyl-ethoxymet-
hyl)-1,6-dihydro-pyridine-3-carboxylic Acid ethyl ester. (5e)
[0225] A microwave vial (20 mL) was charged with intermediate (5d),
5-iodo-methyl-6-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,6-dihydro-pyrid-
ine-3-carboxylic acid ethyl ester (0.87 g, 1.99 mmol), potassium
carbonate (0.825 g, 5.97 mmol), 1-(tert-butoxycarbonyl)
indole-2-boronic acid (0.624 g, 2.39 mmol),
[1,1'-Bis(diphenylphosphino)ferrocene)]dichloropalladium(II),
complex with dichloromethane (0.082 g, 5 mol %), tetrahydrofuran
(14 mL) and water (2.3 mL). The contents of the vial were degassed
and then heated at 60.degree. C. for 1 hour under microwave
irradiation. After cooling, the reaction mixture was partitioned
between brine (50 mL) and ethyl acetate (50 mL). The organic layer
was separated, dried (Na.sub.2SO.sub.4) and concentrated in vacuo.
The resultant crude product was purified by flash chromatography on
SiO.sub.2 with hexane-15% ethyl acetate/hexane (gradient) to afford
the title compound as a yellow foam, 1.02 g, 97%.
Step 6: Preparation of
2-Methyl-5-(1-methyl-1H-indol-2-yl)-6-oxo-1-(2-trimethylsilanyl-ethoxymet-
hyl)-1,6-dihydro-pyridine-3-carboxylic Acid (5f)
[0226] The title compound was prepared according to the
experimental used in Example 1, Step 3 using intermediate (5e),
2-methyl-5-(1-methyl-1H-indol-2-yl)-6-oxo-1-(2-trimethylsilanyl-ethoxymet-
hyl)-1,6-dihydro-pyridine-3-carboxylic acid ethyl ester. After the
usual work up, the title compound was isolated as a yellow solid,
419 mg, 92%.
Step 7: Preparation of
2-Methyl-5-(1-methyl-1H-indol-2-yl)-6-oxo-1-(2-trimethylsilanyl-ethoxymet-
hyl)-1,6-dihydro-pyridine-3-carboxylic Acid
(1-benzyl-1H-pyrazol-4-yl)-amide (5 g)
[0227] The title compound was prepared according to the
experimental used in Example 16, Step 4 with intermediate (5f),
2-methyl-5-(1-methyl-1H-indol-2-yl)-6-oxo-1-(2-trimethylsilanyl-ethoxymet-
hyl)-1,6-dihydro-pyridine-3-carboxylic acid. After the usual work
up, the crude product was purified by flash chromatography on
SiO.sub.2 eluting with hexane-33% ethyl acetate/hexane (gradient)
to afford the desired title compound as a yellow solid, 110 mg,
84%.
Step 8: Preparation of the Title Compound:
5-(1H-Indol-2-yl)-2-methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic
Acid (1-benzyl-1H-pyrazol-4-yl)-amide
[0228] The title compound was prepared according to the
experimental used in Example 1, Step 5 with intermediate (5 g),
2-methyl-5-(1-methyl-1H-indol-2-yl)-6-oxo-1-(2-trimethylsilanyl-ethoxymet-
hyl)-1,6-dihydro-pyridine-3-carboxylic acid
(1-benzyl-1H-pyrazol-4-yl)-amide. Purification of the crude product
was accomplished using trituration with acetonitrile. The title
compound was isolated as a yellow solid, 14 mg, 20%.
[0229] LC/MS: RT=2.29 Min (270 nm), m/z=424 [M+H]. Total run time
3.75 min (short pos).
[0230] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.46 (s, 3H), 5.32 (s,
2H), 6.97 (t, 1H), 7.07 (t, 1H), 7.22-7.38 (m, 6H), 7.47 (d, 1H),
7.52 (d, 1H), 7.57 (s, 1H), 8.10 (s, 1H), 8.26 (s, 1H), 10.31 (s,
1H), 11.39 (s, 1H), 12.28 (br s, 1H).
Example 18:
5-(1H-Indol-2-yl)-2-methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic
Acid [1-(3-fluoro-benzyl)-1H-pyrazol-4-yl]-amide
##STR00044##
[0232] The title compound was prepared by the route outlined in
Scheme 5, following the same procedures as for Example 17.
[0233] LC/MS: RT=2.28 Min (270 nm), m/z=442 [M+H]. Total run time
3.75 min (short pos).
[0234] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.47 (s, 3H), 5.35 (s,
2H), 6.97-7.16 (m, 5H), 7.21 (s, 1H), 7.40 (m, 1H), 7.47 (d, 1H),
7.52 (d, 1H), 7.59 (s, 1H), 8.16 (s, 1H), 8.27 (s, 1H), 10.33 (s,
1H), 11.39 (s, 1H), 12.28 (br s, 1H).
Example 19:
5-(1H-Indol-2-yl)-2-methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic
Acid [1-(3,4-difluoro-benzyl)-1H-pyrazol-4-yl]-amide
##STR00045##
[0236] The title compound was prepared by the route outlined in
Scheme 5, following the same procedures as for Example 17.
[0237] LC/MS: RT=2.32 Min (270 nm), m/z=460 [M+H]. Total run time
3.75 min (short pos).
[0238] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.47 (s, 3H), 5.32 (s,
2H), 6.98-7.59 (m, 9H), 8.17 (s, 1H), 8.26 (s, 1H), 10.33 (s, 1H),
11.39 (s, 1H), 12.28 (br s, 1H).
Example 20: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00046##
[0240] The title compound was prepared by the route outlined in
Scheme 6.
Step 1: Preparation of
3-Iodo-5-nitro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyridin-2-one
(6a)
[0241] The title compound was prepared according to the
experimental used in Example 1, Step 1 using
2-hydroxy-3-iodo-5-nitro pyridine. After the usual work up, the
resultant crude product was purified by flash chromatography on
SiO.sub.2 eluting first with hexane and then 20% ethyl
acetate/hexane to firstly afford the undesired oxygen substituted
compound and then the desired title compound as a yellow oil, 4.36
g, 59%.
Step 2: Preparation of
2-[5-Nitro-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin--
3-yl]-indole-1-carboxylic Acid tert-butyl ester (6b)
[0242] The title compound was prepared according to the
experimental used in Example 17, Step 5 using intermediate (6a),
3-iodo-5-nitro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyridin-2-one.
[0243] After the usual work up, the crude product was purified by
flash chromatography on SiO.sub.2 eluting with hexane-20% ethyl
acetate/hexane (gradient) to afford the desired title compound as
an oil 0.523 g, 64%.
Step 3: Preparation of
2-[5-Amino-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin--
3-yl]-indole-1-carboxylic Acid tert-butyl ester (6c)
[0244] A round bottom flask was charged with intermediate (6b),
2-[5-nitro-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin--
3-yl]-indole-1-carboxylic acid tert-butyl ester (0.485 g, 1 mmol),
tetrahydrofuran (5 mL) and palladium acetate (11 mg, 5 mol %). The
flask was sealed and purged with nitrogen. While purging the flask
with nitrogen, a solution of potassium fluoride (116 mg, 2 mmol) in
water (2 mL), which had been thoroughly degassed, was added via
syringe. The nitrogen inlet was removed and replaced with a balloon
of nitrogen. Poly(methylhydrosiloxane) (0.44 mL) was added drop
wise and the reaction was stirred at ambient temperature for 18
hours. The reaction mixture was diluted with dichloromethane (20
mL) and aqueous saturated sodium bicarbonate solution (20 mL). The
organic layer was separated, filtered through a bed of celite and
concentrated in vacuo. The resultant crude product was purified by
flash chromatography on SiO.sub.2 eluting with hexane-50% ethyl
acetate/hexane (gradient) to afford the desired title compound as a
brown solid 0.308 g, 67%.
Step 4: Preparation of
2-[5-[(1-Benzyl-1H-pyrazole-4-carbonyl)-amino]-2-oxo-1-(2-trimethylsilany-
l-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic Acid
tert-butyl ester (6d)
[0245] To a solution of (6c),
2-[5-amino-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin--
3-yl]-indole-1-carboxylic acid tert-butyl ester (0.3 g, 0.659 mmol)
in acetonitrile (10 mL) was added 1-benzyl-1H-pyrazole-4-carboxylic
acid (0.111 g, 0.549 mmol) and triethylamine (0.133 g, 0.184 mL,
1.32 mmol).
O-benzotriazole-N,N,N',N'-tetramethyluroniumhexafluorophosphate
(0.312 g, 0.823 mmol) was added last and the reaction mixture was
stirred at ambient temperature for 18 hours. The reaction mixture
was concentrated in vacuo and the residue was partitioned between
ethyl acetate (25 mL) and aqueous saturated sodium hydrogen
carbonate solution (20 mL). The organic layer was separated and the
aqueous was extracted with a further portion of ethyl acetate (25
mL). The combined ethyl acetate layers were washed with brine,
dried (Na.sub.2SO.sub.4) and concentrated in vacuo. The resultant
crude product was purified by flash chromatography on SiO.sub.2
eluting with hexane-35% ethyl acetate/hexane-50% ethyl
acetate/hexane (gradient) to afford the desired title compound as a
light brown solid, 0.246 g, 70%.
Step 5: Preparation of the Title Compound:
1-Benzyl-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
[0246] The title compound was prepared according to the
experimental used in Example 1, Step 5 with intermediate (6d),
2-[5-[(1-benzyl-1H-pyrazole-4-carbonyl)-amino]-2-oxo-1-(2-trimethylsilany-
l-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic acid
tert-butyl ester.
[0247] The resultant crude product was purified by trituration with
acetonitrile, to afford the title compound as a yellow solid, 64
mg, 42%.
[0248] LC/MS: RT=2.16 Min (270 nm), m/z=410 [M+H]. Total run time
3.75 min (short pos).
[0249] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.41 (s, 2H), 6.99 (t,
1H), 7.06-7.10 (m, 2H), 7.29-7.41 (m, 5H), 7.52 (t, 2H), 7.81 (d,
1H), 8.03 (s, 1H), 8.18 (d, 1H), 8.40 (s, 1H), 9.77 (s, 1H), 11.54
(s, 1H), 11.98 (br s, 1H).
Example 21: 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00047##
[0251] The title compound was prepared by the route outlined in
Scheme 6, following the same procedures as for Example 20, but
using intermediate (6e) in Step 4.
Preparation of 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic Acid
(6e)
[0252] 1H-Pyrazole-4-carboxylic acid ethyl ester (1 g, 7.14 mmol)
was stirred in acetone (15 mL) with potassium carbonate (4.93 g,
35.7 mmol) and 4-fluorobenzyl bromide (1.62 g, 0.746 mL, 8.56 mmol)
was added. The reaction was heated at 50.degree. C. for 4 hours.
The reaction was cooled and the inorganics were separated via
filtration. The filter cake was washed through with ethyl acetate
(2.times.10 mL) and the combined washings and filtrate were
concentrated in vacuo.
[0253] The residue was refluxed in methanol (10 mL) containing
potassium hydroxide (0.8 g, 14.28 mmol), for 18 hours. The reaction
was cooled and concentrated in vacuo. The residue was dissolved in
H.sub.2O and washed with dichloromethane. The aqueous layer was
separated and carefully acidified using an aqueous 6N hydrochloric
acid solution. The resulting precipitate was filtered, washed with
copious amounts of water and dried in vacuo to afford the title
compound, 1.05 g, 67%.
[0254] The title compound, Example 21, was purified by trituration
with acetonitrile, and isolated as a green solid, 80 mg, 51%.
[0255] LC/MS: RT=1.14 Min (270 nm), m/z=428 [M+H]. Total run time
1.9 min (super short pos).
[0256] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.44 (s, 2H), 6.96-7.01
(m, 1H), 7.05-7.20 (m, 5H), 7.40-7.47 (m, 1H), 7.49-7.55 (m, 2H),
7.80-7.84 (m, 1H), 8.06 (s, 1H), 8.18 (d, 1H), 8.44 (s, 1H), 9.80
(s, 1H), 11.56 (br s, 1H), 12.01 (br s, 1H).
Example 22: 1-(3-Fluoro-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00048##
[0258] The title compound was prepared by the route outlined in
Scheme 6, following the same experimental procedures as for
Examples 20 and 21.
[0259] LC/MS: RT=1.14 Min (270 nm), m/z=428 [M+H]. Total run time
1.9 min (super short pos).
[0260] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.44 (s, 2H), 6.96-7.01
(m, 1H), 7.05-7.22 (m, 5H), 7.40-7.47 (m, 1H), 7.50-7.55 (m, 2H),
7.82 (m, 1H), 8.06 (s, 1H), 8.19 (d, 1H), 8.45 (s, 1H), 9.81 (s,
1H), 11.56 (br s, 1H), 12.02 (br s, 1H).
Example 23: 1-(3-Trifluoromethyl-benzyl)-1H-pyrazole-4-carboxylic
Acid [5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00049##
[0262] The title compound was prepared by the route outlined in
Scheme 6, following the same experimental procedures as for
Examples 20 and 21.
[0263] LC/MS: RT=1.21 Min (270 nm), m/z=478 [M+H]. Total run time
1.9 min (super short pos).
[0264] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.53 (s, 2H), 6.96-7.01
(m, 1H), 7.05-7.10 (m, 2H), 7.49-7.72 (m, 6H), 7.80-7.84 (m, 1H),
8.07 (s, 1H), 8.18 (d, 1H), 8.48 (s, 1H), 9.80 (s, 1H), 11.56 (br
s, 1H), 12.02 (br s, 1H).
Example 24: 1-(3,4-Difluoro-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00050##
[0266] The title compound was prepared by the route outlined in
Scheme 6, following the same experimental procedures as for
Examples 20 and 21.
[0267] LC/MS: RT=1.16 Min (270 nm), m/z=446 [M+H]. Total run time
1.9 min (super short pos).
[0268] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.41 (s, 2H), 6.96-7.01
(m, 1H), 7.05-7.10 (m, 2H), 7.12-7.18 (m, 1H), 7.37-7.55 (m, 4H),
7.81 (d, 1H), 8.05 (s, 1H), 8.19 (d, 1H), 8.44 (s, 1H), 9.80 (s,
1H), 11.56 (br s, 1H), 12.01 (br s, 1H).
Example 25: 1-(4-Trifluoromethyl-benzyl)-1H-pyrazole-4-carboxylic
Acid [5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00051##
[0270] The title compound was prepared by the route outlined in
Scheme 6, following the same experimental procedures as for
Examples 20 and 21.
[0271] LC/MS: RT=1.21 Min (270 nm), m/z=478 [M+H]. Total run time
1.9 min (super short pos).
[0272] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.54 (s, 2H), 6.95-7.01
(m, 1H), 7.05-7.10 (m, 2H), 7.44-7.56 (m, 4H), 7.76 (d, 2H), 8.08
(s, 1H), 8.19 (d, 1H), 8.48 (s, 1H), 9.82 (s, 1H), 11.56 (br s,
1H), 11.91 (br s, 1H), NH not seen.
Example 26: 1-(3-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00052##
[0274] The title compound was prepared by the route outlined in
Scheme 6, following the same experimental procedures as for
Examples 20 and 21.
[0275] LC/MS: RT=2.29 Min (270 nm), m/z=424 [M+H]. Total run time
3.75 min (short pos).
[0276] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.30 (s, 3H), 5.36 (s,
2H), 6.95-7.01 (m, 1H), 7.04-7.17 (m, 5H), 7.24-7.29 (m, 1H),
7.48-7.56 (m, 2H), 7.81 (s, 1H), 8.04 (s, 1H), 8.18 (d, 1H), 8.39
(s, 1H), 9.78 (s, 1H), 11.55 (br s, 1H), 12.01 (br s, 1H).
Example 27: 1-(3-Chloro-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00053##
[0278] The title compound was prepared by the route outlined in
Scheme 6, following the same experimental procedures as for
Examples 20 and 21.
[0279] LC/MS: RT=2.31 Min (270 nm), m/z=444, 446 [M+H]. Total run
time 3.75 min (short pos).
[0280] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.43 (s, 2H), 6.95-7.11
(m, 3H), 7.22-7.28 (m, 1H), 7.34-7.57 (m, 5H), 7.81 (d, 1H), 8.06
(s, 1H), 8.19 (d, 1H), 8.45 (s, 1H), 9.81 (s, 1H), 11.56 (br s,
1H), 12.02 (br s, 1H).
Example 28: 1-(4-Chloro-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00054##
[0282] The title compound was prepared by the route outlined in
Scheme 6, following the same experimental procedures as for
Examples 20 and 21.
[0283] LC/MS: RT=2.31 Min (270 nm), m/z=444, 446 [M+H]. Total run
time 3.75 min (short pos).
[0284] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.41 (s, 2H), 6.96-7.11
(m, 3H), 7.29-7.34 (m, 2H), 7.43-7.56 (m, 4H), 7.81 (d, 1H), 8.05
(s, 1H), 8.18 (d, 1H), 8.42 (s, 1H), 9.80 (s, 1H), 11.56 (br s,
1H), 12.02 (br s, 1H).
Example 29: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00055##
[0286] The title compound was prepared by the route outlined in
Scheme 6, following the same experimental procedures as for
Examples 20 and 21.
[0287] LC/MS: RT=2.28 Min (270 nm), m/z=424 [M+H]. Total run time
3.75 min (short pos).
[0288] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.29 (s, 3H), 5.35 (s,
2H), 6.94-7.11 (m, 3H), 7.19 (m, 4H), 7.48-7.56 (m, 2H), 7.81 (d,
1H), 8.02 (s, 1H), 8.18 (d, 1H), 8.37 (s, 1H), 9.77 (s, 1H), 11.56
(br s, 1H), 12.01 (br s, 1H).
Example 30: 1-(3-Fluoro-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-2-methyl-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00056##
[0290] The title compound was prepared by the route outlined in
Scheme 7.
Step 1: Preparation of 3-Iodo-6-methyl-5-nitro-1H-pyridin-2-one
(7a)
[0291] The title compound was prepared according to the
experimental used in Example 17, Step 3 using
2-hydroxy-6-methyl-5-nitropyridine. The usual work up afforded the
title compound as a pale yellow solid, 4.95 g, 81%.
Step 2: Preparation of
3-Iodo-6-methyl-5-nitro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyridin-2--
one (7b)
[0292] The title compound was prepared according to the
experimental used in Example 1, Step 1, using intermediate (7a),
3-iodo-6-methyl-5-nitro-1H-pyridin-2-one. After the usual work up,
the crude product was purified by flash chromatography on SiO.sub.2
eluting first with hexane and then 10% ethyl acetate/hexane to
firstly afford the undesired oxygen substituted compound and then
the desired title compound as a yellow oil, 3.6 g, 42%.
Step 3: Preparation of
2-[6-Methyl-5-nitro-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-
-pyridin-3-yl]-indole-1-carboxylic Acid tert-butyl ester (7c)
[0293] The title compound was prepared according to the
experimental used in Example 17, Step 5, with intermediate 7(b),
3-iodo-6-methyl-5-nitro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyridin-2--
one. After the usual work up, the crude product was purified by
flash chromatography on SiO.sub.2 with hexane-10% ethyl
acetate/hexane (gradient) to afford the title compound as a cream
coloured solid, 3.46 g, 72%.
Step 4: Preparation of
2-[5-Amino-6-methyl-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-
-pyridin-3-yl]-indole-1-carboxylic Acid tert-butyl ester (7d)
[0294] The title compound was prepared according to the
experimental used in Example 20, Step 3 with intermediate (7c),
2-[6-methyl-5-nitro-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-
-pyridin-3-yl]-indole-1-carboxylic acid tert-butyl ester. After the
usual work up, the crude product was purified by flash
chromatography on SiO.sub.2 with hexane-65% ethyl acetate/hexane
(gradient) to afford the title compound as a yellow foam, 2.27 g,
83%.
Step 5: Preparation of
2-[5-{[1-(3-Fluoro-benzyl)-1H-pyrazole-4-carbonyl]-amino}-6-methyl-2-oxo--
1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-car-
boxylic Acid tert-butyl ester (7e)
[0295] The title compound was prepared according to the
experimental used in Example 20, Step 4 with intermediate (7d),
2-[5-amino-6-methyl-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-
pyridin-3-yl]-indole-1-carboxylic acid tert-butyl ester, and
1-(3-Fluoro-benzyl)-1H-pyrazole-4-carboxylic acid, which was
synthesised according to the protocol described for intermediate
(6e) in Example 21. The resultant crude product was purified by
flash chromatography on SiO.sub.2 with hexane-50% ethyl
acetate/hexane (gradient) to afford the title compound as a yellow
oil, 80 mg, 70%.
Step 6: Preparation of the Title Compound:
1-(3-Fluoro-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-2-methyl-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
[0296] The title compound was prepared according to the
experimental from Example 1, Step 5, with intermediate (7e),
2-[5-{[1-(3-fluoro-benzyl)-1H-pyrazole-4-carbonyl]-amino}-6-methyl-2-oxo--
1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-car-
boxylic acid tert-butyl ester. The title compound was purified by
trituration with acetonitrile, and isolated as a pale green solid,
8 mg, 15%.
[0297] LC/MS: RT=1.93 Min (270 nm), m/z=442 [M+H]. Total run time
3.75 min (short pos).
[0298] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.18 (s, 3H), 5.45 (s,
2H) 6.95-7.01 (m, 1H), 7.04-7.1 (m, 1H), 7.12-7.22 (m, 4H),
7.42-7.56 (m, 3H), 7.99 (s, 1H), 8.07 (s, 1H), 8.46 (s, 1H), 9.57
(s, 1H), 11.45 (br s, 1H), 12.18 (br s, 1H).
Example 31: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-2-methyl-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00057##
[0300] The title compound was prepared by the route outlined in
Scheme 7, following the same procedures as for Example 30.
[0301] LC/MS: RT=2.15 Min (270 nm), m/z=424 [M+H]. Total run time
3.75 min (short pos).
[0302] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.16 (s, 3H), 5.40 (s,
2H), 6.96 (t, 1H), 7.05 (t, 1H), 7.16 (s, 1H), 7.29-7.40 (m, 5H),
7.44 (d, 1H), 7.49 (d, 1H), 7.96 (s, 1H), 8.03 (s, 1H), 8.40 (s,
1H), 9.50 (s, 1H), 11.42 (s, 1H), 12.14 (br s, 1H).
Example 32: 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-2-methyl-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00058##
[0304] The title compound was prepared by the route outlined in
Scheme 7, following the same procedures as for Example 30.
[0305] LC/MS: RT=2.18 Min (270 nm), m/z=442 [M+H]. Total run time
3.75 min (short pos).
[0306] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.16 (s, 3H), 5.40 (s,
2H), 6.96 (t, 1H), 7.05 (t, 1H), 7.16 (s, 1H), 7.19-7.39 (m, 4H),
7.44 (d, 1H), 7.49 (d, 1H), 7.95 (s, 1H), 8.03 (s, 1H), 8.40 (s,
1H), 9.50 (s, 1H), 11.42 (s, 1H), 12.14 (br s, 1H).
Example 33: 1-(3,4-Difluoro-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-2-methyl-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00059##
[0308] The title compound was prepared by the route outlined in
Scheme 7, following the same procedures as for Example 30.
[0309] LC/MS: RT=2.21 Min (270 nm), m/z=460 [M+H]. Total run time
3.75 min (short pos).
[0310] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.16 (s, 3H), 5.40 (s,
2H), 6.96 (t, 1H), 7.05 (t, 1H), 7.16 (m, 2H), 7.38-7.50 (m, 4H),
7.96 (s, 1H), 8.05 (s, 1H), 8.42 (s, 1H), 9.52 (s, 1H), 11.43 (s,
1H), 12.15 (br s, 1H).
Example 34:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
(1-cyclohexylmethyl-1H-pyrazol-4-yl)-amide
##STR00060##
[0312] The title compound was prepared according to the general
route outlined in Scheme 1.
[0313] LC/MS: RT=2.20 Min (270 nm), m/z=416 [M+H]. Total run time
3.75 min (short pos).
[0314] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.92-1.02 (m, 2H),
1.15-1.26 (m, 3H) 1.53 (d, 2H), 1.6-1.72 (m, 3H), 1.75-1.85 (m,
1H), 3.95 (d, 2H), 6.99-7.03 (m, 1H), 7.09-7.13 (m, 1H), 7.28 (d,
1H), 7.51 (d, 1H), 7.56-7.59 (m, 2H), 7.99 (s, 1H), 8.13 (br s,
1H), 8.59 (d, 1H), 10.28 (br s, 1H), 11.52 (br s, 1H), 12.49 (br s,
1H).
Example 35:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
(1-pyridin-3-ylmethyl-1H-pyrazol-4-yl)-amide
##STR00061##
[0316] The title compound was prepared according to the general
route outlined in Scheme 1.
[0317] LC/MS: RT=1.83 Min (270 nm), m/z=409 [M-H]. Total run time
3.75 min (short pos/neg).
[0318] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.38 (s, 2H), 6.98 (td,
1H), 7.10 (td, 1H), 7.24 (d, 1H), 7.38 (ddd, 1H), 7.48 (dd, 1H),
7.54 (d, 1H), 7.62 (d, 1H), 7.65 (dt, 1H), 8.11 (d, 1H), 8.17 (s,
1H), 8.51 (m, 2H), 8.56 (d, 1H), 10.31 (s, 1H), 11.52 (br s, 1H),
12.50 (br s, 1H).
Example 36:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
(1-pyridin-4-ylmethyl-1H-pyrazol-4-yl)-amide
##STR00062##
[0320] The title compound was prepared according to the general
route outlined in Scheme 1.
[0321] LC/MS: RT=1.78 Min (270 nm), m/z=411 [M+H]. Total run time
3.75 min (short pos/neg).
[0322] .sup.1H NMR (d.sub.6 DMSO): .delta. 5.41 (s, 2H), 6.98 (td,
1H), 7.09 (t, 1H), 7.12 (d, 2H), 7.25 (d, 1H), 7.48 (d, 1H), 7.54
(d, 1H), 7.66 (s, 1H), 8.13 (d, 1H), 8.19 (s, 1H), 8.53 (m, 2H),
8.55 (d, 1H), 10.34 (s, 1H), 11.53 (br s, 1H), 12.45 (br s, 1H)
Example 37: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic acid
{5-[5-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00063##
[0324] The title compound was prepared according to the route
outlined in Scheme 8.
Step 1: Preparation of (1H-Indol-5-yl)-methanol (8a)
[0325] To a mechanically stirred solution of indole-5-carboxylic
Acid (26.3 g, 163 mmol) in tetrahydrofuran (600 mL), was added a
solution of lithium aluminium hydride 1.0M in tetrahydrofuran (200
mL, 200 mmol) drop wise at ambient temperature. A solution of
lithium aluminium hydride 2.0M in tetrahydrofuran (22 mL, 44 mmol)
was added drop wise at ambient temperature, and then the reaction
mixture was carefully heated up to reflux and held there for 1
hour. The reaction mixture was cooled to ambient temperature and
then water (13 mL) was added drop wise, followed by an aqueous 10%
sodium hydroxide solution (13 mL), and water (20 mL). The
suspension was stirred at ambient temperature for 30 minutes,
filtered through a bed of celite and the filter cake washed with
ethyl acetate (2.times.200 mL). The filtrate and the washings were
combined and the organics were separated, dried (Na.sub.2SO.sub.4)
and concentrated in vacuo, to give a dark red oil. The resultant
crude product was suspended in hexane (200 mL), and ethyl acetate
(10 mL) was added. This mixture was stirred at ambient temperature
for 18 hours, and the solids were separated via filtration and
washed with hexane to afford the title compound as a light brown
solid, 22.25 g, 93%.
Step 2: Preparation of
5-(tert-Butyl-dimethyl-silanyloxymethyl)-indole-1-carboxylic Acid
tert-butyl ester (8b)
[0326] To a mechanically stirred solution of
(1H-Indol-5-yl)-methanol, (8a), (22.2 g, 151 mmol) in
dichloromethane (300 mL) at ambient temperature was added
N,N-diisopropylethylamine (39.0 g, 52.6 mL, 302 mmol) followed by a
solution of tert-butyldimethylsilyl chloride (25 g, 166 mmol) in
dichloromethane (400 mL). 4-Dimethylaminopyridine (1.84 g, 15.1
mmol) was added and the reaction was stirred at ambient temperature
for 2 hours. The reaction mixture was concentrated in vacuo and the
residue was taken up in ethyl acetate (400 mL), washed with an
aqueous 0.5N hydrochloric acid solution (600 mL), brine, dried
(Na.sub.2SO.sub.4) and concentrated in vacuo to yield a red
oil.
[0327] This red oil was dissolved in dichloromethane (350 mL) and
to this was added di-tert-butyl dicarbonate (36.2 g, 166 mmol) drop
wise at ambient temperature as a solution in dichloromethane (50
mL). 4-Dimethylaminopyridine (1.84 g, 15.1 mmol) was added and the
reaction stirred at ambient temperature for 2 hours. The reaction
mixture was concentrated in vacuo and the residue was taken up in
ethyl acetate (300 mL), washed with an aqueous 0.5N hydrochloric
acid solution (200 mL), brine, dried (Na.sub.2SO.sub.4) and
concentrated in vacuo to yield a light brown oil. The resultant
crude product was purified by flash chromatography on SiO.sub.2
eluting first with hexane and then 10% ethyl acetate/hexane to
afford the desired title compound as a white solid, 52.22 g,
96%.
Step 3: Preparation of
5-(tert-Butyl-dimethyl-silanyloxymethyl)-2-[3-nitro-6-oxo-5-(2-trimethyls-
ilanyl-ethoxymethyl)-cyclohexa-1,3-dienyl]-indole-1-carboxylic Acid
tert-butyl ester (8c)
[0328] To a solution of diisopropylamine (2.1 g, 2.89 mL, 20.8
mmol) in anhydrous tetrahydrofuran (10 mL) was added butyllithium
solution 2.5M in hexanes (7.71 mL, 19.3 mmol) drop wise at
-78.degree. C. After addition the reaction mixture was allowed to
attain 0.degree. C., where it was stirred for 30 minutes to form
the lithiumdiisopropyl amide solution.
5-(tert-Butyl-dimethyl-silanyloxymethyl)-indole-1-carboxylic acid
tert-butyl ester (8b) (5.89 g, 16.3 mmol) was stirred in
tetrahydrofuran (80 mL) and triisopropyl borate (4.18 g, 5.13 mL,
22.2 mmol) was added, and the reaction mixture was cooled to
-5.degree. C. To this was added the previously described
lithiumdiisopropyl amide solution drop wise keeping the temperature
between -5.degree. C. and 0.degree. C. After addition the reaction
was stirred at -5.degree. C. for 30 mins and then allowed to attain
ambient temperature. The reaction mixture was concentrated in vacuo
to yield crude indole-2-boronic
acid-5-(tert-Butyl-dimethyl-silanyloxymethyl)-indole-1-carboxylic
acid tert-butyl ester, which was dissolved in tetrahydrofuran (100
mL). Water (20 mL), potassium carbonate (6.17 g, 44.6 mmol),
3-iodo-5-nitro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyridin-2-one,
intermediate (6a) (5.87 g, 14.8 mmol) in tetrahydrofuran (20 mL)
and [1,1'-Bis(diphenylphosphino)ferrocene)]dichloropalladium(II),
complex with dichloromethane (0.605 g, 5 mol %) were added. The red
suspension was degassed for 10 minutes and then heated at
60.degree. C. for 2 hours. The reaction mixture was cooled and was
partitioned between ethyl acetate (200 mL) and aqueous saturated
sodium bicarbonate solution (200 mL). The organic layer was
separated and the aqueous was extracted with a further portion of
ethyl acetate. The combined ethyl acetate layers were washed with
brine, dried (Na.sub.2SO.sub.4), filtered through a plug of celite
and concentrated in vacuo. The resultant crude product was purified
by flash chromatography on SiO.sub.2 eluting with hexane-15% ethyl
acetate/hexane (gradient) to afford the desired title compound as a
yellow solid, 8.44 g, 90%.
Step 4: Preparation of
2-[5-Amino-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin--
3-yl]-5-(tert-butyl-dimethyl-silanyloxymethyl)-indole-1-carboxylic
Acid tert-butyl ester (8d)
[0329] The title compound was prepared by the route outlined in
Scheme 8 and using the experimental from Example 20, Step 3, with
intermediate (8c)
5-(tert-butyl-dimethyl-silanyloxymethyl)-2-[3-nitro-6-oxo-5-(2-trime-
thylsilanyl-ethoxymethyl)-cyclohexa-1,3-dienyl]-indole-1-carboxylic
acid tert-butyl ester (11.58 g, 18.4 mmol).
[0330] The resultant crude product was purified by flash
chromatography on SiO.sub.2 with hexane-50% ethyl acetate/hexane
(gradient) to afford the title compound as a dark yellow foam,
10.21 g, 93%.
Step 5: Preparation of
5-(tert-Butyl-dimethyl-silanyloxymethyl)-2-[5-{[1-(4-methyl-benzyl)-1H-py-
razole-4-carbonyl]-amino}-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-di-
hydro-pyridin-3-yl]-indole-1-carboxylic Acid tert-butyl ester
(8e)
[0331] The title compound was prepared by the route outlined in
Scheme 8 and using the experimental from Example 20, step 4, with
intermediate (8d),
2-[5-amino-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-py-
ridin-3-yl]-5-(tert-butyl-dimethyl-silanyloxymethyl)-indole-1-carboxylic
acid tert-butyl ester (1.0 g, 1.67 mmol) and
1-(4-methyl-benzyl)-1H-pyrazole-4-carboxylic acid (0.43 g, 1.99
mmol) which had been synthesised according to the protocol
described for intermediate (6e) in example 21.
[0332] The resultant crude product was purified by flash
chromatography on SiO.sub.2 with hexane-50% ethyl acetate/hexane
(gradient) to afford the title compound as a pink oil, 0.721 g,
54%.
Step 6: Preparation of
5-Formyl-2-[5-{[1-(4-methyl-benzyl)-1H-pyrazole-4-carbonyl]-amino}-2-oxo--
1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-car-
boxylic Acid tert-butyl ester (8f)
[0333] Intermediate 8(e),
5-(tert-butyl-dimethyl-silanyloxymethyl)-2-[5-{[1-(4-methyl-benzyl)-1H-py-
razole-4-carbonyl]-amino}-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-di-
hydro-pyridin-3-yl]-indole-1-carboxylic acid tert-butyl ester (0.72
g, 0.9 mmol) was stirred in tetrahydrofuran (20 mL) and cooled to
0.degree. C. Tetrabutylammonium fluoride solution 1.0M in
tetrahydrofuran (0.9 mL, 0.9 mmol) was added drop wise at 0.degree.
C., and then the reaction was allowed to attain ambient
temperature, where it was stirred for a further 2 hours. The
reaction mixture was diluted with ethyl acetate (30 mL), washed
with water (30 mL), aqueous 0.5N hydrochloric acid solution (30
mL), brine, dried (Na.sub.2SO.sub.4) and concentrated in vacuo to
yield a green foam.
[0334] This green foam was dissolved in anhydrous dichloromethane
(20 mL) and manganese dioxide (1.17 g, 13.5 mmol) was added. The
reaction was refluxed for 1 hour and, after cooling, the mixture
was filtered through a bed of celite. The filter cake was washed
through with tetrahydrofuran (20 mL) and the filtrate was
concentrated in vacuo. The resultant crude product was purified by
flash chromatography on SiO.sub.2 with hexane-50% ethyl
acetate/hexane (gradient) to afford the title compound as a tan
solid, 0.454 g, 74%.
Step 7: Preparation of
5-(4-Fluoro-piperidin-1-ylmethyl)-2-[5-{[1-(4-methyl-benzyl)-1H-pyrazole--
4-carbonyl]-amino}-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-p-
yridin-3-yl]-indole-1-carboxylic Acid tert-butyl ester (8 g)
[0335] To a solution of intermediate (8f),
5-Formyl-2-[5-{[1-(4-methyl-benzyl)-1H-pyrazole-4-carbonyl]-amino}-2-oxo--
1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-car-
boxylic acid tert-butyl ester, (150 mg, 0.22 mmol) in
dichloromethane (10 mL) was added 4-fluoropiperidine hydrochloride
(61 mg, 0.44 mmol), sodium triacetoxyborohydride (140 mg, 0.66
mmol) and acetic acid (1 drop). The reaction mixture was stirred at
ambient temperature for 3 hours and then diluted with ethyl
acetate. The mixture was washed with saturated aqueous sodium
bicarbonate solution, brine, dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. The resultant crude product was purified by
flash chromatography on SiO.sub.2 with hexane-ethyl acetate
(gradient) and then ion exchange using an SCX-2 column to afford
the title compound as a yellow solid, 96 mg, 57%.
Step 8: Preparation of the Title Compound:
1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
[0336] A 2-5 mL microwave vial was charged with intermediate (8 g),
5-(4-fluoro-piperidin-1-ylmethyl)-2-[5-{[1-(4-methyl-benzyl)-1H-pyrazole--
4carbonyl]amino}-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyr-
idin-3-yl]-indolecarboxylic acid tert-butyl ester (96 mg, 0.125
mmol), tetrahydrofuran (3 mL), 1,2-diaminoethane (38 mg, 42 ul,
0.63 mmol) and finally tetrabutylammonium fluoride solution 1.0M in
tetrahydrofuran (0.63 mL, 0.63 mmol).
[0337] The vial was heated under microwave irradiation at
120.degree. C. for 20 mins. After cooling, the reaction mixture was
diluted with ethyl acetate (20 mL) and washed with water
(4.times.20 mL) and brine (4.times.20 mL). The organics were dried
(Na.sub.2SO.sub.4) and concentrated in vacuo. The resultant yellow
solid was purified via trituration using acetonitrile, to afford
the title compound as a yellow solid, 42 mg, 63%.
[0338] LC/MS: RT=1.51 Min (270 nm), m/z=539 [M+H]. Total run time
3.75 min (short pos).
[0339] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.66-1.88 (m, 4H),
2.26-2.32 (m, 5H), 2.55 (m, 2H), 3.50 (s, 2H), 4.59-4.75 (m, 1H),
5.34 (s, 2H), 7.00-7.05 (m, 2H), 7.19 (m, 4H), 7.41 (s, 1H), 7.44
(d, 1H), 7.81 (d, 1H), 8.01 (s, 1H), 8.16 (d, 1H), 8.36 (s, 1H),
9.76 (s, 1H), 11.50 (s, 1H), 11.96 (br s, 1H).
Example 38: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
[6-oxo-5-(5-piperidin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridin-3-yl]-
-amide
##STR00064##
[0341] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37. It was purified by trituration with acetonitrile, and isolated
as a yellow solid, 70 mg, 66%.
[0342] LC/MS: RT=1.51 Min (270 nm), m/z=521 [M+H]. Total run time
3.75 min (short pos).
[0343] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.37-1.48 (m, 6H),
2.29-2.33 (m, 7H), 3.45 (s, 2H), 5.34 (s, 2H), 7.00-7.04 (m, 2H),
7.19 (m, 4H), 7.40-7.44 (d, 2H), 7.81 (d, 1H), 8.01 (s, 1H), 8.16
(d, 1H), 8.36 (s, 1H), 9.76 (s, 1H), 11.49 (s, 1H), 11.96 (br s,
1H).
Example 39: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic acid
{5-[5-(4-hydroxymethyl-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dih-
ydro-pyridin-3-yl}-amide
##STR00065##
[0345] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37.
[0346] The crude product was purified by flash chromatography on
SiO.sub.2 with dichloromethane-40% methanol/dichloromethane
(gradient) and then trituration with diethyl ether to afford the
title compound as a yellow solid, 9 mg, 13%.
[0347] LC/MS: RT=1.44 Min (270 nm), m/z=551 [M+H]. Total run time
3.75 min (short pos).
[0348] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.06-1.15 (m. 2H), 1.32
(m, 1H), 1.59 (m, 2H), 1.86 (m, 2H), 2.29 (s, 3H), 2.81 (m, 2H),
3.22 (m, 2H), 3.46 (s, 2H), 4.36 (t, 1H), 5.34 (s, 2H), 6.99-7.03
(m, 2H), 7.19 (m, 4H), 7.39-7.43 (d, 2H), 7.81 (d, 1H), 8.01 (s,
1H), 8.15 (d, 1H), 8.36 (s, 1H), 9.76 (s, 1H), 11.50 (s, 1H), NH
not seen.
Example 40: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic acid
[5-(5-morpholin-4-ylmethyl-1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-
-amide
##STR00066##
[0350] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37.
[0351] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 39 mg, 51%.
[0352] LC/MS: RT=1.41 Min (270 nm), m/z=523 [M+H]. Total run time
3.75 min (short pos).
[0353] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.29 (s, 3H), 2.36 (m,
4H), 3.49 (s, 2H), 3.56 (m, 4H), 5.34 (s, 2H), 7.00-7.05 (m, 2H),
7.19 (m, 4H), 7.43-7.46 (d, 2H), 7.82 (d, 1H), 8.01 (s, 1H), 8.16
(d, 1H), 8.36 (s, 1H), 9.76 (s, 1H), 11.51 (s, 1H), 11.97 (br s,
1H).
Example 41: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
[6-oxo-5-(5-pyrrolidin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridin-3-yl-
]-amide
##STR00067##
[0355] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37.
[0356] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 35 mg, 56%.
[0357] LC/MS: RT=1.47 Min (270 nm), m/z=507 [M+H]. Total run time
3.75 min (short pos).
[0358] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.68 (m, 4H), 2.29 (s,
3H), 2.43 (m, 4H), 3.61 (s, 2H), 5.34 (s, 2H), 7.00-7.05 (m, 2H),
7.19 (m, 4H), 7.42-7.44 (d, 2H), 7.82 (d, 1H), 8.01 (s, 1H), 8.16
(d, 1H), 8.36 (s, 1H), 9.75 (s, 1H), 11.49 (s, 1H), 11.96 (br s,
1H).
Example 42: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(3-hydroxy-azetidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00068##
[0360] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37.
[0361] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 18 mg, 40%.
[0362] LC/MS: RT=1.42 Min (270 nm), m/z=509 [M+H]. Total run time
3.75 min (short pos).
[0363] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.29 (s, 3H), 2.74 (m,
2H), 3.44 (m, 2H), 3.57 (s, 2H), 4.16 (m, 1H), 5.23 (d, 1H), 5.34
(s, 2H), 6.97-7.02 (m, 2H), 7.19 (m, 4H), 7.38-7.42 (d, 2H), 7.81
(d, 1H), 8.01 (s, 1H), 8.15 (d, 1H), 8.36 (s, 1H), 9.75 (s, 1H),
11.49 (s, 1H), 11.90 (br s, 1H).
Example 43: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(5-{[(2-hydroxy-ethyl)-methyl-amino]-methyl}-1H-indol-2-yl)-6-oxo-1,6--
dihydro-pyridin-3-yl]-amide
##STR00069##
[0365] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37.
[0366] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 37 mg, 50%.
[0367] LC/MS: RT=1.42 Min (270 nm), m/z=511 [M+H]. Total run time
3.75 min (short pos).
[0368] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.15 (s, 3H), 2.29 (s,
3H), 2.43 (t, 2H), 3.48-3.55 (m, 4H), 4.32 (t, 1H), 5.35 (s, 2H),
7.00-7.05 (m, 2H), 7.19 (m, 4H), 7.42-7.44 (d, 2H), 7.82 (d, 1H),
8.01 (s, 1H), 8.15 (d, 1H), 8.36 (s, 1H), 9.75 (s, 1H), 11.49 (s,
1H), 11.96 (br s, 1H).
Example 44: 1-(4-Chloro-benzyl)-1H-pyrazole-4-carboxylic Acid
[6-oxo-5-(5-piperidin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridin-3-yl]-
-amide
##STR00070##
[0370] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37.
[0371] The title compound was purified by flash chromatography on
SiO.sub.2 with dichloromethane-12% methanol/dichloromethane-12%
methanol/2% ammonia solution 7N in methanol/dichloromethane
(gradient) and isolated as a yellow solid, 2.1 mg, 12%.
[0372] LC/MS: RT=0.93 Min (270 nm), m/z=541 [M+H]. Total run time
1.9 min (super short pos).
[0373] .sup.1H NMR (d.sub.6 DMSO): .quadrature..delta. 1.24-1.26
(m, 2H), 1.34-1.39 (m, 2H), 1.48-1.49 (m, 4H), 2.32-2.36 (m, 2H),
3.45-3.51 (m, 2H), 5.41 (s, 2H), 7.01 (d, 1H), 7.04 (dd, 1H), 7.31
(d, 2H), 7.41-7.42 (m, 4H), 7.82 (d, 1H), 8.04 (s, 1H), 8.17 (d,
1H), 8.42 (s, 1H), 9.79 (1H, s), 11.51 (1H, s), NH not seen.
Example 45: 1-(4-Chloro-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(5-{[ethyl-(2-hydroxy-ethyl)-amino]-methyl}-1H-indol-2-yl)-6-oxo-1,6-d-
ihydro-pyridin-3-yl]-amide
##STR00071##
[0375] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37.
[0376] The resultant crude product was purified by trituration with
acetonitrile to afford the title compound as brown solid, 8 mg,
20%
[0377] LC/MS: RT=0.91 Min (270 nm), m/z=545 [M+H]. Total run time
1.9 min (super short pos).
[0378] .sup.1H NMR (d.sub.6 DMSO): .quadrature..delta. 1.27 (t,
3H), 3.11-3.18 (m, 4H), 3.66-3.75 (m, 2H), 4.38 (d, 2H), 5.39 (s,
2H), 7.11 (s, 1H), 7.22 (dd, 1H), 7.30 (d, 2H), 7.41 (d, 2H), 7.58
(d, 1H), 7.72 (s, 1H), 7.83 (d, 1H), 8.03 (s, 1H), 8.26 (d, 1H),
8.40 (s, 1H), 9.18 (s, 1H), 9.80 (s, 1H), 11.76 (s, 1H), NH not
seen.
Example 46: 1-(4-Chloro-benzyl)-1H-pyrazole-4-carboxylic Acid
(5-{5-[(2-hydroxy-ethylamino)-methyl]-1H-indol-2-yl}-6-oxo-1,6-dihydro-py-
ridin-3-yl)-amide
##STR00072##
[0380] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37.
[0381] The resultant crude product was taken up in methanol (1 mL)
and loaded onto a 5 g SCX column. The column was flushed with
methanol and then eluted with ammonia solution 7N in methanol. The
eluent was concentrated in vacuo and the residue further purified
by preparative HPLC at pH 4 to afford the title compound as a
yellow solid, 3 mg, 8%.
[0382] LC/MS: RT=0.90 Min (270 nm), m/z=456 [Fragment]. Total run
time 1.9 min (super short pos).
[0383] .sup.1H NMR (d.sub.6 DMSO): .quadrature. .delta. 2.90-2.93
(m, 2H), 3.63 (m, 2H), 4.15 (s, 2H), 5.10 (s, 1H), 5.41 (s, 2H),
7.09 (d, 1H), 7.20 (dd, 1H), 7.31 (d, 2H), 7.50 (d, 2H), 7.55 (d,
1H), 7.66 (s, 1H), 7.80 (d, 1H), 8.05 (s, 1H), 8.25 (d, 1H), 8.43
(s, 1H), 9.82 (s, 1H), 11.68 (s, 1H), NHs not seen.
Example 47: 1-(4-Chloro-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00073##
[0385] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37.
[0386] The title compound was purified by flash chromatography on
SiO.sub.2 with dichloromethane-10% methanol/dichloromethane-10%
methanol/1% ammonia solution 7N in methanol/dichloromethane
(gradient) and isolated as a yellow solid, 30 mg, 65%.
[0387] LC/MS: RT=1.73 Min (270 nm), m/z=560, 561 [M+H]. Total run
time 3.75 min (short pos).
[0388] .sup.1H NMR (d.sub.6 DMSO): .quadrature..delta. 1.23 (m,
2H), 1.69 (m, 2H), 1.79-1.86 (m, 2H), 2.29-2.33 (m, 2H), 3.51 (s,
2H), 4.61-4.73 (m, 1H), 5.41 (s, 2H), 7.01 (d, 1H), 7.04 (dd, 1H),
7.31 (d, 2H), 7.42-7.46 (m, 4H), 7.82 (d, 1H), 8.04 (s, 1H), 8.17
(d, 1H), 8.41 (s, 1H), 9.78 (s, 1H), 11.51 (s, 1H), 11.98 (s,
1H).
Example 48: 1-(4-Chloro-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-hydroxy-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-p-
yridin-3-yl}-amide
##STR00074##
[0390] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37.
[0391] It was purified by flash chromatography on SiO.sub.2 with
dichloromethane-10% methanol/dichloromethane-10% methanol/1%
ammonia solution 7N in methanol/dichloromethane (gradient) and then
by trituration with acetonitrile. The desired compound was isolated
as a yellow solid, 8 mg, 10%.
[0392] LC/MS: RT=0.91 Min (270 nm), m/z=557 [M+H]. Total run time
1.9 min (super short pos).
[0393] .sup.1H NMR (d.sub.6 DMSO): .quadrature..delta. 1.36-1.39
(m, 2H), 1.68-1.71 (m, 2H), 2.01 (m, 2H), 2.67 (m, 2H), 3.46 (m,
2H), 4.51 (s, 1H), 5.41 (s, 2H), 7.01-7.03 (m, 2H), 7.31 (d, 2H),
7.44 (m, 4H), 7.82 (d, 1H), 8.04 (s, 1H), 8.17 (d, 1H), 8.42 (s,
1H), 9.78 (s, 1H), 11.50 (s, 1H), 11.98 (s, 1H), OH not seen.
Example 49: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00075##
[0395] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37.
[0396] Purification by trituration with acetonitrile afforded the
title compound as a yellow solid, 51 mg, 85%
[0397] LC/MS: RT=0.91 Min (270 nm), m/z=525 [M+H]. Total run time
1.9 min (super short pos/neg).
[0398] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.68 (m, 2H), 1.78 (m,
2H), 2.26 (m, 2H), 2.60 (m, 2H), 3.50 (s, 2H), 4.66 (dm, 1H), 5.40
(s, 2H), 6.99 (d, 1H), 7.02 (dd, 1H), 7.40 (m, 7H), 7.85 (d, 1H),
8.07 (s, 1H), 8.25 (d, 1H), 8.46 (s, 1H), 9.92 (s, 1H), 11.51 (br
s, 1H), 11.96 (br s, 1H)
Example 50: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
[6-oxo-5-(5-pyrrolidin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridin-3-yl-
]-amide
##STR00076##
[0400] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37.
[0401] Purification by trituration with acetonitrile afforded the
title compound as a yellow solid, 38 mg, 46%
[0402] LC/MS: RT=0.90 Min (270 nm), m/z=493 [M+H]. Total run time
1.9 min (super short pos/neg).
[0403] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.68 (br s, 4H), 2.43
(br s, 4H), 3.61 (br s, 2H), 5.40 (s, 2H), 6.99 (d, 1H), 7.04 (dd,
1H), 7.38 (m, 7H), 7.84 (d, 1H), 8.06 (s, 1H), 8.22 (br s, 1H),
8.44 (s, 1H), 9.87 (s, 1H), 11.49 (s, 1H), 11.96 (br s, 1H)
Example 51:1-Benzyl-1H-pyrazole-4-carboxylic Acid
[5-(5-morpholin-4-ylmethyl-1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-
-amide
##STR00077##
[0405] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37, with a slight modification to the protocol in Step 5.
Step 5: Preparation of
5-(tert-Butyl-dimethyl-silanyloxymethyl)-2-[5-{[1-(4-methyl-benzyl)-1H-py-
razole-4-carbonyl]-amino}-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-di-
hydro-pyridin-3-yl]-indole-1-carboxylic Acid tert-butyl ester
(8e)
[0406] Intermediate (8d),
2-[5-amino-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin--
3-yl]-5-(tert-butyl-dimethyl-silanyloxymethyl)-indole-1-carboxylic
acid tert-butyl ester, (600 mg, 1 mmol) was stirred in
dichloromethane (50 mL) at RT with triethylamine (202 mg, 0.278 mL,
2 mmol). The reaction mixture was cooled to 5.degree. C. and then a
solution of 1-Benzyl-1H-pyrazole-4-carbonyl chloride (265 mg, 1.2
mmol), which had been prepared according to the protocol below, in
dichloromethane (10 ml), was added drop wise. After addition the
reaction was stirred at RT for 18 hrs and then the reaction mixture
was washed with saturated sodium hydrogen carbonate solution
(2.times.50 mL), brine (50 ml), dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. The resultant crude product was purified by
flash chromatography on SiO.sub.2 eluting with hexane-50% ethyl
acetate/hexane (gradient) to afford the desired compound as a pale
green foam, 750 mg, 96%.
Preparation of 1-Benzyl)-1H-pyrazole-4-carbonyl chloride Used in
Step 5, Above
[0407] 1-Benzyl-1H-pyrazole-4-carboxylic Acid (1.6 g, 7.92 mmol)
was stirred as a suspension in toluene (20 mL) at RT and thionyl
chloride (1.88 g, 1.15 mL, 15.8 mmol) was added. The reaction
mixture was slowly heated to reflux and heating continued for 4
hrs. After cooling the reaction was concentrated in vacuo. Toluene
was added to the residue and concentrated in vacuo. This was
repeated a further three times with toluene and twice with
isohexane. The crude oil obtained was used without further
purification, 1.65 g, 95%.
[0408] The title compound was purified by trituration with
acetonitrile afforded the title compound as a yellow solid, 25 mg,
36%
[0409] LC/MS: RT=1.64 Min (270 nm), m/z=509 [M+H]. Total run time
3.75 min (short pos).
[0410] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.29-2.39 (m, 4H), 3.50
(s, 2H), 3.52-3.60 (m, 4H), 5.41 (s, 2H), 7.00-7.02 (m, 2H),
7.28-7.46 (m, 7H), 7.82 (s, 1H), 8.04 (s, 1H), 8.16-8.19 (d, 1H),
8.40 (s, 1H), 9.77 (s, 1H), 11.51 (s, 1H), 11.96 (br s, 1H).
Example 52: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
[6-oxo-5-(5-piperidin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridin-3-yl]-
-amide
##STR00078##
[0412] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0413] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 0.467 g, 42%.
[0414] LC/MS: RT=1.44 Min (270 nm), m/z=507 [M+H]. Total run time
3.75 min (short pos).
[0415] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.37 (m, 2H), 1.47 (m,
4H), 2.32 (m, 4H), 3.45 (s, 2H), 5.41 (s, 2H), 7.00-7.03 (m, 2H),
7.28-7.44 (m, 7H), 7.82 (d, 1H), 8.03 (s, 1H), 8.16 (d, 1H), 8.41
(s, 1H), 9.79 (s, 1H), 11.50 (s, 1H), 11.99 (br s, 1H).
Example 53: 1-(4-Chloro-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00079##
[0417] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0418] The title compound was purified by preparative HPLC at pH9
and isolated as a yellow solid, 3 mg, 4%.
[0419] LC/MS: RT=1.64 Min (270 nm), m/z=556 [M+H]. Total run time
3.75 min (short pos).
[0420] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.14 (s, 3H), 2.20-2.40
(m, 8H), 3.48 (s, 2H), 5.41 (s, 2H), 7.0-7.48 (m, 8H), 7.81 (d,
1H), 8.04 (s, 1H), 8.16 (d, 1H), 8.42 (s, 1H), 9.78 (s, 1H), 11.50
(s, 1H), 11.92 (br s, 1H).
Example 54: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
(5-{5-[(2-hydroxy-ethylamino)-methyl]-1H-indol-2-yl}-6-oxo-1,6-dihydro-py-
ridin-3-yl)-amide
##STR00080##
[0422] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0423] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 5 mg, 9%.
[0424] LC/MS: RT=1.41 Min (270 nm), m/z=497 [M+H]. Total run time
3.75 min (short pos).
[0425] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.29 (s, 3H), 2.60 (q,
2H), 3.47 (q, 2H), 3.75 (s, 2H), 4.45 (t, 1H), 5.34 (s, 2H), 7.00
(s, 1H), 7.05 (d, 1H), 7.19 (m, 4H), 7.41-7.45 (m, 2H), 7.82 (d,
1H), 8.01 (s, 1H), 8.16 (d, 1H), 8.36 (s, 1H), 9.75 (s, 1H), 11.48
(s, 1H).
Example 55: 1-(4-Chloro-benzyl)-1H-pyrazole-4-carboxylic Acid
[6-oxo-5-(5-pyrrolidin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridin-3-yl-
]-amide
##STR00081##
[0427] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0428] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 33 mg, 49%.
[0429] LC/MS: RT=0.96 Min (270 nm), m/z=527 [M+H]. Total run time
1.9 min (super short pos).
[0430] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.62 (m, 4H), 2.40-2.48
(m, 4H), 3.60 (s, 2H), 5.41 (s, 2H), 6.96-7.46 (m, 8H), 7.80-7.84
(d, 1H), 8.04 (s, 1H), 8.17 (d, 1H), 8.42 (s, 1H), 9.78 (s, 1H),
11.50 (s, 1H), 11.90-12.00 (br s, 1H).
Example 56: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
[5-(5-{[ethyl-(2-hydroxy-ethyl)-amino]-methyl}-1H-indol-2-yl)-6-oxo-1,6-d-
ihydro-pyridin-3-yl]-amide
##STR00082##
[0432] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0433] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 13 mg, 17%.
[0434] LC/MS: RT=0.88 Min (270 nm), m/z=511 [M+H]. Total run time
1.9 min (super short pos).
[0435] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.97-1.01 (t, 3H),
3.41-3.47 (q, 2H), 3.60 (s, 2H), 4.24-4.27 (t, 1H), 5.41 (s, 2H),
6.99-7.44 (m, 9H), 7.81-7.82 (d, 1H), 8.03 (s, 1H), 8.16-8.17 (d,
1H), 8.41 (s, 1H), 9.78 (s, 1H), 11.51 (s, 1H), 11.90-11.98 (br s,
1H).
Example 57: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(3-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00083##
[0437] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0438] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 25 mg, 33%.
[0439] LC/MS: RT=0.91 Min (270 nm), m/z=525 [M+H]. Total run time
1.9 min (super short pos).
[0440] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.40-1.60 (m, 2H),
1.64-1.73 (m, 1H), 1.76-1.80 (m, 1H), 2.17-2.25 (m, 1H), 2.26-2.36
(m, 1H), 2.40-2.47 (m, 1H), 2.64-2.76 (m, 1H), 3.49-3.59 (d, 2H),
4.51-4.69 (m, 1H), 5.41 (s, 2H), 7.01-7.46 (m, 9H), 7.81-7.82 (d,
1H), 8.03 (s, 1H), 8.16-8.17 (d, 1H), 8.40 (s, 1H), 9.77 (s, 1H),
11.53 (s, 1H), 11.85-11.95 (br s, 1H).
Example 58: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00084##
[0442] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0443] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 34 mg, 47%.
[0444] LC/MS: RT=1.55 Min (270 nm), m/z=522 [M+H]. Total run time
3.75 min (short pos).
[0445] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.14 (s, 3H), 2.24-2.41
(m, 8H), 3.48 (s, 2H), 5.41 (s, 2H), 7.00-7.44 (m, 9H), 7.81-7.82
(d, 1H), 8.03 (s, 1H), 8.16-8.18 (d, 1H), 8.41 (s, 1H), 9.78 (s,
1H), 11.52 (s, 1H), 11.94-11.96 (br s, 1H).
Example 59: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00085##
[0447] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0448] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 63 mg, 62%.
[0449] LC/MS: RT=1.39 Min (270 nm), m/z=536 [M+H]. Total run time
3.75 min (short pos).
[0450] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.14 (s, 3H), 2.26-2.44
(m, 11H), 3.48 (s, 2H), 5.34 (s, 2H), 7.00-7.03 (m, 2H), 7.19 (m,
4H), 7.41-7.44 (m, 2H), 7.82 (d, 1H), 8.01 (s, 1H), 8.16 (d, 1H),
8.36 (s, 1H), 9.76 (s, 1H), 11.50 (s, 1H), 11.97 (br s, 1H).
Example 60: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-hydroxy-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-p-
yridin-3-yl}-amide
##STR00086##
[0452] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0453] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 18 mg, 35%.
[0454] LC/MS: RT=1.59 Min (270 nm), m/z=523 [M+H]. Total run time
3.75 min (short pos).
[0455] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.30-1.43 (m, 2H),
1.64-1.73 (m, 2H), 1.97-2.03 (t, 2H), 2.63-2.72 (m, 2H), 3.40-3.44
(m, 1H), 3.46 (s, 2H), 4.49-4.50 (d, 1H), 5.41 (s, 2H), 6.99-7.43
(m, 9H), 7.82-7.84 (d, 1H), 8.03 (s, 1H), 8.16-8.17 (d, 1H), 8.41
(s, 1H), 9.78 (s, 1H), 11.58 (s, 1H), 11.90 (br s, 1H).
Example 61: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
(5-{5-[(2-hydroxy-ethylamino)-methyl]-1H-indol-2-yl}-6-oxo-1,6-dihydro-py-
ridin-3-yl)-amide
##STR00087##
[0457] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0458] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 8 mg, 15%.
[0459] LC/MS: RT=1.58 Min (270 nm), m/z=422 [Fragment]. Total run
time 3.75 min (short pos).
[0460] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.57-2.61 (t, 2H),
3.45-3.49 (m, 2H), 3.74 (s, 2H), 4.39-4.46 (m, 1H), 5.41 (s, 2H),
6.99-7.45 (m, 9H), 7.82-7.83 (d, 1H), 8.03 (s, 1H), 8.17-8.18 (d,
1H), 8.41 (s, 1H), 9.78 (s, 1H), 11.51 (s, 1H).
Example 62: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
(5-{5-[4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl]-1H-indol-2-yl}-6-oxo-1,6-
-dihydro-pyridin-3-yl)-amide
##STR00088##
[0462] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0463] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 26 mg, 23%.
[0464] LC/MS: RT=1.38 Min (270 nm), m/z=566 [M+H]. Total run time
3.75 min (short pos).
[0465] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.29 (s, 3H), 2.32-2.45
(m, 10H), 3.44-3.48 (m, 4H), 4.32 (t, 1H), 5.34 (s, 2H), 7.00-7.03
(m, 2H), 7.19 (m, 4H), 7.41-7.44 (m, 2H), 7.82 (d, 1H), 8.01 (s,
1H), 8.16 (d, 1H), 8.36 (s, 1H), 9.76 (s, 1H), 11.50 (s, 1H), 11.96
(br s, 1H).
Example 63: 1-(4-Chloro-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(3-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00089##
[0467] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0468] The title compound was purified by preparative HPLC at pH9
and isolated as a yellow solid, 4 mg, 6%.
[0469] LC/MS: RT=0.95 Min (270 nm), m/z=559 [M+H]. Total run time
1.9 min (super short pos).
[0470] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.39-1.55 (m, 2H),
1.64-1.73 (m, 1H), 1.76-1.89 (m, 1H), 2.19-2.25 (m, 1H), 2.28-2.35
(m, 1H), 2.41-2.46 (m, 1H), 2.64-2.76 (m, 1H), 3.54-3.55 (d, 2H),
4.50-4.70 (m, 1H), 5.41 (s, 2H), 7.00-7.48 (m, 8H), 7.82-7.83 (d,
1H), 8.04 (s, 1H), 8.17-8.18 (d, 1H), 8.42 (s, 1H), 9.79 (s, 1H),
11.52 (s, 1H), 11.93-12.02 (br s, 1H).
Example 64: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(4,4-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydr-
o-pyridin-3-yl}-amide
##STR00090##
[0472] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0473] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 17 mg, 48%.
[0474] LC/MS: RT=0.94 Min (270 nm), m/z=422 [other]. Total run time
1.9 min (super short pos).
[0475] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.90-1.99 (m, 4H), 3.56
(s, 2H), 5.41 (s, 2H), 7.01-7.46 (m, 9H), 7.82-7.83 (d, 1H), 8.04
(s, 1H), 8.19-8.20 (d, 1H), 8.42 (s, 1H), 9.82 (s, 1H), 11.54 (s,
1H).
Example 65: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
(5-{5-[4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl]-1H-indol-2-yl}-6-oxo-1,6-
-dihydro-pyridin-3-yl)-amide
##STR00091##
[0477] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0478] The title compound was purified by preparative HPLC at pH 4
and isolated as a yellow solid, 4 mg, 5%.
[0479] LC/MS: RT=0.85 Min (270 nm), m/z=552 [M+H]. Total run time
1.9 min (super short pos).
[0480] .sup.1H NMR (d.sub.4 MeOD): .delta. 2.74-3.13 (m, 10H),
3.70-3.73 (t, 2H), 3.97 (s, 2H), 5.40 (s, 2H), 7.05-7.58 (m, 9H),
7.90-7.91 (d, 1H), 8.05 (s, 1H), 8.24-8.25 (d, 1H), 8.50 (s,
1H).
Example 66: 1-(4-Chloro-benzyl)-1H-pyrazole-4-carboxylic Acid
(5-{5-[4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl]-1H-indol-2-yl}-6-oxo-1,6-
-dihydro-pyridin-3-yl)-amide
##STR00092##
[0482] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0483] The title compound was purified by preparative HPLC at pH9
followed by trituration with acetonitrile and isolated as a yellow
solid, 0.5 mg, 1%.
[0484] LC/MS: RT=0.89 Min (270 nm), m/z=586 [M+H]. Total run time
1.9 min (super short pos).
[0485] .sup.1H NMR (d.sub.4 MeOD): .delta. 2.48-2.71 (m, 8H),
3.62-3.68 (m, 4H), 5.40 (s, 2H), 7.02-7.51 (m, 8H), 7.93-7.94 (d,
1H), 8.06 (s, 1H), 8.21-8.22 (d, 1H), 8.28 (s, 1H), 8.54 (s,
1H).
Example 67: 1-(4-Chloro-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(5-morpholin-4-ylmethyl-1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-
-amide
##STR00093##
[0487] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0488] The title compound was purified by preparative HPLC at pH9
and isolated as a yellow solid, 6 mg, 10%.
[0489] LC/MS: RT=0.92 Min (270 nm), m/z=456 [Fragment]. Total run
time 1.9 min (super short pos).
[0490] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.32-2.38 (m, 4H), 3.49
(s, 2H), 3.55-3.57 (m, 4H), 5.41 (s, 2H), 7.01-7.05 (m, 2H),
7.28-7.32 (m, 2H), 7.41-7.47 (m, 4H), 7.82-7.83 (d, 1H), 8.05 (s,
1H), 8.17-8.18 (d, 1H), 8.42 (s, 1H), 9.81 (s, 1H), 11.53 (s, 1H),
11.96-12.04 (br s, 1H).
Example 68: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
(5-{5-[(2-methanesulfonyl-ethylamino)-methyl]-1H-indol-2-yl}-6-oxo-1,6-di-
hydro-pyridin-3-yl)-amide
##STR00094##
[0492] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0493] The title compound was purified by preparative HPLC at pH9
and isolated as a yellow solid, 3 mg, 4%.
[0494] LC/MS: RT=0.86 Min (270 nm), m/z=422 [Fragment]. Total run
time 1.9 min (super short pos).
[0495] .sup.1H NMR (d.sub.6 DMSO): .delta. 3.13 (s, 3H), 3.52-3.62
(m, 4H), 4.22-4.28 (m, 2H), 5.41 (s, 2H), 7.12-7.40 (m, 7H),
7.58-7.60 (d, 1H), 7.69 (s, 1H), 7.80 (s, 1H), 8.05 (s, 1H),
8.26-8.27 (d, 1H), 8.43 (s, 1H), 9.85 (s, 1H), 11.75 (s, 1H),
12.04-12.11 (br s, 1H).
Example 69: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(2,6-dimethyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydr-
o-pyridin-3-yl}-amide
##STR00095##
[0497] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0498] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 2 mg, 10%.
[0499] LC/MS: RT=0.92 Min (254 nm), m/z=537 [M+H]. Total run time
1.9 min (super short pos).
[0500] .sup.1H NMR (d.sub.4 MeOD): .delta. 1.10 (d, 6H), 1.76, (t,
2H), 2.79 (d, 2H), 3.58 (s, 2H), 3.62-3.72 (m, 2H), 5.4 (s, 2H),
7.01 (s, 1H), 7.12 (dd, 1H), 7.28-7.42 (m, 6H), 7.49 (s, 1H), 7.94
(d, 1H), 8.06 (s, 1H), 8.22 (d, 1H), 8.25 (s, 1H)
Example 70: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(3,4-dimethyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydr-
o-pyridin-3-yl}-amide
##STR00096##
[0502] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0503] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 17 mg, 23%.
[0504] LC/MS: RT=0.87 Min (254 nm), m/z=536 [M+H]. Total run time
1.9 min (super short pos).
[0505] .sup.1H NMR (d.sub.4 MeOD): .delta. 1.03 (d, 3H), 1.91 (t,
1H), 2.15-2.26 (br m, 2H), 2.27 (s, 3H), 2.34 (m, 1H), 2.75-2.88
(m, 3H), 3.55-3.63 (m, 2H), 5.4 (s, 2H), 7.12 (s, 1H), 8.04-8.1
(dd, 1H), 7.28-7.41 (m, 6H), 7.48 (s, 1H), 7.94 (d, 1H), 8.06 (s,
1H), 8.21 (d, 1H), 8.25 (s, 1H).
Example 71: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(cis-2,6-dimethyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-di-
hydro-pyridin-3-yl}-amide
##STR00097##
[0507] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0508] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 84 mg, 62%.
[0509] LC/MS: RT=1.56 Min (270 nm), m/z=537 [M+H]. Total run time
3.75 min (short pos).
[0510] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.00 (d, 6H), 1.62 (m,
2H), 2.68 (m, 2H), 3.47 (s, 2H), 3.55 (m, 2H), 5.41 (s, 2H),
7.01-7.04 (m, 2H), 7.28-7.46 (m, 7H), 7.82 (d, 1H), 8.03 (s, 1H),
8.16 (d, 1H), 8.41 (s, 1H), 9.79 (s, 1H), 11.53 (s, 1H), 11.99 (br
s, 1H).
Example 72: 1-(4-Isopropylbenzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(2,6-dimethylmorpholin-4-ylmethyl)-1H-indol-2-yl)-6-oxo-1,6-dihydro-
pyridin-3-yl}-amide
##STR00098##
[0512] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0513] The title compound was purified by flash chromatography on
silica eluting with dichloromethane/methanol (19:1) to give a pale
brown gum followed by trituration with diethyl ether, and isolated
as a yellow powder, 30 mg, 23%.
[0514] LC/MS: RT=1.76 Min (270 nm), m/z=579 [M+H]. Total run time
3.75 min (short pos).
[0515] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.10 (br s, 6H), 1.25
(d, 6H), 1.70 (br s, 2H), 2.80 (br m, 2H), 2.90 (m, 1H), 3.60 (br
m, 3H), 5.40 (s, 2H), 7.10 (br s, 1H), 7.30 (m, 3H), 7.50 (br s,
2H), 7.90 (br s, 1H), 8.10 (s, 1H), 8.20 (br s, 1H), 8.50 (s, 1H),
9.85 (s, 1H), 11.52 (br s, 1H), 12.00 (br s, 1H).
Example 73: 1-(4-Isopropylbenzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-fluoropiperidin-1-ylmethyl)-1H-indol-2-yl)-6-oxo-1,6-dihydropyri-
din-3-yl}-amide
##STR00099##
[0517] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0518] The title compound was purified by flash chromatography on
silica eluting with dichloromethane/methanol (19:1) to give a pale
brown gum followed by trituration with diethyl ether, and isolated
as a yellow powder, 35 mg, 23%.
[0519] LC/MS: RT=1.65 Min (270 nm), m/z=567 [M+H]. Total run time
3.75 min (short pos).
[0520] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.25 (d, 6H), 1.75 (br
m, 2H), 1.90 (br m, 2H), 2.35 (br m, 2H), 2.90 (m, 1H), 3.60 (s,
2H), 4.70 (br s, 1H), 4.80 (br s, 1H), 5.40 (s, 2H), 7.00 (m, 2H),
7.30 (m, 4H), 7.50 (m, 2H), 7.85 (d, 1H), 8.10 (s, 1H), 8.20 (d,
1H), 8.45 (s, 1H), 9.85 (s, 1H), 11.54 (br s, 1H), 12.00 (br s,
1H).
Example 74: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(cis-2,6-dimethyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-di-
hydro-pyridin-3-yl}-amide
##STR00100##
[0522] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0523] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 34 mg, 42%.
[0524] LC/MS: RT=0.98 Min (270 nm), m/z=551 [M+H]. Total run time
1.9 min (super short pos).
[0525] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.0 (d, 6H), 1.62 (dd,
2H), 2.3 (s, 3H), 2.68 (dd, 2H) 3.46 (s, 2H), 3.5-3.6 (m, 2H), 5.35
(s, 2H), 7.0-7.05 (m, 2H), 7.2 (s, 4H), 7.40-7.46 (m, 2H), 7.82 (d,
1H), 8.01 (s, 1H), 8.16 (s, 1H), 8.37 (s, 1H), 9.79 (br s, 1H),
11.55 (br s, 1H), 11.95 (br s, 1H)
Example 75: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(5-diethylaminomethyl-1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-a-
mide
##STR00101##
[0527] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0528] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 36 mg, 48%.
[0529] LC/MS: RT=0.95 Min (270 nm), m/z=509 [M+H]. Total run time
1.9 min (super short pos).
[0530] .sup.1H NMR (de DMSO): .delta. 0.98 (q, 6H), 2.28 (s, 3H),
2.46 (q, 4H), 3.55 (s, 2H), 5.34 (s, 2H), 7.0 (d, 1H), 7.05 (dd,
1H), 7.19 (s, 4H), 7.41-7.44 (m, 2H), 7.81 (d, 1H), 8.01 (s, 1H),
8.15 (s, 1H), 8.37 (s, 1H), 9.78 (br s, 1H), 11.5 (br s, 1H), 11.95
(br s, 1H)
Example 76: 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(cis-2,6-dimethyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-di-
hydro-pyridin-3-yl}-amide
##STR00102##
[0532] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0533] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 2 mg, 6%.
[0534] LC/MS: RT=1.57 Min (270 nm), m/z=555 [M+H]. Total run time
3.75 min (short pos).
[0535] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.00 (d, 6H), 1.60 (t,
2H), 2.7 (d, 2H), 3.45 (s, 2H), 3.55 (m, 2H), 5.40 (s, 2H), 6.89
(br, 1H), 7.00 (dd, 1H), 7.20 (t, 2H), 7.40 (m, 4H), 7.82 (d, 1H),
8.05 (s, 1H), 8.15 (br, 1H), 8.40 (s, 1H), 9.70 (s, 1H).
Example 77: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
(5-{5-[(cyclohexyl-methyl-amino)-methyl]-1H-indol-2-yl}-6-oxo-1,6-dihydro-
-pyridin-3-yl)-amide
##STR00103##
[0537] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0538] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 26 mg, 44%.
[0539] LC/MS: RT=1.65 Min (270 nm), m/z=535 [M+H]. Total run time
3.75 min (short pos).
[0540] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.05-1.33 (m, 5H), 1.57
(m, 1H), 1.73-1.81 (m, 4H), 2.09 (s, 3H), 2.41 (m, 1H), 3.57 (s,
2H), 5.41 (s, 2H), 6.98-7.04 (m, 2H), 7.28-7.43 (m, 7H), 7.82 (d,
1H), 8.03 (s, 1H), 8.15 (d, 1H), 8.41 (s, 1H), 9.79 (s, 1H), 11.50
(s, 1H), 11.98 (br s, 1H).
Example 78: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-methyl-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00104##
[0542] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0543] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 34 mg, 62%.
[0544] LC/MS: RT=1.61 Min (270 nm), m/z=521 [M+H]. Total run time
3.75 min (short pos).
[0545] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.87 (d, 3H), 1.12 (m,
2H), 1.29 (m, 1H), 1.53 (d, 2H), 1.87 (t, 2H), 2.78 (d, 2H), 3.46
(s, 2H), 5.41 (s, 2H), 7.00-7.02 (m, 2H), 7.28-7.44 (m, 7H), 7.82
(d, 1H), 8.03 (s, 1H), 8.16 (d, 1H), 8.41 (s, 1H), 9.79 (s, 1H),
11.50 (s, 1H), 11.99 (br s, 1H).
Example 79: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
[5-(5-{[(2-methoxy-ethyl)-methyl-amino]-methyl}-1H-indol-2-yl)-6-oxo-1,6--
dihydro-pyridin-3-yl]-amide
##STR00105##
[0547] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0548] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 20 mg, 31%.
[0549] LC/MS: RT=1.52 Min (270 nm), m/z=511 [M+H]. Total run time
3.75 min (short pos).
[0550] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.15 (s, 3H), 2.50 (t,
2H), 3.22 (s, 3H), 3.44 (t, 2H), 3.52 (s, 2H), 5.41 (s, 2H),
7.00-7.04 (m, 2H), 7.28-7.45 (m, 7H), 7.82 (d, 1H), 8.03 (s, 1H),
8.16 (d, 1H), 8.41 (s, 1H), 9.79 (s, 1H), 11.51 (s, 1H), 11.99 (br
s, 1H).
Example 80: 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic Acid
[6-oxo-5-(5-piperidin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridin-3-yl]-
-amide
##STR00106##
[0552] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0553] The title compound was purified by trituration with
acetonitrile followed by preparative HPLC at pH 4 and isolated as a
yellow solid, 3 mg, 5%.
[0554] LC/MS: RT=0.93 Min (270 nm), m/z=525 [M+H]. Total run time
1.9 min (super short pos).
[0555] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.4 (m, 2H), 1.50 (m,
5H), 2.40 (m, 3H), 3.45 (s, 2H), 5.40 (s, 2H), 7.02 (br, 2H), 7.05
(m, 1H), 7.22 (t, 1H), 7.35 (m, 2H), 7.45 (m, 2H), 7.80 (d, 1H),
8.05 (s, 1H), 8.16 (d, 1H), 8.40 (s, 1H), 9.80 (s, 1H), 11.52 (s,
1H)
Example 81: 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00107##
[0557] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0558] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 20 mg, 37%.
[0559] LC/MS: RT=1.58 Min (270 nm), m/z=543 [M+H]. Total run time
3.75 min (short pos).
[0560] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.70 (m, 2H), 1.85 (m,
2H), 2.3 (m, 2H), 3.50 (s, 2H), 4.65 (br d, 1H), 5.40 (s, 2H), 6.95
(br s, 1H), 7.00 (dd, 1H), 7.25 (t, 2H), 7.40 (m, 4H), 7.85 (d,
1H), 8.05 (s, 1H), 8.15 (s, 1H), 8.40 (s, 1H), 9.75 (s, 1H),
Example 82: 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-methyl-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00108##
[0562] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0563] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 49 mg, 48%.
[0564] LC/MS: RT=1.63 Min (270 nm), m/z=539 [M+H]. Total run time
3.75 min (short pos).
[0565] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.90 (d, 3H), 1.10 (m,
2H), 1.30 (m, 1H), 1.58 (d, 2H), 1.85 (t, 2H), 2.80 (d, 2H), 3.40
(s, 2H), 5.4 (s, 2H), 6.90 (br, 1H), 7.00 (dd, 1H), 7.22 (t, 2H),
7.38 (m, 4H), 7.84 (d, 1H), 8.05 (s, 1H), 8.10 (s, 1H), 8.40 (s,
1H), 9.75 (s, 1H),
Example 83: 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic Acid
[5-(5-ethylaminomethyl-1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-ami-
de
##STR00109##
[0567] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0568] The title compound was purified by trituration with
acetonitrile followed by preparative HPLC at pH 4, to furnish the
title compound as a yellow solid, 16 mg, 18%.
[0569] LC/MS: RT=0.92 Min (270 nm), m/z=440 [Fragment]. Total run
time 1.9 min (super short pos).
[0570] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.05 (t, 3H), 2.65 (q,
2H), 3.88 (s, 2H), 5.4 (s, 2H), 7.04 (d, 1H), 7.06 (dd, 1H), 7.22
(t, 2H), 7.38 (m, 2H), 7.55 (dd, 1H), 7.58 (s, 1H), 7.80 (s, 1H),
8.05 (s, 1H), 8.25 (d, 1H), 8.35 (s, 1H), 8.44 (s, 1H) 9.85 (s,
1H), 11.6 (s, 1H).
Example 84: 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic Acid
(5-{5-(cyclohexyl-methyl-amino)-methyl]-1H-indol-2-yl}-6-oxo-1,6-dihydrop-
yridin-3-yl)-amide
##STR00110##
[0572] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0573] The title compound was purified by trituration with
acetonitrile followed by preparative HPLC at pH9, to furnish the
title compound as a yellow solid, 12 mg, 15%.
[0574] LC/MS: RT=1.68 Min (270 nm), m/z=553 [M+H]. Total run time
3.75 min (short pos).
[0575] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.0-1.2 (m, 4H), 1.2-1.4
(m, 2H), 1.6 (d, 1H), 1.66-1.84 (m, 4H), 2.28 (s, 3H), 3.62, (s,
2H), 5.4 (s, 2H), 7.02 (d, 1H), 7.04-7.08 (dd, 1H), 7.24 (t, 2H),
7.34-7.40 (m, 2H), 7.42-7.46 (m, 2H), 7.8 (d, 1H), 8.02 (s, 1H),
8.18 (s, 1H), 8.20 (s, 1H), 9.56 (s, 1H), 11.5 (s, 1H).
Example 85: 1-(1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic Acid
[6-oxo-5-(5-piperidin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridin-3-yl]-
-amide
##STR00111##
[0577] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0578] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 37 mg, 54%.
[0579] LC/MS: RT=0.95 Min (270 nm), m/z=521 [M+H]. Total run time
1.9 min (super short pos).
[0580] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.32-1.42 (m, 2H),
1.43-1.52 (m, 4H), 1.83-1.84 (d, 3H), 2.25-2.36 (m, 4H), 3.45 (s,
2H), 5.67-5.72 (q, 1H), 7.01-7.44 (m, 9H), 7.82-7.83 (d, 1H), 8.03
(s, 1H), 8.16-8.17 (d, 1H), 8.45 (s, 1H), 9.78 (s, 1H), 11.51 (s,
1H), 11.92-12.03 (br s, 1H).
Example 86: 1-(1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic Acid
[5-(5-morpholin-4-ylmethyl-1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-
-amide
##STR00112##
[0582] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0583] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 15 mg, 23%.
[0584] LC/MS: RT=0.89 Min (270 nm), m/z=523 [M+H]. Total run time
1.9 min (super short pos).
[0585] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.83-1.85 (d, 3H), 2.35
(m, 4H), 3.49 (s, 2H), 3.55-3.57 (m, 4H), 5.67-5.74 (q, 1H),
6.99-7.46 (m, 9H), 7.82-7.83 (d, 1H), 8.04 (s, 1H), 8.16-8.17 (d,
1H), 8.45 (s, 1H), 9.78 (s, 1H), 11.53 (s, 1H), 11.90-12.05 (br s,
1H).
Example 87: 1-(1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00113##
[0587] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0588] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 16 mg, 46%.
[0589] LC/MS: RT=0.93 Min (270 nm), m/z=539 [M+H]. Total run time
1.9 min (super short pos).
[0590] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.66-1.76 (m, 2H),
1.83-1.85 (m, 5H), 2.23-2.32 (m, 2H), 3.50 (s, 2H), 4.60-4.70 (d,
1H), 5.67-5.72 (q, 1H), 7.0-7.05 (m, 2H), 7.26-7.45 (m, 7H),
7.82-7.83 (d, 1H), 8.04 (s, 1H), 8.16-8.17 (d, 1H), 8.45 (s, 1H),
9.78 (s, 1H), 11.53 (s, 1H), 11.95-12.00 (br s, 1H).
Example 88: 1-[1-(4-Fluoro-phenyl)-ethyl]-1H-pyrazole-4-carboxylic
Acid
[6-oxo-5-(5-piperidin-1-ylmethyl-1-H-indol-2-yl)-1,6-dihydro-pyridin-3-yl-
]-amide
##STR00114##
[0592] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0593] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 3 mg, 9%.
[0594] LC/MS: RT=0.95 Min (254 nm), m/z=539 [M+H]. Total run time
1.9 min (super short pos).
[0595] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.36-1.40 (br s, 2H),
1.43-1.50 (br m, 4H), 1.82 (d, 3H), 2.26-2.32 (br m, 4H), 3.44 (s,
2H), 5.70 (q, 1H), 7.00 (m, 2H), 7.20 (m, 2H), 7.32-7.44 (m, 4H),
7.82 (d, 1H), 8.02 (s, 1H), 8.18 (d, 1H), 8.44 (s, 1H), 9.80 (s,
1H), 11.52 (s, 1H), 12.00 (br s, 1H)
Example 89: 1-[1-(4-Fluoro-phenyl)-ethyl]-1H-pyrazole-4-carboxylic
Acid
{5-[5-(4-methylpiperazin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyr-
idin-3-yl}-amide
##STR00115##
[0597] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0598] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 9 mg, 30%.
[0599] LC/MS: RT=0.89 Min (254 nm), m/z=554 [M+H]. Total run time
1.9 min (super short pos).
[0600] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.80 (d, 3H), 2.15 (s,
3H), 2.2-2.4 (br m, 8H), 3.42 (s, 2H), 5.70 (q, 1H), 7.00 (m, 2H),
7.18-7.22 (m, 2H), 7.36-7.40 (m, 2H), 7.4-7.48 (m, 2H), 7.82 (d,
1H), 8.04 (s, 1H), 8.16 (d, 1H), 8.44 (s, 1H), 9.78 (s, 1H), 11.52
(s, 1H), 12.00 (br s, 1H).
Example 90: 1-[1-(Fluoro-phenyl)-ethyl]-1H-pyrazole-4-carboxylic
Acid
{5-[5-(4-fluoro-piperidin-1ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyr-
idin-3-yl}-amide
##STR00116##
[0602] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0603] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 2 mg, 14%.
[0604] LC/MS: RT=0.95 Min (254 nm), m/z=557 [M+H]. Total run time
1.9 min (super short pos).
[0605] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.60-1.73 (m, 2H),
1.73-1.90 (m, 2H), 1.81 (d, 3H), 2.20-2.30 (m, 2H), 2.43-2.55 (m,
2H obscured by DMSO peak), 3.50 (s, 2H), 4.56-4.76 (m, 1H), 5.70
(q, 1H), 7.00 (m, 2H), 7.20 (m, 2H), 7.32-7.38 (m, 2H), 7.4-7.46
(m, 2H), 7.82 (d, 1H), 8.04 (s, 1H), 8.16 (d, 1H), 8.44 (s, 1H),
9.78 (s, 1H), 11.52 (s, 1H), 11.98 (br s, 1H)
Example 91: 1-(1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(cis-2,6-dimethyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-di-
hydro-pyridin-3-yl}-amide
##STR00117##
[0607] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0608] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 34 mg, 31%.
[0609] LC/MS: RT=1.61 Min (270 nm), m/z=550 [M+H]. Total run time
3.75 min (short pos).
[0610] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.0 (d, 6H), 1.62 (t,
2H), 1.82 (d, 3H), 2.68 (m, 2H), 3.48 (s, 2H), 3.55 (m, 2H), 5.7
(q, 1H), 7.0 (m, 2H), 7.20-7.42 (m, 7H), 7.80 (d, 1H), 8.05 (s,
1H), 8.10 (s, 1H), 8.42 (s, 1H), 9.78 (s, 1H),
Example 92: 1-(1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-methyl-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00118##
[0612] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51. The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 57 mg, 49%.
[0613] LC/MS: RT=1.66 Min (270 nm), m/z=535 [M+H]. Total run time
3.75 min (short pos).
[0614] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.87 (d, 3H), 1.12 (m,
2H), 1.30 (m, 1H), 1.54 (m, 2H), 1.84 (d, 3H), 1.87 (m, 2H), 2.78
(m, 2H), 3.46 (s, 2H), 5.70 (q, 1H), 7.00-7.03 (m, 2H), 7.28-7.44
(m, 7H), 7.82 (d, 1H), 8.04 (s, 1H), 8.15 (d, 1H), 8.45 (s, 1H),
9.78 (s, 1H), 11.51 (s, 1H), 11.99 (br s, 1H).
Example 93: 1-(1-Phenylethyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-6-oxo-1,6-dihydropyridin-3-yl]-amide
##STR00119##
[0616] The title compound was prepared by the route outlined in
Scheme 6, following the same experimental procedures as for Example
20, except that the relevant carboxylic acid,
1-(1-phenyl-ethyl)-1H-pyrazole-4-carboxylic acid, was converted to
1-(1-phenyl-ethyl)-1H-pyrazole-4-carbonyl chloride and then coupled
to the amine using the same experimental described for Example
51.
[0617] The title compound was purified by flash chromatography on
SiO.sub.2 with ethyl acetate and isolated as a yellow solid, 57 mg,
49%.
[0618] LC/MS: RT=2.03 Min (270 nm), m/z=424 [M+H]. Total run time
3.75 min (short pos).
[0619] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.85 (d, 3H), 5.70 (q,
1H), 6.95 (t, 1H), 7.10 (m, 2H), 7.30 (m, 3H), 7.35 (m, 2H), 7.55
(m, 2H), 7.80 (d, 1H), 8.05 (s, 1H), 8.20 (d, 1H), 8.45 (s, 1H),
9.75 (s, 1H), 11.54 (br s, 1H), 11.99 (br s, 1H).
Example 94: 1-(3-Phenyl-propyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00120##
[0621] The title compound was prepared by the route outlined in
Scheme 6, following the same experimental procedures as for Example
20, except that the relevant carboxylic acid,
1-(3-Phenyl-propyl)-1H-pyrazole-4-carboxylic acid, was converted to
1-(3-Phenyl-propyl)-1H-pyrazole-4-carbonyl chloride, and then
coupled to the amine using the same experimental described for
Example 51.
[0622] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 30 mg, 48%.
[0623] LC/MS: RT=2.22 Min (270 nm), m/z=436 [M-H]. Total run time
3.75 min (short pos/neg).
[0624] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.12 (t, 2H), 2.55 (m,
2H), 4.17 (t, 2H), 6.97 (m, 1H), 7.07 (m, 2H) 7.22 (m, 3H), 7.30
(m, 2H), 7.52 (t, 2H), 7.82 (s, 1H), 8.03 (s, 1H), 8.20 (s, 1H),
8.35 (s, 1H), 9.77 (br s, 1H), 11.57 (br s, 1H), 12.0 (br s,
1H)
Example 95: 1-[2-(4-Fluoro-phenyl)-ethyl]-1H-pyrazole-4-carboxylic
Acid
[6-oxo-5-(5-piperidin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridin-3-yl]-
-amide
##STR00121##
[0626] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[0627] The title compound was purified by trituration with diethyl
ether, and isolated as a yellow solid, 30 mg, 42%.
[0628] LC/MS: RT=0.94 Min (270 nm), m/z=539 [M+H]. Total run time
1.9 min (super short pos).
[0629] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.34-1.42 (m, 2H),
1.46-1.52 (m, 4H), 2.30-2.37 (m, 4H), 3.11-3.16 (m, 2H), 3.45 (s,
2H), 4.38-4.42 (t, 2H), 6.97-7.21 (m, 6H), 7.40-7.43 (m, 2H),
7.82-7.83 (d, 1H), 8.03 (s, 1H), 8.17-8.18 (d, 1H), 8.19 (s, 1H),
9.76 (s, 1H), 11.58 (s, 1H), 11.95-12.00 (br s, 1H).
Example 96: 1-[2-(4-Fluoro-phenyl)-ethyl]-1H-pyrazole-4-carboxylic
Acid
{5-[5-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00122##
[0631] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51. The title compound was purified by trituration with diethyl
ether, and isolated as a yellow solid, 36 mg, 51%.
[0632] LC/MS: RT=0.94 Min (270 nm), m/z=557 [M+H]. Total run time
1.9 min (super short pos).
[0633] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.69-1.92 (m, 4H),
2.24-2.33 (m, 2H), 3.11-3.18 (m, 4H), 3.50 (s, 2H), 4.38-4.42 (t,
2H), 4.59-4.75 (m, 1H), 7.00-7.21 (m, 6H), 7.41-7.44 (m, 2H),
7.83-7.84 (d, 1H), 8.03 (s, 1H), 8.19-8.20 (m, 2H), 9.78 (s, 1H),
11.62-11.69 (br s, 1H).
Example 97:
5-[5-(4-Fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyr-
idine-3-carboxylic Acid
[1-(3,4-difluoro-benzyl)-1H-pyrazol-4-yl]-amide
##STR00123##
[0635] The title compound was prepared by the route outlined in
Scheme 9, using intermediate (8b) and applying the same the
experimental procedures as for Example 1. The title compound was
purified by trituration with acetonitrile followed by preparative
HPLC at pH 4 and isolated as a yellow solid, 24 mg, 14%.
[0636] LC/MS: RT=0.95 Min (270 nm), m/z=561 [M+H]. Total run time
1.9 min (super short pos).
[0637] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.75 (br m, 2H), 1.85
(br m, 2H), 2.30 (br m, 2H), 2.55 (br m, 2H), 3.53 (s, 2H), 4.65
(m, 1H), 5.35 (s, 2H), 7.05 (dd, 1H), 7.15 (m, 1H), 7.25 (d, 1H),
7.30 (m, 1H), 7.45 (m, 3H), 7.55 (d, 1H), 8.10 (d, 1H), 8.15 (s,
1H), 8.25 (s, 1H), 8.55 (d, 1H), 10.40 (s, 1H), 11.48 (br s,
1H).
Example 98:
6-Oxo-5-(5-pyrrolidin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridine-3-ca-
rboxylic Acid [1-(3,4-difluoro-benzyl)-1H-pyrazol-4-yl]-amide
##STR00124##
[0639] The title compound was prepared by the route outlined in
Scheme 9, using intermediate (8b) and applying the same the
experimental procedures as for Example 1. The title compound was
purified by trituration with acetonitrile followed by preparative
HPLC at pH 4 and isolated as a yellow solid, 12 mg, 8%.
[0640] LC/MS: RT=0.95 Min (270 nm), m/z=529 [M+H]. Total run time
1.9 min (super short pos).
[0641] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.75 (br s, 4H), 2.60
(s, 4H), 3.75 (s, 2H), 5.30 (s, 2H), 7.10 (m, 2H), 7.20 (d, 1H),
7.45 (m, 3H), 7.65 (d, 1H), 8.10 (d, 1H), 8.15 (s, 1H), 8.25 (br s,
1H), 8.55 (d, 1H), 10.40 (s, 1H), 11.51 (br s, 1H).
Example 99:
5-(5-Morpholin-4-ylmethyl-1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-car-
boxylic Acid [1-(3,4-difluoro-benzyl)-1H-pyrazol-4-yl]-amide
##STR00125##
[0643] The title compound was prepared by the route outlined in
Scheme 9, using intermediate (8b) and applying the same the
experimental procedures as for Example 1. The title compound was
purified by trituration with acetonitrile, and isolated as a yellow
solid, 65 mg, 27%.
[0644] LC/MS: RT=1.70 Min (270 nm), m/z=545 [M+H]. Total run time
3.75 min (short pos).
[0645] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.40 (br s, 4H), 3.50
(s, 2H), 3.60 (t, 4H), 5.30 (s, 2H), 7.10 (m, 2H), 7.20 (d, 1H),
7.35 (m, 1H), 7.45 (m, 3H), 7.65 (d, 1H), 8.15 (d, 1H), 8.20 (d,
1H), 8.65 (d, 1H), 10.35 (s, 1H), 11.46 (br s, 1H), 12.44 (br s,
1H).
Example 100:
5-[5-(4-Hydroxypiperidin-1-ylmethyl)-1H-indol-2yl]-6-oxo-1,6-dihydropyrid-
ine-3-carboxylic
Acid[1-(3,4-difluorobenzyl)-1H-pyrazol-4-yl]-amide
##STR00126##
[0647] The title compound was prepared by the route outlined in
Scheme 9, using intermediate (8b) and applying the same the
experimental procedures as for Example 1. The crude product was
purified by preparative HPLC at pH 4 and isolated as a yellow
solid, 15 mg (7%)
[0648] LC/MS: RT=0.91 Min (270 nm); m/z=559 [M+H]. Total run time
1.9 min (super short pos).
[0649] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.45 (m, 2H), 1.85 (m,
2H), 2.25 (m, 2H), 2.85 (m, 2H), 3.55 (m, 1H), 3.75 (s, 2H), 5.40
(s, 2H), 7.10 (m, 2H), 7.25 (d, 1H), 7.35 (m, 1H), 7.45 (m, 3H),
7.65 (d, 1H), 8.15 (d, 1H), 8.20 (d, 1H), 8.35 (br s, 1H), 8.65 (d,
1H), 10.45 (s, 1H), 11.52 (br s, 1H).
Example 101:
5-(5-{[(2-Hydroxyethyl)-methylamino]-methyl}-1H-indol-2yl)-6-oxo-1,6-dihy-
dropyridine-3-carboxylic
Acid[1-(3,4-difluorobenzyl)-1H-pyrazol-4-yl]-amide
##STR00127##
[0651] The title compound was prepared by the route outlined in
Scheme 9, using intermediate (8b) and applying the same the
experimental procedures as for Example 1. The crude product was
purified by preparative HPLC at pH 4 to give the product as a
yellow solid, 21 mg, 11%.
[0652] LC/MS: RT=0.91 Min (270 nm), m/z=533 [M+H]. Total run time
1.9 min (super short pos).
[0653] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.25 (s, 3H), 2.45 (t,
2H), 3.55 (t, 2H), 3.65 (s, 2H), 5.35 (s, 2H), 7.10 (m, 2H), 7.25
(d, 1H), 7.35 (m, 1H), 7.45 (m, 3H), 7.65 (d, 1H), 8.10 (d, 1H),
8.15 (d, 1H), 8.25 (br s, 1H), 8.60 (d, 1H), 10.35 (s, 1H), 11.50
(br s, 1H).
Example 102:
5-(5-{[Ethyl-(2-hydroxyethyl)aminol-methyl}-1H-indol-2yl)-6-oxo-1,6-dihyd-
ropyridine-3-carboxylic
Acid[-(3,4-difluorobenzyl)-1H-pyrazol-4-yl]-amide
##STR00128##
[0655] The title compound was prepared by the route outlined in
Scheme 9, using intermediate (8b) and applying the same the
experimental procedures as for Example 1. The crude product was
purified by preparative HPLC at pH 4 to give the product as a
yellow solid, 18 mg, 9%.
[0656] LC/MS: RT=0.93 Min (270 nm), m/z=547.2 [M+H]. Total run time
1.9 min (super short pos).
[0657] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.05 (t, 3H), 2.55 (t,
2H), 2.60 (t, 2H), 3.50 (t, 2H), 3.69 (s, 2H), 5.35 (s, 2H), 7.10
(dd, 2H), 7.25 (d, 1H), 7.35 (m, 1H), 7.45 (m, 3H), 7.65 (d, 1H),
8.10 (d, 1H), 8.15 (d, 1H), 8.25 (br s, 1H), 8.60 (d, 1H), 10.35
(s, 1H), 11.50 (br s, 1H).
Example 103:
5-{5-[(2-Hydroxyethylamino)-methyl]-1H-indol-2yl}-6-oxo-1,6-dihydropyridi-
ne-3-carboxylic
Acid[1-(3,4-difluorobenzyl)-1H-pyrazol-4-yl]-amide
##STR00129##
[0659] The title compound was prepared by the route outlined in
Scheme 9, using intermediate (8b) and applying the same the
experimental procedures as for Example 1. The crude product was
purified by preparative HPLC at pH 4 to give the product as a
yellow solid, 12 mg, 6%.
[0660] LC/MS: RT=0.91 Min (270 nm), m/z=458 [Fragment]. Total run
time 1.9 min (super short pos).
[0661] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.75 (t, 2H), 3.55 (t,
2H), 3.93 (s, 2H), 5.35 (s, 2H), 7.10 (m, 1H), 7.15 (d, 1H), 7.25
(m, 1H), 7.35 (m, 1H), 7.45 (m, 2H), 7.55 (s, 1H), 7.65 (d, 1H),
8.10 (d, 1H), 8.15 (d, 1H), 8.20 (s, 1H), 8.30 (br s, 1H), 8.60 (d,
1H), 10.40 (s, 1H), 11.58 (br s, 1H).
Example 104:
5-[5-(4-Methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyr-
idine-3-carboxylic Acid
[1-(3,4-difluoro-benzyl)-1H-pyrazol-4-yl]-amide
##STR00130##
[0663] The title compound was prepared by the route outlined in
Scheme 9, using intermediate (8b) and applying the same the
experimental procedures as for Example 1. The crude product was
purified by preparative HPLC at pH 4 to give the product as a
yellow solid, 10 mg, 5%.
[0664] LC/MS: RT=0.92 Min (270 nm), m/z=558 [M+H]. Total run time
1.9 min (super short pos).
[0665] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.35 (s, 3H), 2.55 (br
s, 6H), 3.95 (br s, 4H), 5.50 (s, 2H), 7.20 (dd, 1H), 7.25 (m, 1H),
7.40 (d, 1H), 7.50 (m, 1H), 7.60 (m, 3H), 7.80 (s, 1H), 8.25 (d,
1H), 8.30 (d, 1H), 8.75 (d, 1H), 10.50 (s, 1H), 11.50 (br s,
1H).
Example 105:
5-{5-[4-(2-Hydroxyethyl)-piperazin-1-ylmethyl]-1H-indol-2l}-6-oxo-1,6-dih-
ydropyridine-3-carboxylic
Acid[1-(3,4-difluorobenzyl)-1H-pyrazol-4-yl]-amide
##STR00131##
[0667] The title compound was prepared by the route outlined in
Scheme 9, using intermediate (8b) and applying the same the
experimental procedures as for Example 1. The crude product was
purified by preparative HPLC at pH 4 to give the product as a
yellow solid, 8 mg, 3%.
[0668] LC/MS: RT=0.91 Min (270 nm), m/z=588 [M+H]. Total run time
1.9 min (super short pos).
[0669] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.40 (m, 10H), 3.45 (m,
4H), 5.35 (s, 2H), 7.04 (dd, 1H), 7.10 (m, 1H), 7.21 (d, 1H), 7.33
(m, 1H), 7.42 (m, 3H), 7.63 (s, 1H), 8.15 (d, 1H), 8.20 (s, 1H),
8.25 (br s, 1H), 8.60 (d, 1H), 10.40 (s, 1H), 11.50 (br s, 1H).
Example 106: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
[5-(4-dimethylaminomethyl-1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]--
amide
##STR00132##
[0671] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51, except (1H-Indol-4-yl)-methanol was used.
[0672] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 13 mg, 33%.
[0673] LC/MS RT=0.88 Min (270 nm), m/z=467 [M+H]. Total run time
1.9 min (super short pos/neg).
[0674] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.19 (s, 3H), 2.49 (s,
3H), 3.64 (s, 2H), 5.40 (s, 2H), 6.89 (d, 1h), 7.01 (t, 1H), 7.14
(br d, 1h), 7.38 (m, 6H), 7.88 (br s, 1H), 8.03 (s, 1H), 8.20 (d,
1H), 8.41 (s, 1H), 9.89 (s, 1H), 11.60 (s, 1H)
Example 107: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[4-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00133##
[0676] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51, except (1H-Indol-4-yl)-methanol was used. The title compound
was purified by trituration with acetonitrile, and isolated as a
yellow solid, 17 mg, 26%.
[0677] LC/MS RT=0.89 Min (270 nm), m/z=522 [M+H]. Total run time
1.9 min (super short pos/neg).
[0678] .sup.1H NMR (d.sub.6 DMSO): .delta. .quadrature.2.13 (s,
3H), 2.33 (br s, 4H), 2.41 (br s, 4H), 3.33 (s, 2H), 4.29 (s, 2H),
6.91 (d, 1H), 7.02 (d, 1H), 7.14 (br s, 1H), 7.34 (m, 6H), 7.85 (br
s, 1H), 8.03 (s, 1H), 8.19 (d, 1H), 8.41 (s, 1H), 9.78 (s, 1H),
11.56 (s, 1H), 12.00 (br s, 1H)
Example 108: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
[6-oxo-5-(4-piperidin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridin-3-yl]-
-amide
##STR00134##
[0680] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51, except (1H-Indol-4-yl)-methanol was used. The final step,
deprotection, was achieved using the following alternative to the
usual procedure.
2-[5-[(1-Benzyl-1H-pyrazole-4-carbonyl)-amino]-2-oxo-1-(2-trimethylsilany-
l-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-4-piperidin-1-ylmethyl-indole-1--
carboxylic acid tert-butyl ester (110 mg, 0.149 mmol) was stirred
in dichloromethane (5 mL) at -78.degree. C. and then boron
tribromide 1.0M solution in dichloromethane (2 mL, 2 mmol) was
added drop wise. After addition the cooling was removed and the
reaction was stirred at RT for 1 hour. The reaction mixture was
cooled to -78.degree. C. and methanol (2 mL) was added. Again the
cooling was removed and the reaction stirred at RT, followed by
concentration in vacuo. The residue was partitioned between ethyl
acetate and water. The organics were separated, washed with sodium
hydrogen bicarbonate, dried (Na.sub.2SO.sub.4) and concentrated in
vacuo to furnish a dark yellow solid. This was purified by
trituration with ethyl acetate to give the title compound as a
yellow solid, 31 mg, 41%.
[0681] LC/MS RT=1.55 Min (270 nm), m/z=507 [M+H]. Total run time
3.75 min (short pos).
[0682] .sup.1H NMR (d.sub.4-MeOD): .delta. 1.57 (m, 2H), 1.73 (m,
4H) 2.92 (m, 4H), 4.17 (m, 2H), 5.43 (s, 2H), 7.13 (d, 1H), 7.20
(m, 1H), 7.28 (s, 1H), 7.36 (m, 5H), 7.48 (m, 1H), 7.88 (s, 1H),
8.08 (s, 1H), 8.29 (s, 1H), 8.34 (s, 1H).
Example 109: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[4-(cis-2,6-dimethyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-di-
hydro-pyridin-3-yl}-amide
##STR00135##
[0684] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51, except (1H-Indol-4-yl)-methanol was used and the alternative
deprotection method described for Example 108 was adopted.
[0685] The title compound was purified by trituration with ethyl
acetate, and isolated as a yellow solid, 45 mg, 56%.
[0686] LC/MS RT=1.56 Min (270 nm), m/z=537 [M+H]. Total run time
3.75 min (short pos).
[0687] .sup.1H NMR (d.sub.4-MeOD): .delta. 1.11 (d, 6H), 1.88 (t,
2H) 2.86 (d, 2H), 3.70 (m, 2H), 3.83 (s, 2H), 5.42 (s, 2H), 7.03
(m, 1H), 7.13 (m, 1H), 7.25 (s, 1H), 7.37 (m, 6H), 7.95 (d, 1H),
8.09 (s, 1H), 8.28 (m, 2H).
Example 110:
5-(1H-Indol-2-yl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic Acid
[1-(6-fluoro-pyridin-3-ylmethyl)-1H-pyrazol-4-yl]-amide
##STR00136##
[0689] The title compound was prepared by the route outlined in
Scheme 1, following the same experimental procedures as for
Examples 1 and 2.
[0690] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 4 mg, 8%.
[0691] LC/MS RT=1.12 Min (270 nm), m/z=429 [M+H]. Total run time
1.9 min (super short pos/neg).
[0692] .sup.1H NMR (d.sub.6 DMSO): .delta. .quadrature.5.38 (s,
2H), 7.00 (td, 1H), 7.09 (td, 1H), 7.19 (dd, 1H), 7.24 (br d, 1H),
7.49 (br d, 1H), 7.55 (br d, 1H), 7.62 (s, 1H), 7.87 (td, 1H), 8.11
(d, 1H), 8.19 (s, 1H), 8.21 (br s, 1H), 8.55 (d, 1H), 10.31 (br s,
1H), 11.50 (br s, 1H).
Example 111:
1-(6-Fluoro-pyridin-3-ylmethyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00137##
[0694] The title compound was prepared by the route outlined in
Scheme 6, following the same experimental procedures as for
Examples 20 and 21.
[0695] The crude product was purified by preparative HPLC at pH 4
to give the product as a yellow solid, 3 mg, 11%.
[0696] LC/MS RT=1.08 Min (270 nm), m/z=429 [M+H]. Total run time
1.9 min (super short pos/neg).
[0697] .sup.1H NMR (d.sub.4-MeOD): .delta. .quadrature.5.45 (s,
2H), 7.00 (t, 1H), 7.02 (s, 1H), 7.09 (m, 2H), 7.41 (d, 1H), 7.53
(d, 1H), 7.92 (m, 2H), 8.07 (s, 1H), 8.21 (m, 2H), 8.33 (s,
1H).
Example 112: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-methyl-piperazin-1-yl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin--
3-yl}-amide
##STR00138##
[0699] The title compound was prepared according to the route
outlined in Scheme 10.
Step 1: Preparation of
1-Methyl-4-(3-methyl-4-nitro-phenyl)-piperazine (10a)
[0700] A mixture of 5-fluoro-2-nitrotoluene (2.5 g, 16 mmol),
N-methylpiperazine (2 mL, 18 mmol) and potassium carbonate (2.7 g,
19 mmol) in DMSO (7 mL) was stirred and heated at 100.degree. C.
for 2 hours. The reaction mixture was cooled to ambient temperature
and then diluted with ethyl acetate (100 mL), washed with water
(3.times.30 mL), brine, dried (MgSO.sub.4) and concentrated in
vacuo. The resultant crude product was purified by flash
chromatography on SiO.sub.2 eluting with dichloromethane-40%
methanol/dichloromethane (gradient) to afford the desired title
compound as a yellow solid, 3.67 g, 97%.
Step 2: Preparation of 5-(4-Methyl-piperazin-1-yl)-1H-indole
(10b)
[0701] A solution of
1-methyl-4-(3-methyl-4-nitro-phenyl)-piperazine (10a), (2.63 g,
11.2 mmol), N,N-dimethylformamide dimethyl acetal (4.7 mL, 35.84
mmol) and pyrrolidine (1.5 mL, 17.9 mmol) in anhydrous
N,N-dimethylformamide (20 mL) was heated at 120.degree. C. for 18
hours. The reaction mixture was concentrated in vacuo, taken up in
ethanol (50 mL) containing 2 mL of water and to this was added
ammonium formate (3.67 g, 58.2 mmol). Palladium, 10 wt. % on
activated carbon (0.84 g) was added and the suspension was stirred
and heated at 50.degree. C. for 30 minutes. The reaction mixture
was then filtered through a celite pad and the pad rinsed with hot
methanol (20 mL). The combined filtrate and washings were
concentrated in vacuo and the residue was taken up in ethyl acetate
(100 mL), washed with aqueous saturated sodium bicarbonate solution
(2.times.100 mL), brine, dried (MgSO.sub.4) and concentrated in
vacuo.
[0702] The resultant crude product was purified by flash
chromatography on SiO.sub.2 eluting first with hexane and then 15%
ethyl acetate/hexane to afford the desired title compound as an
off-white solid, 1.44 g, 60%.
Step 3: Preparation of
5-(4-Methyl-piperazin-1-yl)-indole-1-carboxylic Acid tert-butyl
ester (10c)
[0703] A solution of 5-(4-methyl-piperazin-1-yl)-1H-indole (10b),
(1.67 g, 7.7 mmol) in dichloromethane (40 mL) was added
di-tert-butyl dicarbonate (1.87 g, 8.6 mmol) drop wise at ambient
temperature as a solution in dichloromethane (5 mL).
4-Dimethylaminopyridine (0.095 g, 0.8 mmol) was added and the
reaction stirred at ambient temperature for 18 hours. The reaction
mixture was washed with aqueous saturated sodium bicarbonate
solution (100 mL), brine, dried (MgSO.sub.4) and concentrated in
vacuo. The resultant crude product was purified by flash
chromatography on SiO.sub.2 eluting with dichloromethane-15%
methanol/dichloromethane (gradient) to afford the desired title
compound as a yellow solid, 2.33 g, 95%.
Step 4: Preparation of
5-(4-Methyl-piperazin-1-yl)-2-[5-nitro-2-oxo-1-(2-trimethylsilanyl-ethoxy-
methyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic Acid
tert-butyl ester (10d)
[0704] The title compound was prepared by the route outlined in
Scheme 10 and using the experimental from Example 37, Step 3, with
intermediate (10c), 5-(4-methyl-piperazin-1-yl)-indole-1-carboxylic
acid tert-butyl ester (2.33 g, 7.4 mmol) and
3-iodo-5-nitro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyridin-2-one
(2.66 g, 6.7 mmol) which had been synthesised according to the
protocol described for intermediate (6a) in example 20. The
resultant solid was purified via trituration using diethyl ether,
to afford the title compound as a pale brown solid, 1.73 g,
40%.
Step 5: Preparation of
2-[5-Amino-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin--
3-yl]-5-(4-methyl-piperazin-1-yl)-indole-1-carboxylic Acid
tert-butyl ester (10e)
[0705] The title compound was prepared by the route outlined in
Scheme 10 and using the experimental from Example 20, Step 3, with
intermediate (10d),
5-(4-methyl-piperazin-1-yl)-2-[5-nitro-2-oxo-1-(2-trimethylsilanyl-
-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic acid
tert-butyl ester (0.73 g, 1.2 mmol). The resultant crude product
was purified by flash chromatography on SiO.sub.2 eluting with
dichloromethane-20% methanol/dichloromethane (gradient) to afford
the desired title compound as a dark yellow foam, 0.435 g, 63%.
Step 6: preparation of
2-[5-{[1-(4-Methyl-benzyl)-1H-pyrazole-4-carbonyl]-amino}-2-oxo-1-(2-trim-
ethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-5-(4-methyl-piperazin-
-1-yl)-indole-1-carboxylic Acid tert-butyl ester (10f)
[0706] The title compound was prepared by the route outlined in
Scheme 10 and using the experimental from Example 115, Step 4, with
intermediate (10e),
2-[5-amino-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-p-
yridin-3-yl]-5-(4-methyl-piperazin-1-yl)-indole-1-carboxylic acid
tert-butyl ester (0.1 g, 0.18 mmol) and
1-(4-methyl-benzyl)-1H-pyrazole-4-carbonyl chloride (0.047 g, 0.2
mmol). The resultant crude product was purified by flash
chromatography on SiO.sub.2 eluting with dichloromethane-8%
methanol/dichloromethane (gradient) to afford the desired title
compound as a pale brown solid, 0.107 g, 79%.
Step 7: Preparation of the Title Compound:
1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-methyl-piperazin-1-yl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin--
3-yl}-amide
[0707] The title compound was prepared by the route outlined in
Scheme 10, following the same experimental procedures as for
Example 37. It was purified by trituration with acetonitrile, and
isolated as a yellow solid, 43 mg, 59%.
[0708] LC/MS: RT=1.45 Min (270 nm), m/z=522 [M+H]. Total run time
3.75 min (short pos).
[0709] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.23 (s, 3H), 2.29 (s,
3H), 2.48 (m, 4H), 3.04 (m, 4H), 5.34 (s, 2H), 6.86-6.89 (m, 2H),
6.97 (m, 1H), 7.19 (m, 4H), 7.37 (d, 1H), 7.82 (d, 1H), 8.01 (s,
1H), 8.11 (d, 1H), 8.37 (s, 1H), 9.76 (s, 1H), 11.37 (s, 1H), 11.96
(br s, 1H).
Example 113: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-methyl-piperazin-1-yl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin--
3-yl}-amide
##STR00139##
[0711] The title compound was prepared by the route outlined in
Scheme 10, following the same experimental procedures as for
Example 112. The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 40 mg, 61%.
[0712] LC/MS: RT=1.49 Min (270 nm), m/z=508 [M+H]. Total run time
3.75 min (short pos).
[0713] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.23 (s, 3H), 2.48 (m,
4H), 3.05 (m, 4H), 5.40 (s, 2H), 6.86-6.89 (m, 2H), 6.97 (m, 1H),
7.28-7.40 (m, 6H), 7.82 (d, 1H), 8.03 (s, 1H), 8.12 (d, 1H), 8.41
(s, 1H), 9.78 (s, 1H), 11.36 (s, 1H), 11.97 (br s, 1H).
Example 114: 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-methyl-piperazin-1-yl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin--
3-yl}-amide
##STR00140##
[0715] The title compound was prepared by the route outlined in
Scheme 10, following the same experimental procedures as for
Example 112. The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 38 mg, 57%.
[0716] LC/MS: RT=1.52 Min (270 nm), m/z=526 [M+H]. Total run time
3.75 min (short pos).
[0717] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.22 (s, 3H), 2.48 (m,
4H), 3.05 (m, 4H), 5.39 (s, 2H), 6.86-6.89 (m, 2H), 6.97 (m, 1H),
7.19-7.24 (m, 2H), 7.34-7.39 (m, 3H), 7.82 (d, 1H), 8.03 (s, 1H),
8.12 (d, 1H), 8.41 (s, 1H), 9.78 (s, 1H), 11.36 (s, 1H), 11.97 (br
s, 1H).
Example 115: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{6-oxo-5-[5-(2-piperidin-1-yl-ethoxy)-1H-indol-2-yl]-1,6-dihydro-pyridin--
3-yl}-amide
##STR00141##
[0719] The title compound was prepared according to the route
outlined in Scheme 11.
Step 1: Preparation of
5-(tert-Butyl-dimethyl-silanyloxy)-indole-1-carboxylic Acid
tert-butyl ester (11a)
[0720] The title compound was prepared by the route outlined in
Scheme 11 and using the experimental from Example 37, Step 2, with
intermediate 1H-Indol-5-ol (5.54 g, 7.4 mmol).
[0721] The resultant crude product was purified by flash
chromatography on SiO.sub.2 with hexane-10% ethyl acetate/hexane
(gradient) to afford the title compound as a white solid, 13.41 g,
93%.
Step 2: Preparation of
5-(tert-Butyl-dimethyl-silanyloxy)-2-[5-nitro-2-oxo-1-(2-trimethylsilanyl-
-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic Acid
tert-butyl ester (11b)
[0722] The title compound was prepared by the route outlined in
Scheme 11 and using the experimental from Example 37, Step 3, with
intermediate 5-(tert-butyl-dimethyl-silanyloxy)-indole-1-carboxylic
acid tert-butyl ester (11a) (2.90 g, 8.3 mmol) and (6a),
3-iodo-5-nitro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyridin-2-one
(3 g, 7.6 mmol). The resultant crude product was purified by flash
chromatography on SiO.sub.2 with hexane-20% ethyl acetate/hexane
(gradient) to afford after trituration using hexane, the title
compound as a pale yellow solid, 3.67 g, 79%.
Step 3: Preparation of
2-[5-Amino-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin--
3-yl]-5-(tert-butyl-dimethyl-silanyloxy)-indole-1-carboxylic Acid
tert-butyl ester (11c)
[0723] The title compound was prepared by the route outlined in
Scheme 11 and using the experimental from Example 20, Step 3, with
intermediate (11b)
5-(tert-butyl-dimethyl-silanyloxy)-2-[5-nitro-2-oxo-1-(2-trimethyls-
ilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic
acid tert-butyl ester (3.65 g, 5.93 mmol). The resultant crude
product was purified by flash chromatography on SiO.sub.2 with
hexane-40% ethyl acetate/hexane (gradient) to afford the title
compound as a dark yellow foam, 2.615 g, 75%.
Step 4: Preparation of
5-(tert-Butyl-dimethyl-silanyloxy)-2-[5-{[1-(4-methyl-benzyl)-1H-pyrazole-
-4-carbonyl]-amino}-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro--
pyridin-3-yl]-indole-1-carboxylic Acid tert-butyl ester (11d)
[0724] Intermediate (11c),
2-[5-amino-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin--
3-yl]-5-(tert-butyl-dimethyl-silanyloxy)-indole-1-carboxylic acid
tert-butyl ester (1.3 g, 2.2 mmol) was stirred in dichloromethane
(50 mL) at RT with triethylamine (444 mg, 0.612 mL, 4.4 mmol). The
reaction mixture was cooled to 5.degree. C. and then a solution of
1-(4-methyl-benzyl)-1H-pyrazole-4-carbonyl chloride (2.86 mmol,
0.67 g), which had been prepared according to the protocol below,
in dichloromethane (10 ml), was added drop wise. After addition the
reaction was stirred at RT for 3 hrs and then the reaction mixture
was washed with saturated sodium hydrogen carbonate solution
(2.times.50 mL), brine (50 ml), dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. The resultant crude product was purified by
flash chromatography on SiO.sub.2 eluting with hexane-50% ethyl
acetate/hexane (gradient) and further purified via trituration with
isohexane (20 mL) and diethyl ether (20 mL). The solids were
separated by filtration and dried in vacuo to afford the desired
intermediate as a white solid, 1.56 g, 90%.
Preparation of 1-(4-Methyl-benzyl)-1H-pyrazole-4-carbonyl chloride
used in Step 4, above
[0725] 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic acid (0.618 g,
2.86 mmol), which had been prepared according to the protocol
described for intermediate (6e), in Example 21, was stirred in
toluene (20 mL) at RT and thionyl chloride (681 mg, 0.42 mL, 5.72
mmol) was added. The reaction mixture was slowly heated to
90.degree. C. and heating continued for 3 hrs. After cooling the
reaction was concentrated in vacuo. Toluene was added to the
residue and concentrated in vacuo. This was repeated a further
three times and the crude solid obtained was triturated using
isohexane. The solids were separated by filtration washed with
isohexane and dried in vacuo to afford
1-(4-methyl-benzyl)-1H-pyrazole-4-carbonyl chloride as a white
solid, 0.67 g, quant.
Step 5: Preparation of
5-Hydroxy-2-[5-{[1-(4-methyl-benzyl)-1H-pyrazole-4-carbonyl]-amino}-2-oxo-
-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-ca-
rboxylic Acid tert-butyl ester (11e)
[0726] Intermediate (11d),
5-(tert-butyl-dimethyl-silanyloxy)-2-[5-{[1-(4-methyl-benzyl)-1H-pyrazole-
-4-carbonyl]-amino}-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro--
pyridin-3-yl]-indole-1-carboxylic acid tert-butyl ester (1.55 g,
1.97 mmol) was stirred in tetrahydrofuran (40 mL) and cooled to
0.degree. C. Tetrabutylammonium fluoride solution 1.0M in
tetrahydrofuran (2.08 mL, 2.08 mmol) was added drop wise at
0.degree. C., and then the reaction was allowed to attain ambient
temperature, where it was stirred for a further 2 hours. The
reaction mixture was diluted with ethyl acetate (30 mL), washed
with water (30 mL), aqueous 0.5N hydrochloric acid solution (30
mL), brine, dried (Na.sub.2SO.sub.4) and concentrated in vacuo. The
resultant green foam was purified via trituration using diethyl
ether, to afford the title compound as a pale yellow solid, 0.946
g, 71%.
Step 6: Preparation of
2-[5-{[1-(4-Methyl-benzyl)-1H-pyrazole-4-carbonyl]-amino}-2-oxo-1-(2-trim-
ethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-5-(2-piperidin-1-yl-e-
thoxy)-indole-1-carboxylic Acid tert-butyl ester (11f)
[0727] To a solution of intermediate (11e),
5-hydroxy-2-[5-{[1-(4-methyl-benzyl)-1H-pyrazole-4-carbonyl]-amino}-2-oxo-
-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-ca-
rboxylic acid tert-butyl ester (150 mg, 0.22 mmol) in
N,N-dimethylformamide (3 mL) was added 1-(2-chloroethyl)-piperidine
hydrochloride (62 mg, 0.33 mmol) and cesium carbonate (219 mg, 0.67
mmol). The reaction mixture was heated at 50.degree. C. for 5
hours, and cooled to ambient temperature. The reaction mixture was
cooled and partitioned between ethyl acetate and water. The ethyl
acetate layer was separated and washed with brine, dried
(Na.sub.2SO.sub.4) and concentrated in vacuo. The title compound
was purified by flash chromatography on SiO.sub.2 eluting with
dichloromethane-5% methanol/dichloromethane (gradient) to afford
the desired title compound as a pale yellow solid, 94 mg, 54%.
Step 7: Preparation of the Title Compound:
1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{6-oxo-5-[5-(2-piperidin-1-yl-ethoxy)-1H-indol-2-yl]-1,6-dihydro-pyridin--
3-yl}-amide
[0728] The title compound was prepared according to the
experimental used in Example 37, Step 8 with intermediate (11f),
2-[5-{[1-(4-methyl-benzyl)-1H-pyrazole-4-carbonyl]-amino}-2-oxo-1-(2-trim-
ethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-5-(2-piperidin-1-yl-e-
thoxy)-indole-1-carboxylic acid tert-butyl ester. Purification of
the crude product was accomplished using trituration with
acetonitrile. The title compound was isolated as a yellow solid, 41
mg, 62%.
[0729] LC/MS: RT=1.76 Min (270 nm), m/z=551 [M+H]. Total run time
3.75 min (short pos).
[0730] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.38 (m, 2H), 1.50 (m,
4H), 2.29 (s, 3H), 2.44 (m, 4H), 2.65 (t, 2H), 4.04 (t, 2H), 5.34
(s, 2H), 6.71 (dd, 1H), 6.92 (m, 1H), 7.03 (d, 1H), 7.19 (m, 4H),
7.39 (d, 1H), 7.82 (d, 1H), 8.01 (s, 1H), 8.14 (d, 1H), 8.37 (s,
1H), 9.76 (s, 1H), 11.46 (s, 1H), 11.97 (br s, 1H).
Example 116: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
(5-{5-[2-(3-fluoro-piperidin-1-yl)-ethoxy]-1H-indol-2-yl}-6-oxo-1,6-dihyd-
ro-pyridin-3-yl)-amide
##STR00142##
[0732] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115.
[0733] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 21 mg, 75%.
[0734] LC/MS: RT=1.74 Min (270 nm), m/z=569 [M+H]. Total run time
3.75 min (short pos).
[0735] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.42-1.56 (m, 2H),
1.67-1.88 (m, 2H), 2.29 (s, 3H), 2.33-2.57 (m, 3H), 2.75 (d, 2H),
2.86 (m, 1H), 4.06 (t, 2H), 4.63 (m, 1H), 5.34 (s, 2H), 6.71 (dd,
1H), 6.93 (m, 1H), 7.04 (d, 1H), 7.19 (m, 4H), 7.40 (d, 1H), 7.82
(d, 1H), 8.01 (s, 1H), 8.14 (d, 1H), 8.37 (s, 1H), 9.76 (s, 1H),
11.45 (s, 1H), 11.98 (br s, 1H).
Example 117: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(3-morpholin-4-yl-propoxy)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin-
-3-yl}-amide
##STR00143##
[0737] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115.
[0738] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 51 mg, 71%.
[0739] LC/MS: RT=1.72 Min (270 nm), m/z=567 [M+H]. Total run time
3.75 min (short pos).
[0740] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.88 (m, 2H), 2.29 (s,
3H), 2.37 (m, 4H), 2.44 (d, 2H), 3.58 (m, 4H), 3.99 (t, 2H), 5.34
(s, 2H), 6.71 (dd, 1H), 6.93 (m, 1H), 7.01 (d, 1H), 7.19 (m, 4H),
7.40 (d, 1H), 7.82 (d, 1H), 8.01 (s, 1H), 8.14 (d, 1H), 8.37 (s,
1H), 9.77 (s, 1H), 11.44 (s, 1H), 11.98 (br s, 1H).
Example 118: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(2-morpholin-4-yl-ethoxy)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin--
3-yl}-amide
##STR00144##
[0742] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115.
[0743] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 20 mg, 63%.
[0744] LC/MS: RT=1.71 Min (270 nm), m/z=553 [M+H]. Total run time
3.75 min (short pos).
[0745] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.29 (s, 3H), 2.50 (m,
4H), 2.70 (d, 2H), 3.59 (m, 4H), 4.07 (t, 2H), 5.34 (s, 2H), 6.72
(dd, 1H), 6.93 (m, 1H), 7.04 (d, 1H), 7.19 (m, 4H), 7.40 (d, 1H),
7.82 (d, 1H), 8.01 (s, 1H), 8.14 (d, 1H), 8.37 (s, 1H), 9.76 (s,
1H), 11.45 (s, 1H), 11.96 (br s, 1H).
Example 119: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{6-oxo-5-[5-(3-piperidin-1-yl-propoxy)-1H-indol-2-yl]-1,6-dihydro-pyridin-
-3-yl}-amide
##STR00145##
[0747] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115.
[0748] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 47 mg, 87%.
[0749] LC/MS: RT=1.78 Min (270 nm), m/z=565 [M+H]. Total run time
3.75 min (short pos).
[0750] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.38 (m, 2H), 1.49 (m,
4H), 1.86 (m, 2H), 2.29 (s, 3H), 2.33 (m, 4H), 2.39 (t, 2H), 3.97
(t, 2H), 5.34 (s, 2H), 6.70 (dd, 1H), 6.92 (m, 1H), 7.01 (d, 1H),
7.19 (m, 4H), 7.39 (d, 1H), 7.82 (d, 1H), 8.01 (s, 1H), 8.13 (d,
1H), 8.37 (s, 1H), 9.77 (s, 1H), 11.45 (s, 1H), 11.98 (br s,
1H).
Example 120: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(3-dimethylamino-2,2-dimethyl-propoxy)-1H-indol-2-yl]-6-oxo-1,6-dih-
ydro-pyridin-3-yl}-amide
##STR00146##
[0752] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115.
[0753] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 65 mg, 39%.
[0754] LC/MS: RT=1.58 Min (270 nm), m/z=539 [M+H]. Total run time
3.75 min (short pos).
[0755] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.96 (s, 6H), 2.21 (s,
6H), 2.24 (s, 2H), 3.67 (s, 2H), 5.41 (s, 2H), 6.72 (dd, 1H), 6.92
(d. 1H), 7.01 (d, 1H), 7.28-7.40 (m, 6H), 7.84 (d, 1H), 8.03 (s,
1H), 8.14 (d, 1H), 8.41 (s, 1H), 9.79 (s, 1H), 11.43 (s, 1H), 11.99
(br s, 1H).
Example 121: 1-(4-Trifluoromethyl-benzyl)-1H-pyrazole-4-carboxylic
Acid
{6-oxo-5-[5-(2-piperidin-1-yl-ethoxy)-1H-indol-2-yl]-1,6-dihydro-pyridin--
3-yl}-amide
##STR00147##
[0757] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115, but with the following modification to Step 6. A 3-5
mL microwave vial was charged with
5-hydroxy-2-[2-oxo-5-{[1-(4-trifluoromethyl-benzyl)-1H-pyrazole-4-ca-
rbonyl]-amino}-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-y-
l]-indole-1-carboxylic acid tert-butyl ester (150 mg, 0.207 mmol),
triphenyl phosphine (87 mg, 0.33 mmol), tetrahydrofuran (3 mL),
1-(2-hydroxyethyl)piperidine (40 mg, 41 .mu.L 0.31 mmol) and
diisopropyl azidocarboxylate (67 mg, 65 .mu.L, 0.33 mmol). The
reaction mixture was then heated to 140.degree. C. in the microwave
for 30 mins. The crude reaction mixture was purified by flash
chromatography on SiO.sub.2, eluting dichloromethane-15%
methanol/dichloromethane (gradient) to afford the title compound as
a yellow solid, 87 mg, 50%.
[0758] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 33 mg, 52%.
[0759] LC/MS: RT=1.69 Min (270 nm), m/z=605 [M+H]. Total run time
3.75 min (short pos).
[0760] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.38 (m, 2H), 1.50 (m,
4H), 2.44 (m, 4H), 2.66 (t, 2H), 4.04 (t, 2H), 5.54 (s, 2H), 6.71
(dd, 1H), 6.92 (m, 1H), 7.03 (d, 1H), 7.40 (d, 1H), 7.46 (m, 2H),
7.76 (m, 2H), 7.83 (d, 1H), 8.07 (s, 1H), 8.15 (d, 1H), 8.47 (s,
1H), 9.81 (s, 1H), 11.44 (s, 1H), 11.99 (br s, 1H).
Example 122: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(3-dimethylamino-propoxy)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin--
3-yl}-amide
##STR00148##
[0762] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115.
[0763] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 6 mg, 23%.
[0764] LC/MS: RT=0.92 Min (270 nm), m/z=525 [M+H]. Total run time
1.9 min (super short pos).
[0765] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.81-1.88 (m, 2H), 2.15
(s, 6H), 2.29 (s, 3H), 2.34-2.38 (m, 2H), 3.96-3.99 (t, 2H), 5.34
(s, 2H), 6.69-6.72 (dd, 1H), 6.92 (s, 1H), 7.00-7.01 (d, 1H), 7.19
(s, 4H), 7.38-7.41 (d, 1H), 7.82-7.83 (d, 1H), 8.01 (s, 1H),
8.14-8.15 (d, 1H), 8.37 (s, 1H), 9.77 (s, 1H), 11.47 (s, 1H),
11.92-12.00 (br s, 1H).
Example 123: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(3-diethylamino-propoxy)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin-3-
-yl}-amide
##STR00149##
[0767] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0768] The title compound was purified by trituration with
acetonitrile, and isolated as a brown solid, 8 mg, 35%.
[0769] LC/MS: RT=1.63 Min (270 nm), m/z=553 [M+H]. Total run time
3.75 min (short pos).
[0770] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.93-0.97 (t, 6H),
1.79-1.83 (m, 2H), 2.29 (s, 3H), 3.96-3.99 (t, 2H), 5.34 (s, 2H),
6.68-6.70 (d, 1H), 6.89 (s, 1H), 7.00 (s, 1H), 7.19 (s, 4H),
7.37-7.39 (d, 1H), 7.84 (s, 1H), 8.02 (s, 1H), 8.14 (s, 1H), 8.37
(s, 1H), 9.78 (s, 1H), 11.62-11.70 (br s, 1H).
Example 124: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
(5-{5-[3-(4-methyl-piperazin-1-yl)-propoxy]-1H-indol-2-yl}-6-oxo-1,6-dihy-
dro-pyridin-3-yl)-amide
##STR00150##
[0772] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0773] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 13 mg, 29%.
[0774] LC/MS: RT=0.91 Min (270 nm), m/z=580 [M+H]. Total run time
1.9 min (super short pos).
[0775] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.83-1.89 (m, 2H), 2.14
(s, 3H), 2.29 (s, 3H), 2.41-2.44 (t, 2H), 2.31-2.44 (br m, 8H),
3.96-3.99 (t, 2H), 5.34 (s, 2H), 6.69-6.72 (dd, 1H), 6.92 (s, 1H),
7.00-7.01 (d, 1H), 7.19 (s, 4H), 7.38-7.40 (d, 1H), 7.82-7.83 (d,
1H), 8.01 (s, 1H), 8.13-8.14 (d, 1H), 8.37 (s, 1H), 9.78 (s, 1H),
11.46 (s, 1H), 11.90-12.00 (br s, 1H).
Example 125: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(2-diethylamino-ethoxy)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin-3--
yl}-amide
##STR00151##
[0777] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115.
[0778] The title compound was purified by trituration with
acetonitrile, and isolated as a brown solid, 28 mg, 44%.
[0779] LC/MS: RT=0.93 Min (270 nm), m/z=539 [M+H]. Total run time
1.9 min (super short pos).
[0780] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.97-1.00 (t, 6H), 2.29
(s, 3H), 2.53-2.59 (q, 4H), 2.76-2.79 (t, 2H), 3.98-4.01 (t, 2H),
5.34 (s, 2H), 6.69-6.72 (dd, 1H), 6.93 (s, 1H), 7.02-7.03 (d, 1H),
7.19 (s, 4H), 7.39-7.41 (d, 1H), 7.82-7.83 (d, 1H), 8.01 (s, 1H),
8.14-8.15 (d, 1H), 8.37 (s, 1H), 9.78 (s, 1H), 11.45 (s, 1H).
Example 126: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
(5-{5-[2-(4-methyl-piperazin-1-yl)-ethoxy]-1H-indol-2-yl}-6-oxo-1,6-dihyd-
ro-pyridin-3-yl)-amide
##STR00152##
[0782] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115.
[0783] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 2 mg, 23%.
[0784] LC/MS: RT=0.92 Min (270 nm), m/z=566 [M+H]. Total run time
1.9 min (super short pos).
[0785] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.14 (s, 3H), 2.29 (s,
3H), 2.24-2.40 (br m, 8H), 2.64-2.70 (m, 2H), 4.03-4.06 (t, 2H),
5.34 (s, 2H), 6.69-6.72 (dd, 1H), 6.91 (s, 1H), 7.02-7.03 (d, 1H),
7.19 (s, 4H), 7.38-7.40 (d, 1H), 7.82-7.83 (d, 1H), 8.02 (s, 1H),
8.13-8.14 (d, 1H), 8.37 (s, 1H), 9.77 (s, 1H), 11.48-11.61 (br s,
1H).
Example 127: 1-(3-Ethyl-benzyl)-1H-pyrazole-4-carboxylic Acid
(5-{5-[3-(4-methyl-piperazin-1-yl)-propoxy]-1H-indol-2-yl}-6-oxo-1,6-dihy-
dro-pyridin-3-yl)-amide
##STR00153##
[0787] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0788] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 7 mg, 24%.
[0789] LC/MS: RT=0.96 Min (270 nm), m/z=594 [M+H]. Total run time
1.9 min (super short pos).
[0790] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.15-1.19 (t, 3H),
1.84-1.88 (m, 2H), 2.14 (s, 3H), 2.30-2.46 (br m, 8H), 2.41-2.44
(t, 2H), 2.57-2.62 (q, 2H), 3.96-3.99 (t, 2H), 5.37 (s, 2H),
6.69-6.72 (dd, 1H), 6.92 (s, 1H), 7.00-7.01 (d, 1H), 7.07-7.09 (d,
1H), 7.15 (s, 1H), 7.18 (s, 1H), 7.27-7.31 (m, 1H), 7.38-7.41 (d,
1H), 7.82-7.83 (d, 1H), 8.03 (s, 1H), 8.14-8.15 (d, 1H), 8.40 (s,
1H), 9.79 (s, 1H), 11.48 (s, 1H), 11.90-12.00 (br m, 1H).
Example 128: 1-(3-Ethyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(2-dimethylamino-ethoxy)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin-3-
-yl}-amide
##STR00154##
[0792] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0793] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 16 mg, 39%.
[0794] LC/MS: RT=0.95 Min (270 nm), m/z=525 [M+H]. Total run time
1.9 min (super short pos).
[0795] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.15-1.19 (t, 3H), 2.22
(s, 6H), 2.58-2.64 (m, 4H), 4.01-4.04 (t, 2H), 5.37 (s, 2H),
6.69-6.72 (dd, 1H), 6.91 (s, 1H), 7.02-7.03 (d, 1H), 7.07-7.09 (d,
1H), 7.15 (s, 1H), 7.18 (s, 1H), 7.27-7.31 (t, 1H), 7.38-7.41 (d,
1H), 7.82-7.83 (d, 1H), 8.03 (s, 1H), 8.14-8.15 (d, 1H), 8.40 (s,
1H), 9.78 (s, 1H), 11.50-11.61 (s, 1H), 11.86-12.00 (br s, 1H).
Example 129: 1-(3-Ethyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(3-dimethylamino-propoxy)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin--
3-yl}-amide
##STR00155##
[0797] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0798] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 6 mg, 20%.
[0799] LC/MS: RT=0.97 Min (270 nm), m/z=539 [M+H]. Total run time
1.9 min (super short pos).
[0800] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.15-1.19 (t, 3H), 1.85
(m, 2H), 2.15 (s, 6H), 2.33-2.40 (m, 4H), 3.96-3.98 (t, 2H), 5.37
(s, 2H), 6.69-6.72 (d, 1H), 6.91 (s, 1H), 7.01 (s, 1H), 7.07-7.09
(d, 1H), 7.15 (s, 1H), 7.18 (s, 1H), 7.27-7.31 (t, 1H), 7.38-7.40
(d, 1H), 7.84 (s, 1H), 8.03 (s, 1H), 8.15 (s, 1H), 8.41 (s, 1H),
9.78 (s, 1H), 11.50 (s, 1H).
Example 130: 1-(3-Ethyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(2-diethylamino-ethoxy)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin-3--
yl}-amide
##STR00156##
[0802] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0803] The title compound was purified by trituration with
acetonitrile, and isolated as a brown solid, 2 mg, 3%.
[0804] LC/MS: RT=0.98 Min (270 nm), m/z=553 [M+H]. Total run time
1.9 min (super short pos).
[0805] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.97-1.00 (t, 6H),
1.15-1.19 (t, 3H), 2.53-2.60 (m, 6H), 2.76-2.79 (t, 2H), 3.98-4.01
(t, 2H), 5.37 (s, 2H), 6.69-6.72 (dd, 1H), 6.92-6.41 (m, 7H), 7.83
(m, 1H), 8.03 (s, 1H), 8.14-8.15 (s, 1H), 8.40 (s, 1H), 9.79 (s,
1H), 11.44 (s, 1H), 11.90-12.00 (br m, 1H).
Example 131: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
(5-{5-[2-(2,6-dimethyl-morpholin-4-yl)-ethoxy]-1H-indol-2-yl}-6-oxo-1,6-d-
ihydro-pyridin-3-yl)-amide
##STR00157##
[0807] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0808] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 2 mg, 5%.
[0809] LC/MS: RT=0.98 Min (270 nm), m/z=581 [M+H]. Total run time
1.9 min (super short pos).
[0810] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.04 (d, 6H), 1.73 (t,
2H), 2.29 (s, 3H), 2.68 (m, 2H), 2.84 (d, 2H), 3.52-3.61 (m, 2H),
4.06 (t, 2H), 5.34 (s, 2H), 6.71 (dd, 1H), 6.92 (d, 1H), 7.03 (d,
1H), 7.19 (s, 4H), 7.40 (d, 1H), 7.82 (d, 1H), 8.01 (s, 1H), 8.15
(d, 1H), 8.37 (s, 1H), 9.77 (s, 1H), 11.47 (br s, 1H), 11.92 (br s,
1H)
Example 132: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(2-dimethylamino-ethoxy)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin-3-
-yl}-amide
##STR00158##
[0812] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115.
[0813] The title compound was purified by preparative HPLC at pH9
and isolated as a yellow solid, 2 mg, 3%.
[0814] LC/MS: RT=0.91 Min (270 nm), m/z=511 [M+H]. Total run time
1.9 min (super short pos).
[0815] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.23 (s, 6H), 2.29 (s,
3H), 2.63 (t, 2H), 4.03 (t, 2H), 5.34 (s, 2H), 6.72 (dd, 1H), 6.93
(d, 1H), 7.03 (d, 1H), 7.19 (s, 4H), 7.40 (d, 1H), 7.83 (d, 1H),
8.02 (s, 1H), 8.15 (d, 1H), 8.37 (s, 1H), 9.78 (s, 1H), 11.45 (br
s, 1H), 11.98 (br s, 1H)
Example 133: 1-(3-Ethyl-benzyl)-1H-pyrazole-4-carboxylic Acid
(5-{5-[2-(4-methyl-piperazin-1-yl)-ethoxy]-1H-indol-2-yl}-6-oxo-1,6-dihyd-
ro-pyridin-3-yl)-amide
##STR00159##
[0817] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0818] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 12 mg, 20%.
[0819] LC/MS: RT=0.97 Min (270 nm), m/z=580 [M+H]. Total run time
1.9 min (super short pos).
[0820] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.17 (t, 3H), 1.23 (m,
2H), 2.14 (s, 3H), 2.24-2.38 (m, 4H), 2.59 (q, 2H), 2.68 (t, 2H),
4.05 (t, 2H), 5.37 (s, 2H), 6.71 (dd, 1H), 6.92 (d, 1H), 7.03 (d,
1H), 7.08 (d, 1H), 7.14-7.19 (m, 2H), 7.26-7.31 (m, 1H), 7.39 (d,
1H), 7.83 (d, 1H), 8.03 (s, 1H), 8.15 (d, 1H), 8.4 (s, 1H), 9.78
(s, 1H), 11.47 (br s, 1H), 11.95 (br s, 1H)
Example 134: 1-(3-Ethyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{6-oxo-5-[5-(3-piperidin-1-yl-propoxy)-1H-indol-2-yl]-1,6-dihydro-pyridin-
-3-yl}-amide
##STR00160##
[0822] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0823] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 13 mg, 25%.
[0824] LC/MS: RT=1.02 Min (270 nm), m/z=579 [M+H]. Total run time
1.9 min (super short pos).
[0825] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.17 (t, 3H), 1.33-1.41
(m, 2H), 1.46-1.52 (m, 4H), 1.85 (quintet, 2H), 2.30-2.35 (m, 4H),
2.39 (t, 2H), 2.59 (q, 2H), 3.97 (t, 2H), 5.37 (s, 2H), 6.71 (dd,
1H), 6.92 (d, 1H), 7.01 (d, 1H), 7.08 (d, 1H), 7.14-7.20 (m, 2H),
7.26-7.31 (m, 1H), 7.4 (d, 1H), 7.82 (d, 1H), 8.03 (s, 1H), 8.15
(d, 1H), 8.4 (s, 1H), 9.79 (s, 1H), 11.46 (br s, 1H), 11.95 (br s,
1H)
Example 135: 1-(3-Ethyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{6-oxo-5-[5-(2-piperidin-1-yl-ethoxy)-1H-indol-2-yl]-1,6-dihydro-pyridin--
3-yl}-amide
##STR00161##
[0827] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0828] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 13 mg, 23%.
[0829] LC/MS: RT=1.74 Min (270 nm), m/z=565 [M+H]. Total run time
3.75 min (short pos).
[0830] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.17 (t, 3H), 1.4 (m,
2H), 1.5 (m, 4H), 2.45 (m, 4H), 2.6 (q, 2H), 2.65 (t, 2H), 4.04 (t,
2H), 5.37 (s, 2H), 6.71 (dd, 1H), 6.92 (s, 1H), 7.03 (d, 1H), 7.07
(d, 1H), 7.15-7.2 (m, 2H), 7.26-7.31 (m, 1H), 7.4 (d, 1H), 7.82 (d,
1H), 8.03 (s, 1H), 8.15 (d, 1H), 8.4 (s, 1H), 9.78 (br s, 1H),
11.45 (br s, 1H), 11.98 (br s, 1H)
Example 136: 1-(3-Ethyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(3-diethylamino-propoxy)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin-3-
-yl}-amide
##STR00162##
[0832] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0833] The title compound was purified by preparative HPLC at pH9
and isolated as a yellow solid, 6 mg, 12%.
[0834] LC/MS: RT=1.01 Min (270 nm), m/z=567 [M+H]. Total run time
1.9 min (super short pos).
[0835] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.96 (t, 6H), 1.17 (t,
3H), 1.83 (quintet, 2H), 2.44-2.52 (multiplicity partially obscured
by residual DMSO peak, 4H), 2.54-2.62 (m, 4H), 3.98 (t, 2H), 5.37
(s, 2H), 6.71 (dd, 1H), 6.93 (d, 1H), 7.01 (d, 1H), 7.08 (d, 1H),
7.14-7.19 (m, 2H), 7.29 (m, 1H), 7.40 (d, 1H), 7.83 (d, 1H), 8.03
(s, 1H), 8.16 (d, 1H), 8.40 (s, 1H), 9.81 (s, 1H), 11.45 (br s,
1H), 11.96 (br s, 1H)
Example 137: 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(3-dimethylamino-2,2-dimethyl-propoxy)-1H-indol-2-yl]-6-oxo-1,6-dih-
ydro-pyridin-3-yl}-amide
##STR00163##
[0837] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0838] The title compound was purified by trituration with diethyl
ether, and isolated as a yellow solid, 4 mg, 7%.
[0839] LC/MS: RT=1.67 Min (270 nm), m/z=553 [M+H]. Total run time
3.75 min (short pos).
[0840] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.96 (s, 6H), 2.2 (s,
6H), 2.24 (s, 2H), 2.29 (s, 3H), 3.67 (s, 2H), 5.34 (s, 2H), 6.72
(dd, 1H), 6.92 (d, 1H) 7.01 (d, 1H), 7.19 (s, 4H), 7.39 (d, 1H),
7.84 (s, 1H), 8.01 (s, 1H), 8.13 (s, 1H), 8.37 (s, 1H), 9.77 (br s,
1H), 11.43 (br s, 1H), 11.98 (br s, 1H)
Example 138: 1-(3-Ethyl-benzyl)-1H-pyrazole-4-carboxylic Acid
(5-{5-[2-(2,6-dimethyl-morpholin-4-yl)-ethoxy]1H-indol-2-yl}-6-oxo-1,6-di-
hydro-pyridin-3-yl)-amide
##STR00164##
[0842] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0843] The title compound was purified by preparative HPLC at pH 4
and isolated as a brown solid, 5 mg, 19%.
[0844] LC/MS: RT=1.01 Min (270 nm), m/z=595 [M+H]. Total run time
1.9 min (super short pos).
[0845] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.04 (d, 6H), 1.17 (t,
3H), 1.73 (t, 2H), 2.59 (q, 2H), 2.68 (m, 2H), 2.84 (d, 2H),
3.52-3.60 (m, 2H), 4.06 (m, 2H), 5.37 (s, 2H), 6.72 (dd, 1H), 6.92
(d, 1H), 7.03 (d, 1H), 7.08 (d, 1H), 7.14-7.19 (m, 2H), 7.29 (m,
1H), 7.40 (d, 1H), 7.83 (d, 1H), 8.03 (s, 1H), 8.17 (d, 1H), 8.40
(s, 1H), 9.80 (s, 1H), 11.45 (br s, 1H), 11.95 (br s, 1H)
Example 139: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(3-diethylamino-propoxy)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin-3-
-yl}-amide
##STR00165##
[0847] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0848] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 7 mg, 16%.
[0849] LC/MS: RT=0.92 Min (254 nm), m/z=539 [M+H]. Total run time
1.9 min (super short pos).
[0850] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.95 (t, 6H), 1.80
(quintet, 2H), 2.45 (q, 4H), 2.53 (t, 2H), 3.98 (t, 2H), 5.40 (s,
2H), 6.68-6.72 (dd, 1H), 6.92 (d, 1H), 7.02 (d, 1H), 7.26-7.41 (m,
6H), 7.83 (d, 1H), 8.04 (s, 1H), 8.14 (d, 1H), 8.40 (s, 1H), 9.77
(s, 1H), 11.44 (s, 1H), 11.98 (br s, 1H)
Example 140: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
(5-{5-[3-(4-methyl-piperazin-1-yl)-propoxy]-1H-indol-2-yl}-6-oxo-1,6-dihy-
dro-pyridin-3-vi)-amide
##STR00166##
[0852] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0853] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 17 mg, 36%.
[0854] LC/MS: RT=0.88 Min (254 nm), m/z=566 [M+H]. Total run time
1.9 min (super short pos).
[0855] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.85 (quintet, 2H), 2.14
(s, 3H), 2.20-2.50 (br m, 8H), 2.42 (t, 2H), 3.98 (t, 2H), 5.4 (s,
2H), 6.68-6.72 (dd, 1H), 6.91 (d, 1H), 7 (d, 1H), 7.27-7.42 (m,
6H), 7.82 (d, 1H), 8.03 (s, 1H), 8.14 (d, 1H), 8.40 (s, 1H), 9.78
(s, 1H), 11.45 (s, 1H), 11.98 (br s, 1H).
Example 141: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(2-diethylamino-ethoxy)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin-3--
yl}-amide
##STR00167##
[0857] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0858] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 14 mg, 32%.
[0859] LC/MS: RT=1.59 Min (254 nm), m/z=525 [M+H]. Total run time
3.75 min (short pos).
[0860] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.98 (t, 6H), 2.56 (q,
4H), 2.77 (t, 2H), 4, (t, 2H), 5.40 (s, 2H), 6.68-6.72 (dd, 1H),
6.92 (d, 1H), 7.03 (d, 1H), 7.27-7.42 (m, 6H), 7.83 (d, 1H), 8.03
(s, 1H), 8.15 (d, 1H), 8.41 (s, 1H), 9.78 (s, 1H), 11.45 (s, 1H),
11.98 (br s, 1H)
Example 142: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(2-dimethylamino-ethoxy)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin-3-
-yl}-amide
##STR00168##
[0862] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0863] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 5 mg, 22%.
[0864] LC/MS: RT=1.53 Min (254 nm), m/z=497 [M+H]. Total run time
3.75 min (short pos).
[0865] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.22 (s, 6H), 2.63 (t,
2H), 4.02 (t, 2H), 5.4 (s, 2H), 6.7-6.74 (dd, 1H), 6.93 (d, 1H),
7.03 (d, 1H), 7.26-7.42 (m, 6H), 7.82 (d, 1H), 8.04 (s, 1H), 8.14
(d, 1H), 8.41 (s, 1H), 9.78 (s, 1H), 11.45 (s, 1H), 11.98 (br s,
1H)
Example 143: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{6-oxo-5-[5-(3-piperidin-1-yl-propoxy)-1H-indol-2-yl]-1,6-dihydro-pyridin-
-3-yl}-amide
##STR00169##
[0867] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0868] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 13 mg, 30%.
[0869] LC/MS: RT=1.62 Min (254 nm), m/z=551 [M+H]. Total run time
3.75 min (short pos).
[0870] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.37-1.41 (br m, 2H),
1.46-1.54 (m, 4H), 1.85 (quintet, 2H), 2.30-2.36 (br m, 4H), 2.39
(t, 2H), 3.98 (t, 2H), 5.40 (s, 2H), 6.68-6.72 (dd, 1H), 6.92 (d,
1H), 7.01 (d, 1H), 7.26-7.42 (m, 6H), 7.82 (d, 1H), 8.03 (s, 1H),
8.15 (d, 1H), 8.40 (s, 1H), 9.78 (s, 1H), 11.45 (s, 1H), 11.98 (br
s, 1H)
Example 144: 1-Benzyl-1H-pyrazole-4carboxylic Acid
{6-oxo-5-[5-(2-pyrrolidin-1-yl-ethoxy)-1H-indol-2-yl]-1,6-dihydro-pyridin-
-3-yl}-amide
##STR00170##
[0872] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0873] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 14 mg, 42%.
[0874] LC/MS: RT=1.53 Min (254 nm), m/z=523 [M+H]. Total run time
3.75 min (short pos).
[0875] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.68 (m, 4H), 2.52 (m,
obscured by DMSO peak, 4H), 2.78 (t, 2H), 4.04 (t, 2H), 5.40 (s,
2H), 6.68-6.72 (dd, 1H), 6.92 (d, 1H), 7.02 (d, 1H), 7.26-7.42 (m,
6H), 7.82 (d, 1H), 8.04 (s, 1H), 8.15 (d, 1H), 8.41 (s, 1H), 9.78
(s, 1H), 11.46 (s, 1H), 11.98 (br s, 1H)
Example 145: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(3-dimethylamino-propoxy)-1H-indol-2-yl]-6oxo-1,6-dihydro-pyridin-3-
-yl}-amide
##STR00171##
[0877] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0878] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 14 mg, 28%.
[0879] LC/MS: RT=1.55 Min (254 nm), m/z=511 [M+H]. Total run time
3.75 min (short pos).
[0880] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.85 (quintet, 2H), 2.15
(s, 6H), 2.38 (t, 2H), 3.98 (t, 2H), 5.40 (s, 2H), 6.68-6.72 (dd,
1H), 6.92 (d, 1H), 7.02 (d, 1H), 7.26-7.42 (m, 6H), 7.82 (d, 1H),
8.04 (s, 1H), 8.15 (d, 1H), 8.40 (s, 1H), 9.78 (s, 1H), 11.45 (s,
1H), 11.98 (br s, 1H)
Example 146: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
(5-{5-[2-(4-methyl-piperazin-1-yl)-ethoxy]-1H-indol-2-yl}-6-oxo-1,6-dihyd-
ro-pyridin-3-yl)-amide
##STR00172##
[0882] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0883] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 11 mg, 27%.
[0884] LC/MS: RT=1.52 Min (254 nm), m/z=552 [M+H]. Total run time
3.75 min (short pos).
[0885] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.14 (s, 3H), 2.20-2.40
(br m, 4H), 2.68 (t, 2H), 4.05 (t, 2H), 5.40 (s, 2H), 6.69-6.74
(dd, 1H), 6.97 (d, 1H), 7.04 (d, 1H), 7.27-7.42 (m, 6H), 7.83 (d,
1H), 8.04 (s, 1H), 8.15 (d, 1H), 8.40 (s, 1H), 9.78 (s 1H), 11.45
(s, 1H), 11.98 (br s, 1H)
Example 147: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
(5-{5-[2-(2,6-dimethyl-morpholin-4-yl)-ethoxy]-1H-indol-2-yl}-6oxo-1,6-di-
hydro-pyridin-3-yl)-amide
##STR00173##
[0887] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0888] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 5 mg, 11%.
[0889] LC/MS: RT=0.93 Min (254 nm), m/z=567 [M+H]. Total run time
1.9 min (super short pos).
[0890] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.04 (d, 6H), 1.72 (t,
2H), 2.67 (m, 2H), 2.84 (d, 2H), 3.57 (m, 2H), 4.06 (t, 2H), 5.40
(s, 2H), 6.7-6.73 (dd, 1H), 6.93 (d, 1H), 7.04 (d, 1H), 7.28-7.42
(m, 6H), 7.82 (d, 1H), 8.03 (s 1H), 8.15 (d, 1H), 8.41 (s, 1H),
9.78 (s, 1H), 11.44 (s, 1H), 11.98 (br s, 1H)
Example 148: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
(6-oxo-5-{5-[3-(2-oxo-pyrrolidin-1-yl)-propoxy]-1H-indole-2-yl}-1,6-dihyd-
ro-pyridin-3-yl)-amide
##STR00174##
[0892] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0893] The title compound was purified by preparative HPLC at pH 4
and isolated as a yellow solid, 8 mg, 12%.
[0894] LC/MS: RT=1.08 Min (254 nm), m/z=551 [M+H]. Total run time
1.9 min (super short pos).
[0895] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.85-1.95 (m, 4H), 2.20
(t, 2H), 3.35 (m, partially obscured by water peak, 4H), 3.90 (t,
2H), 5.40 (s, 2H), 6.7-6.73 (dd, 1H), 6.94 (d, 1H), 7.00 (d, 1H),
7.28-7.42 (m, 6H), 7.82 (d, 1H), 8.00 (s, 1H), 8.14 (d, 1H), 8.41
(s, 1H), 9.79, (s, 1H), 11.45 (s, 1H), 11.98 (br s, 1H).
Example 149: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{6-oxo-5-[5-(2-piperidin-1-yl-ethoxy)-1H-indol-2-yl]-1,6-dihydro-pyridin--
3-yl}-amide
##STR00175##
[0897] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115.
[0898] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 16 mg, 33%.
[0899] LC/MS: RT=1.73 Min (270 nm), m/z=537 [M+H]. Total run time
3.75 min (short pos).
[0900] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.4 (m, 3H), 1.50 (m,
4H), 2.40 (m, 2H), 2.70 (m, 3H), 4.0 (t, 2H), 5.40 (s, 2H), 6.70
(dd, 2H), 6.8 (s, 1H), 7.00 (s, 1H), 7.3 (m, 5H), 7.80 (s, 1H), 8.0
(s, 1H), 8.10 (s, 1H), 8.40 (s, 1H), 9.70 (s, 1H), 12.00 (br,
1H)
Example 150: 1-(4-Isopropylbenzyl)-1H-pyrazole-4-carboxylic
Acid-{6-oxo-5-[5-(3-piperidin-1-ylpropoxy)-1H-indol-2-yl]-1,6-dihydropyri-
din-3-yl}-amide
##STR00176##
[0902] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0903] The title compound was purified by trituration with diethyl
ether, and isolated as a yellow solid, 70 mg, 35%.
[0904] LC/MS: RT=1.82 Min (270 nm), m/z=593 [M+H]. Total run time
3.75 min (short pos).
[0905] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.20 (d, 6H), 1.40 (br
s, 2H), 1.55 (br s, 4H), 1.90 (br m, 2H), 2.40 (br s, 4H), 2.90 (m,
1H), 4.00 (t, 2H), 5.35 (s, 2H), 6.70 (dd, 1H), 6.95 (d, 1H), 7.05
(d, 1H), 7.25 (m, 4H), 7.40 (d, 1H), 7.85 (d, 1H), 8.00 (s, 1H),
8.20 (d, 1H), 8.45 (s, 1H), 9.85 (s, 1H), 11.44 (br s, 1H), 11.98
(br s, 1H).
Example 151: 1-(4-tert-Butylbenzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(2-piperidin-1-ylethoxy)-1H-indol-2-yl)-6-oxo-1,6-dihydropyridin-3--
yl}-amide
##STR00177##
[0907] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0908] The title compound was purified by trituration with diethyl
ether, and isolated as a yellow solid, 60 mg, 40%.
[0909] LC/MS: RT=1.84 Min (270 nm), m/z=593 [M+H]. Total run time
3.75 min (short pos).
[0910] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.30 (s, 9H), 1.45 (br
m, 2H), 1.55 (m, 4H), 2.45 (br s, 4H), 2.70 (t, 2H), 4.05 (t, 2H),
5.35 (s, 2H), 6.70 (dd, 1H), 6.95 (d, 1H), 7.05 (d, 1H), 7.25 (d,
2H), 7.45 (m, 3H), 7.85 (d, 1H), 8.00 (s, 1H), 8.20 (d, 1H), 8.45
(s, 1H), 9.85 (s, 1H), 11.44 (br s, 1H).
Example 152: 1-(4-Isopropylbenzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(2-piperidin-1-ylethoxy)-1H-indol-2-yl)-6-oxo-1,6-dihydropyridin-3--
yl}-amide
##STR00178##
[0912] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0913] The title compound was purified by trituration with diethyl
ether, and isolated as a yellow solid, 60 mg, 47%.
[0914] LC/MS: RT=1.80 Min (270 nm), m/z=579 [M+H]. Total run time
3.75 min (short pos).
[0915] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.20 (d, 6H), 1.40 (br
m, 2H), 1.55 (m, 4H), 2.45 (br s, 4H), 2.70 (t, 2H), 2.90 (m, 1H),
4.10 (t, 2H), 5.35 (s, 2H), 6.70 (dd, 1H), 6.95 (d, 1H), 7.05 (d,
1H), 7.25 (m, 4H), 7.40 (d, 1H), 7.85 (d, 1H), 8.00 (s, 1H), 8.20
(d, 1H), 8.45 (s, 1H), 9.85 (s, 1H), 11.44 (br s, 1H), 11.90 (br s,
1H).
Example 153: 1-(4-tert-Butylbenzyl)-1H-pyrazole-4-carboxylic
Acid-{6-oxo-5-[5-(3-piperidin-1-ylpropoxy)-1H-indol-2-yl]-1,6-dihydropyri-
din-3-yl}-amide
##STR00179##
[0917] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0918] The title compound was purified by preparative HPLC at pH 4
to give the product as a yellow solid, 50 mg, 28%.
[0919] LC/MS: RT=1.08 Min (270 nm), m/z=607 [M+H]. Total run time
1.9 min (super short pos).
[0920] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.30 (s, 9H), 1.40 (br
m, 2H), 1.55 (m, 4H), 1.90 (m, 2H), 2.45 (br s, 4H), 4.00 (t, 2H),
5.35 (s, 2H), 6.70 (dd, 1H), 6.95 (d, 1H), 7.00 (d, 1H), 7.20 (d,
2H), 7.40 (m, 3H), 7.85 (d, 1H), 8.00 (s, 1H), 8.20 (d, 1H), 8.45
(s, 1H), 9.85 (s, 1H), 11.46 (br s, 1H).
Example 154: 1-(4-tert-Butylbenzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(2-dimethylaminoethoxy)-1H-indol-2-yl)-6-oxo-1,6-dihydropyridin-3-y-
l}-amide
##STR00180##
[0922] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0923] The title compound was purified by trituration with diethyl
ether, and isolated as a yellow solid, 65 mg, 40%.
[0924] LC/MS: RT=1.82 Min (270 nm), m/z=581 [M+H]. Total run time
3.75 min (short pos).
[0925] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.00 (br t, 6H), 1.30
(s, 9H), 2.60 (br s, 4H), 2.85 (br s, 2H), 4.00 (br s, 2H), 5.35
(s, 2H), 6.75 (dd, 1H), 6.95 (d, 1H), 7.05 (d, 1H), 7.25 (d, 2H),
7.40 (m, 3H), 7.85 (d, 1H), 8.00 (s, 1H), 8.20 (d, 1H), 8.45 (s,
1H), 9.85 (s, 1H), 11.44 (br s, 1H), 11.98 (br s, 1H).
Example 155: 1-(4-Isopropylbenzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(2-diethylaminoethoxy)-1H-indol-2-yl)-6-oxo-1,6-dihydropyridin-3-yl-
}-amide
##STR00181##
[0927] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0928] The title compound was purified by trituration with diethyl
ether, and isolated as a yellow solid, 110 mg, 55%.
[0929] LC/MS: RT=1.78 Min (270 nm), m/z=567 [M+H]. Total run time
3.75 min (short pos).
[0930] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.00 (t, 6H), 1.20 (d,
6H), 2.60 (br q, 4H), 2.85 (br s, 2H), 2.90 (m, 1H), 4.00 (t, 2H),
5.35 (s, 2H), 6.70 (dd, 1H), 6.95 (d, 1H), 7.05 (d, 1H), 7.25 (m,
4H), 7.40 (d, 1H), 7.85 (d, 1H), 8.00 (s, 1H), 8.20 (d, 1H), 8.45
(s, 1H), 9.85 (s, 1H), 11.44 (br s, 1H), 11.98 (br s, 1H).
Example 156: 1-(4-tert-butylbenzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(3-dimethylaminopropoxy)-1H-indol-2-yl)-6-oxo-1,6-dihydropyridin-3--
yl}-amide
##STR00182##
[0932] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0933] The title compound was purified by trituration with diethyl
ether, and isolated as a yellow solid, 80 mg, 56%.
[0934] LC/MS: RT=1.80 Min (270 nm), m/z=567 [M+H]. Total run time
3.75 min (short pos).
[0935] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.30 (s, 9H), 1.90 (m,
2H), 2.20 (s, 6H), 2.40 (t, 2H), 4.00 (t, 2H), 5.35 (s, 2H), 6.75
(dd, 1H), 6.95 (d, 1H), 7.05 (d, 1H), 7.25 (d, 2H), 7.40 (m, 3H),
7.85 (d, 1H), 8.00 (s, 1H), 8.20 (d, 1H), 8.45 (s, 1H), 9.85 (s,
1H), 11.44 (br s, 1H), 11.94 (br s, 1H).
Example 157: 1-(4-Isopropylbenzyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(3-dimethylaminopropoxy)-1H-indol-2-yl)-6-oxo-1,6-dihydropyridin-3--
yl}-amide
##STR00183##
[0937] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 121.
[0938] The title compound was purified by trituration with diethyl
ether, and isolated as a yellow solid, 115 mg, 68%.
[0939] LC/MS: RT=1.75 Min (270 nm), m/z=553 [M+H]. Total run time
3.75 min (short pos).
[0940] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.25 (d, 6H), 1.75 (m,
2H), 2.15 (s, 6H), 2.40 (t, 2H), 2.90 (m, 1H), 4.00 (t, 2H), 5.35
(s, 2H), 6.70 (dd, 1H), 6.95 (d, 1H), 7.05 (d, 1H), 7.25 (m, 4H),
7.40 (d, 1H), 7.85 (d, 1H), 8.00 (s, 1H), 8.20 (d, 1H) 8.45 (s,
1H), 9.85 (s, 1H), 11.44 (br s, 1H), 11.96 (br s, 1H).
Example 158: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[4-(2-amino-ethoxy)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin-3-yl}-ami-
de
##STR00184##
[0942] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115, except 1H-Indol-4-ol was used and the alternative
deprotection method described for Example 108 was adopted.
[0943] The title compound was purified by trituration with ethyl
acetate, and isolated as a yellow solid, 7 mg, 10%.
[0944] LC/MS: RT=1.48 Min (270 nm), m/z=469 [M+H]. Total run time
3.75 min (short pos).
[0945] .sup.1H NMR (d.sub.4 MeOD): 3.17 (t, 2H), 4.20 (t, 2H), 5.40
(s, 2H), 6.52 (dd, 1H), 7.06 (m, 2H), 7.20 (s, 1H), 7.33 (m, 5H),
7.86 (d, 1H), 8.05 (s, 1H), 8.23 (d, 1H), 8.26 (s, 1H).
Example 159: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[4-(2-dimethylamino-ethoxy)-1H-indol-2-yl]-6-oxo-1,6-dihydro-pyridin-3-
-yl}-amide
##STR00185##
[0947] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115, except 1H-Indol-4-ol was used and the alternative
deprotection method described for Example 108 was adopted.
[0948] The title compound was purified by trituration with ethyl
acetate, and isolated as a yellow solid, 22 mg, 29%.
[0949] LC/MS: RT=1.51 Min (270 nm), m/z=497 [M+H]. Total run time
3.75 min (short pos).
[0950] .sup.1H NMR (d.sub.4 MeOD): .delta. 2.47 (s, 6H), 2.94 (t,
2H), 4.29 (t, 2H), 5.43 (s, 2H), 6.53 (d, 1H), 7.06 (m, 2H), 7.17
(s, 1H), 7.40 (m, 5H), 7.95 (d, 1H), 8.09 (s, 1H), 8.23 (d, 1H),
8.29 (s, 1H).
Example 160: 1-((S)-1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00186##
[0952] The title compound was prepared by the route outlined in
Scheme 6, following the same procedures as for Example 20, apart
from a modified coupling procedure in Step 4 which utilised
intermediate (6h).
Preparation of 1-((S)-1-Phenyl-ethyl)-1H-pyrazole-4-carbonyl
chloride (6h)
[0953] A 20 mL microwave vial was charged with
1H-pyrazole-4-carboxylic acid ethyl ester (1 g, 7.1 mmol),
(R)-1-phenylethanol (1.31 mL, 10.7 mmol), triphenylphosphine (3 g,
11.4 mmol) and tetrahydrofuran (15 mL). The reaction was stirred at
ambient temperature for 10 minutes before adding diisopropyl
azodicarboxylate (2.25 mL, 11.14 mmol) with cooling. The vial was
heated under microwave irradiation at 140.degree. C. for 15 mins.
After cooling, the solvent was removed in vacuo and the residue
purified by flash chromatography on SiO.sub.2 with hexane-30% ethyl
acetate/hexane (gradient) to afford intermediate (6f),
1-((S)-1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic acid ethyl ester as
an oil, 1.646 g, 94%.
[0954] Intermediate (6f),
1-((S)-1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic acid ethyl ester
(1.525 g, 6.2 mmol) was stirred in a mixture of tetrahydrofuran (20
mL) and water (20 mL). Lithium hydroxide (0.524 g, 12.5 mmol) was
added and the reaction stirred at ambient temperature for 24 hours.
The reaction mixture was reduced in volume and extracted with
diethyl ether (3.times.20 mL). The aqueous layer was carefully
acidified using an aqueous 6N hydrochloric acid solution. The
resulting precipitate was filtered, washed with copious amounts of
water and dried in vacuo to afford intermediate (6 g),
1-((S)-1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic acid as a white
solid, 0.664 g, 49%.
[0955] Intermediate (6 g),
1-((S)-1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic acid (0.5 g, 2.31
mmol) was stirred in toluene (20 mL) at RT and thionyl chloride
(0.34 mL, 4.62 mmol) was added. The reaction mixture was slowly
heated to 90.degree. C. and heating continued for 3 hrs. After
cooling the reaction was concentrated in vacuo. Toluene was added
to the residue and concentrated in vacuo. This was repeated a
further three times and the title compound, intermediate (6h),
1-((S)-1-Phenyl-ethyl)-1H-pyrazole-4-carbonyl chloride, was
isolated as an oil, 0.544 g, quantitative.
[0956] Modified Procedure for Step 4
[0957] Intermediate (6c),
2-[5-Amino-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin--
3-yl]-indole-1-carboxylic acid tert-butyl ester (100 mg, 0.22 mmol)
was stirred in dichloromethane (5 mL) at RT with triethylamine
(0.092 mL, 0.66 mmol). The reaction mixture was cooled to 5.degree.
C. and then a solution of intermediate (6h),
1-((S)-1-Phenyl-ethyl)-1H-pyrazole-4-carbonyl chloride, (54 mg,
0.231 mmol) in dichloromethane (1 mL) was added drop wise. After
addition the reaction was stirred at RT for 1 hour and then the
reaction mixture was concentrated in vacuo and the residue
partitioned between ethyl acetate (10 mL) and aqueous saturated
sodium hydrogen carbonate solution (10 mL). The organic layer was
separated and the aqueous was extracted with a further portion of
ethyl acetate (10 mL). The combined ethyl acetate layers were
washed with brine, dried (Na.sub.2SO.sub.4) and concentrated in
vacuo. The resultant crude product was purified by flash
chromatography on SiO.sub.2 eluting with hexane-50% ethyl
acetate/hexane (gradient) to afford the desired intermediate,
2-(1-Methyl-2-oxo-5-{[1-((S)-1-phenyl-ethyl)-1H-pyrazole-4-carbonyl]-amin-
o}-1,2-dihydro-pyridin-3-yl)-indole-1-carboxylic acid tert-butyl
ester, 0.108 g, 76%.
[0958] The title compound was purified by flash chromatography on
SiO.sub.2 eluting with dichloromethane-10% methanol/dichloromethane
(gradient) to afford the desired title compound as a yellow solid,
22 mg, 31%.
[0959] LC/MS: RT=2.07 Min (270 nm), m/z=424 [M+H]. Total run time
3.75 min (short pos).
[0960] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.84 (d, 3H), 5.69 (q,
1H), 6.98 (m, 1H), 7.05-7.09 (m, 2H), 7.28-7.39 (m, 5H), 7.49-7.54
(m, 2H), 7.81 (d, 1H), 8.04 (s, 1H), 8.18 (d, 1H), 8.45 (s, 1H),
9.77 (s, 1H), 11.56 (s, 1H), 12.00 (br s, 1H).
Example 161: 1-((R)-1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic Acid
[5-(1H-indol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00187##
[0962] The title compound was prepared by the route outlined in
Scheme 6, following the same procedures as for Example 160, except
intermediate (6k), 1-((R)-1-Phenyl-ethyl)-1H-pyrazole-4-carbonyl
chloride, was used in the coupling procedure in Step 4.
[0963] Intermediate (6k),
1-((R)-1-Phenyl-ethyl)-1H-pyrazole-4-carbonyl chloride, was
synthesised using the same procedures as for intermediate (6h), but
starting from (S)-1-phenylethanol. The title compound was purified
by trituration with acetonitrile, and isolated as a yellow solid,
34 mg, 45%.
[0964] LC/MS: RT=2.07 Min (270 nm), m/z=424 [M+H]. Total run time
3.75 min (short pos).
[0965] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.84 (d, 3H), 5.69 (q,
1H), 6.98 (m, 1H), 7.05-7.09 (m, 2H), 7.28-7.39 (m, 5H), 7.49-7.54
(m, 2H), 7.81 (d, 1H), 8.04 (s, 1H), 8.18 (d, 1H), 8.45 (s, 1H),
9.77 (s, 1H), 11.56 (s, 1H), 12.00 (br s, 1H).
Example 162: 1-((S)-1-Phenyl-ethyl)-1H-pyrazole-4carboxylic Acid
[6-oxo-5-(5-piperidin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridin-3-yl]-
-amide
##STR00188##
[0967] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37, reacting intermediate (8d),
2-[5-Amino-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin--
3-yl]-5-(tert-butyl-dimethyl-silanyloxymethyl)-indole-1-carboxylic
acid tert-butyl with intermediate (6h),
1-((S)-1-Phenyl-ethyl)-1H-pyrazole-4-carbonyl chloride in the
coupling step as described for Example 160.
[0968] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 131 mg, 71%.
[0969] LC/MS: RT=1.58 Min (270 nm), m/z=521 [M+H]. Total run time
3.75 min (short pos).
[0970] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.37-1.50 (m, 6H), 1.84
(d, 3H), 2.31 (m, 4H), 3.44 (s, 2H), 5.69 (q, 1H), 7.00-7.03 (m,
2H), 7.28-7.44 (m, 7H), 7.82 (d, 1H), 8.03 (s, 1H), 8.15 (d, 1H),
8.45 (s, 1H), 9.78 (s, 1H), 11.50 (s, 1H), 11.97 (br s, 1H).
Example 163: 1-((S)-1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(cis-2,6-dimethyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-di-
hydro-pyridin-3-yl}-amide
##STR00189##
[0972] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
162. The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 25 mg, 38%.
[0973] LC/MS: RT=1.59 Min (270 nm), m/z=551 [M+H]. Total run time
3.75 min (short pos).
[0974] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.00 (d, 6H), 1.62 (t,
2H), 1.84 (d, 3H), 2.68 (d, 2H), 3.47 (s, 2H), 3.54 (m, 2H), 5.70
(q, 1H), 7.01-7.04 (m, 2H), 7.28-7.46 (m, 7H), 7.82 (d, 1H), 8.04
(s, 1H), 8.16 (d, 1H), 8.45 (s, 1H), 9.78 (s, 1H), 11.53 (s, 1H),
11.99 (br s, 1H).
Example 164: 1-((S)-1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00190##
[0976] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
162. The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 37 mg, 57%.
[0977] LC/MS: RT=1.59 Min (270 nm), m/z=539 [M+H]. Total run time
3.75 min (short pos).
[0978] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.68 (m, 2H), 1.79 (m,
2H), 1.84 (d, 3H), 2.28 (m, 2H), 2.50 (m, 2H), 3.50 (s, 2H),
4.60-4.72 (m, 1H), 5.70 (q, 1H), 7.01-7.04 (m, 2H), 7.28-7.45 (m,
7H), 7.82 (d, 1H), 8.03 (s, 1H), 8.15 (d, 1H), 8.45 (s, 1H), 9.78
(s, 1H), 11.53 (s, 1H), 11.99 (br s, 1H).
Example 165: 1-((S)-1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-methyl-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00191##
[0980] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
162. The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 40 mg, 54%.
[0981] LC/MS: RT=1.65 Min (270 nm), m/z=535 [M+H]. Total run time
3.75 min (short pos).
[0982] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.87 (d, 3H), 1.12 (m,
2H), 1.30 (m, 1H), 1.54 (m, 2H), 1.84 (d, 3H), 1.87 (m, 2H), 2.78
(m, 2H), 3.45 (s, 2H), 5.70 (q, 1H), 7.00-7.03 (m, 2H), 7.28-7.44
(m, 7H), 7.82 (d, 1H), 8.03 (s, 1H), 8.15 (d, 1H), 8.45 (s, 1H),
9.78 (s, 1H), 11.51 (s, 1H), 11.99 (br s, 1H).
Example 166
##STR00192##
[0984] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
37, reacting intermediate (8d),
2-[5-Amino-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin--
3-yl]-5-(tert-butyl-dimethyl-silanyloxymethyl)-indole-1-carboxylic
acid tert-butyl with intermediate (6k),
1-((R)-1-Phenyl-ethyl)-1H-pyrazole-4-carbonyl chloride in the
coupling step as described for Example 161.
[0985] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 47 mg, 55%.
[0986] LC/MS: RT=1.61 Min (270 nm), m/z=551 [M+H]. Total run time
3.75 min (short pos).
[0987] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.01 (d, 6H), 1.62 (t,
2H), 1.84 (d, 3H), 2.68 (m, 2H), 3.47 (s, 2H), 3.54 (m, 2H), 5.70
(q, 1H), 7.01-7.04 (m, 2H), 7.28-7.46 (m, 7H), 7.82 (d, 1H), 8.03
(s, 1H), 8.15 (d, 1H), 8.45 (s, 1H), 9.78 (s, 1H), 11.53 (s, 1H),
11.99 (br s, 1H).
Example 167: 1-((R)-1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-methyl-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00193##
[0989] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
166. The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 54 mg, 56%.
[0990] LC/MS: RT=1.66 Min (270 nm), m/z=535 [M+H]. Total run time
3.75 min (short pos).
[0991] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.87 (d, 3H), 1.12 (m,
2H), 1.30 (m, 1H), 1.54 (m, 2H), 1.84 (d, 3H), 1.87 (m, 2H), 2.78
(m, 2H), 3.46 (s, 2H), 5.70 (q, 1H), 7.00-7.03 (m, 2H), 7.28-7.44
(m, 7H), 7.82 (d, 1H), 8.03 (s, 1H), 8.15 (d, 1H), 8.45 (s, 1H),
9.78 (s, 1H), 11.51 (s, 1H), 11.99 (br s, 1H).
Example 168: 1-((R)-1-Phenyl-ethyl)-1H-pyrazole-4carboxylic Acid
[6-oxo-5-(5-piperidin-1-ylmethyl-1H-indol-2-yl)-1,6-dihydro-pyridin-3-yl]-
-amide
##STR00194##
[0993] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
166. The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 48 mg, 58%.
[0994] LC/MS: RT=1.60 Min (270 nm), m/z=521 [M+H]. Total run time
3.75 min (short pos).
[0995] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.37-1.50 (m, 6H), 1.84
(d, 3H), 2.31 (m, 4H), 3.44 (s, 2H), 5.70 (q, 1H), 7.00-7.03 (m,
2H), 7.28-7.44 (m, 7H), 7.82 (d, 1H), 8.03 (s, 1H), 8.15 (d, 1H),
8.45 (s, 1H), 9.78 (s, 1H), 11.51 (s, 1H), 11.99 (br s, 1H).
Example 169: 1-((R)-1-Phenyl-ethyl)-1H-pyrazole-4-carboxylic Acid
{5-[5-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydro-py-
ridin-3-yl}-amide
##STR00195##
[0997] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
166. The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 49 mg, 53%.
[0998] LC/MS: RT=1.56 Min (270 nm), m/z=539 [M+H]. Total run time
3.75 min (short pos).
[0999] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.68 (m, 2H), 1.79 (m,
2H), 1.84 (d, 3H), 2.28 (m, 2H), 2.52 (m, 2H), 3.50 (s, 2H),
4.60-4.72 (m, 1H), 5.70 (q, 1H), 7.01-7.04 (m, 2H), 7.28-7.45 (m,
7H), 7.83 (d, 1H), 8.03 (s, 1H), 8.16 (d, 1H), 8.45 (s, 1H), 9.78
(s, 1H), 11.52 (s, 1H), 11.99 (br s, 1H).
Example 170: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
[5-(5-{[(2-dimethylamino-ethyl)-methyl-amino]-methyl}-1H-indol-2-yl)-6-ox-
o-1,6-dihydro-pyridin-3-yl]-amide
##STR00196##
[1001] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[1002] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 28 mg, 24%.
[1003] LC/MS: RT=1.45 Min (270 nm), m/z=522 [M-H]. Total run time
3.75 min (short neg).
[1004] .sup.1H NMR (d.sub.6 DMSO): .delta. 2.15 (s, 9H), 2.42 (s,
4H), 3.52 (s, 2H), 5.41 (s, 2H), 6.98-7.06 (m, 2H), 7.25-7.45 (m,
7H), 7.82 (s, 1H), 8.04 (s, 1H), 8.17 (d, 1H), 8.42 (s, 1H), 9.81
(br s, 1H), 11.52 (br s, 1H), 12.0 (br s, 1H).
Example 171: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-((S)-2-methyl-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydr-
o-pyridin-3-yl}-amide
##STR00197##
[1006] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[1007] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 58 mg, 56%.
[1008] LC/MS: RT=1.68 Min (270 nm), m/z=519 [M-H]. Total run time
3.75 min (short neg).
[1009] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.15 (d, 3H), 1.22-1.36
(m, 4H), 1.88 (m, 1H), 2.3 (m, 1H), 2.65 (m, 1H), 3.12 (d, 1H), 4.0
(d, 1H), 5.4 (s, 2H), 6.99-7.04 (m, 2H), 7.27-7.44 (m, 7H), 7.82
(m, 1H), 8.03 (s, 1H), 8.15 (d, 1H), 8.41 (s, 1H), 9.8 (br s, 1H),
11.5 (br s, 1H), 11.99 (br s, 1H).
Example 172: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-((R)-3-dimethylamino-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,-
6-dihydro-pyridin-3-yl}-amide
##STR00198##
[1011] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[1012] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 42 mg, 31%.
[1013] LC/MS: RT=1.45 Min (270 nm), m/z=534 [M-H]. Total run time
3.75 min (short neg).
[1014] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.58 (m 1H), 1.82 (m,
1H), 2.05 (s, 6H), 2.22 (m, 1H), 2.42 (m, 1H), 2.56 (m, 1H), 2.66
(m, 2H), 3.58 (dd, 2H), 5.41 (s, 2H), 7.01 (m, 2H), 7.25-7.45 (m,
7H), 7.82 (s, 1H), 8.03 (s, 1H), 8.17 (s, 1H), 8.41 (s, 1H), 9.8
(br s, 1H), 11.5 (br s, 1H), 11.99 (br s, 1H).
Example 173: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-((R)-2-methyl-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihydr-
o-pyridin-3-yl}-amide
##STR00199##
[1016] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[1017] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 20 mg, 20%.
[1018] LC/MS: RT=1.69 Min (270 nm), m/z=519 [M-H]. Total run time
3.75 min (short neg).
[1019] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.15 (d, 3H), 1.22-1.36
(m, 4H), 1.88 (m, 1H), 2.3 (m, 1H), 2.65 (m, 1H), 3.12 (d, 1H), 4.0
(d, 1H), 5.4 (s, 2H), 6.99-7.04 (m, 2H), 7.27-7.44 (m, 7H), 7.82
(m, 1H), 8.03 (s, 1H), 8.15 (d, 1H), 8.41 (s, 1H), 9.82 (br s, 1H),
11.51 (br s, 1H), 11.99 (br s, 1H).
Example 174: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihyd-
ro-pyridin-3-yl}-amide
##STR00200##
[1021] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[1022] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 20 mg, 20%.
[1023] LC/MS: RT=1.63 Min (270 nm), m/z=509 [M-H]. Total run time
3.75 min (short neg).
[1024] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.77-1.93 (m, 1H),
2.05-2.2 (m, 1H), 2.3 (q, 1H), 2.53-2.64 (m, 1H), 2.7-2.82 (m, 2H),
3.63 (s, 2H), 5.18 (dt, 1H), 5.4 (s, 2H), 7.0-7.07 (m, 2H),
7.27-7.46 (m, 7H), 7.82 (d, 1H), 8.03 (s, 1H), 8.17 (d, 1H), 8.41
(s, 1H), 9.79 (s, 1H), 11.52 (br s, 1H), 12.01 (br s, 1H).
Example 175: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-((S)-3-fluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-dihyd-
ro-pyridin-3-yl}-amide
##STR00201##
[1026] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[1027] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 76 mg, 81%.
[1028] LC/MS: RT=1.62 Min (270 nm), m/z=509 [M-H]. Total run time
3.75 min (short neg).
[1029] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.77-1.93 (m, 1H),
2.05-2.2 (m, 1H), 2.3 (q, 1H), 2.53-2.64 (m, 1H), 2.7-2.82 (m, 2H),
3.63 (s, 2H), 5.18 (dt, 1H), 5.4 (s, 2H), 7.0-7.07 (m, 2H),
7.27-7.46 (m, 7H), 7.82 (d, 1H), 8.03 (s, 1H), 8.17 (d, 1H), 8.41
(s, 1H), 9.8 (s, 1H), 11.52 (br s, 1H), 12.01 (br s, 1H).
Example 176: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
[5-(5-{[(3-dimethylamino-2,2-dimethyl-propyl)-ethyl-amino]-methyl}-1H-ind-
ol-2-yl)-6-oxo-1,6-dihydro-pyridin-3-yl]-amide
##STR00202##
[1031] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51.
[1032] Purification by trituration with acetonitrile afforded the
title compound as a yellow solid, 30 mg, 43%
[1033] LC/MS: RT=1.49 Min (270 nm), m/z=580 [M+H]. Total run time
3.75 min (short pos).
[1034] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.86 (s, 6H), 0.92 (t,
3H), 2.09 (s, 2H), 2.19 (s, 6H), 2.31 (s, 2H), 2.42 (q, 2H), 3.64
(s, 2H), 5.41 (s, 2H), 7.01 (s, 1H), 7.11 (dd, 1H), 7.28-7.45 (m,
7H), 7.80 (d, 1H), 8.03 (s, 1H), 8.16 (d, 1H), 8.41 (s, 1H), 9.79
(s, 1H), 11.49 (s, 1H), 11.99 (br s, 1H)
Example 177: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(cis-2,6-dimethyl-piperidin-1-ylmethyl)-1H-indol-2-yl]-6-oxo-1,6-di-
hydro-pyridin-3-yl}-amide
##STR00203##
[1036] The title compound was prepared by the route outlined in
Scheme 8, following the same experimental procedures as for Example
51, with the following modification.
[1037] Deprotection of intermediate (8e),
5-(tert-Butyl-dimethyl-silanyloxymethyl)-2-[5-{[1-(4-methyl-benzyl)-1H-py-
razole-4-carbonyl]-amino}-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-di-
hydro-pyridin-3-yl]-indole-1-carboxylic acid tert-butyl ester, in
the usual manner, yielded
2-[5-[(1-benzyl-1H-pyrazole-4-carbonyl)-amino]-2-oxo-1-(2-trimethylsilany-
l-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-5-hydroxymethyl-indole-1-carboxy-
lic acid tert-butyl ester. DIPEA (153 .mu.L, 0.9 mmol) and
2-[5-[(1-benzyl-1H-pyrazole-4-carbonyl)-amino]-2-oxo-1-(2-trimethylsilany-
l-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-5-hydroxymethyl-indole-1-carboxy-
lic acid tert-butyl ester (0.2 g, 0.3 mmol) were stirred in
1,2-dichloroethane (5 mL) and cooled to 0.degree. C.
Methanesulfonyl chloride (27 .mu.L, 0.36 mmol) was added drop wise
at 0.degree. C. and stirred for a further 2 hours at 0.degree. C.
cis-2,6-Dimethylpiperidine (118 .mu.L 0.9 mmol) was added drop wise
at 0.degree. C. and then the reaction was allowed to attain ambient
temperature. The reaction mixture was heated at reflux overnight
followed by cooling to ambient temperature. The reaction mixture
was diluted with ethyl acetate (30 mL), washed with water (30 mL),
saturated sodium hydrogen carbonate solution (30 mL), brine, dried
(Na.sub.2SO.sub.4) and concentrated in vacuo. The resultant crude
product was taken up in methanol (1 mL) and loaded onto a 5 g SCX
column. The column was flushed with methanol and then eluted with
ammonia solution 7N in methanol. The eluent was concentrated in
vacuo to afford the title compound as a light brown solid, 120 mg,
53%.
[1038] Global deprotection in the usual manner afforded the title
compound which was purified by trituration with diethyl ether, and
isolated as a yellow solid, 20 mg, 24%.
[1039] LC/MS: RT=1.72 Min (270 nm), m/z=535 [M+H]. Total run time
3.75 min (short pos).
[1040] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.02 (d, 6H), 1.26 (m,
3H), 1.53-1.60 (m, 3H), 2.45 (m, 2H), 3.78 (s, 2H), 5.41 (s, 2H),
7.00 (s, 1H), 7.08 (d, 1H), 7.28-7.40 (m, 6H), 7.49 (s, 1H), 7.80
(s, 1H), 8.03 (s, 1H), 8.14 (d, 1H), 8.41 (s, 1H), 9.79 (s, 1H),
11.45 (s, 1H), 11.98 (br s, 1H).
Example 178: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(3-diethylamino-2,2-dimethyl-propoxy)-1H-indol-2-yl]-6-oxo-1,6-dihy-
dro-pyridin-3-yl}-amide
##STR00204##
[1042] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115.
[1043] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 50 mg, 47%.
[1044] LC/MS: RT=1.78 Min (270 nm), m/z=567.3 [M+H]. Total run time
3.75 min (short pos).
[1045] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.90 (t, 6H), 0.95 (s,
6H), 2.35 (s, 2H), 2.50 (q, 4H), 3.65 (s, 2H), 5.40 (s, 2H), 6.70
(dd, 1H), 6.90 (d, 1H), 7.00 (d, 1H), 7.25-7.45 (m, 6H), 7.85 (d,
1H), 8.05 (s, 1H), 8.15 (d, 1H), 8.40 (s, 1H), 9.80 (s, 1H), 11.40
(s, 1H), 12.00 (br s, 1H).
Example 179: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(2-dimethylamino-1,1-dimethyl-ethoxy)-1H-indol-2-yl]-6-oxo-1,6-dihy-
dro-pyridin-3-yl}-amide
##STR00205##
[1047] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115. In this instance the chloroalkyl intermediate,
(2-chloro-2-methyl-propyl)-dimethyl-amine hydrochloride, required
for Step 6 was not commercially available and was synthesised
according to the following methodology.
Preparation of (2-chloro-2-methyl-propyl)-dimethyl-amine
hydrochloride
[1048] 2-Dimethylamino-2-methyl-propan-1-01 as an 80% solution in
water (10 mL, 9.1 g, 78 mmol) was dissolved in toluene (100 mL) and
then after stirring for 30 mins, the organic layer separated, dried
over Mg.sub.2SO.sub.4 and then concentrated to a volume of
approximately 50 mL. Thionyl chloride (95 mmol, 6.9 mL, 11.3 g) was
added to this solution and the mixture heated at 80.degree. C. for
3 hrs. After cooling, the mixture was concentrated in vacuo.
Anhydrous toluene was added and the mixture was concentrated in
vacuo. This process was repeated a further three times with toluene
and once with isohexane. The residue obtained was slurried in
diethyl ether, separated via filtration and washed with copious
amounts of diethylether before being dried in vacuo at RT. The
compound obtained was a mixture of the desired title compound
(2-chloro-2-methyl-propyl)-dimethyl-amine hydrochloride (70%) and
the isomer (2-chloro-1,1-dimethyl-ethyl)-dimethyl-amine (30%) by
NMR. The total yield was 5.23 g (49%).
[1049] This mixture containing 70% desired intermediate and 30%
undesired isomer was used in the subsequent alkylation step without
further purification and so a mixture of two possible products was
obtained. These two products were duly separated, prior to global
deprotection, by flash chromatography on SiO.sub.2 and the desired
product was eluted using dichloromethane-10%
methanol/dichloromethane (gradient). The undesired product of this
reaction remained on the column.
[1050] The title compound was purified by trituration with diethyl
ether, and isolated as a yellow solid, 58 mg, 64%.
[1051] LC/MS: RT=1.65 Min (270 nm), m/z=523 [M-H]. Total run time
3.75 min (short neg).
[1052] .sup.1H NMR (d.sub.6 DMSO): .delta. 1.21 (s, 6H), 2.34 (s,
6H) 5.41 (s, 2H), 6.74 (dd, 1H), 6.97 (s, 1H), 7.1 (s, 1H),
7.27-7.41 (m, 6H), 7.82 (d, 1H), 8.03 (s, 1H), 8.15 (d, 1H), 8.42
(s, 1H), 9.8 (br s, 1H), 11.48 (s, 1H), 12.0 (br s, 1H).
Example 180: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(2,2-dimethyl-3-pyrrolidin-1-yl-propoxy)-1H-indol-2-yl]-6-oxo-1,6-d-
ihydro-pyridin-3-yl}-amide
##STR00206##
[1054] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115. In this instance the chloroalkyl intermediate,
1-(3-chloro-2,2-dimethyl-propyl)-pyrrolidine, required for Step 6,
was not commercially available and was synthesised according to the
following methodology.
Preparation of 1-(3-Chloro-2,2-dimethyl-propyl)-pyrrolidine
[1055] 3-Chloro-2,2-dimethyl-propionyl chloride (0.5 g, 3.2 mmol)
was stirred in dichloromethane (20 mL) at RT with triethylamine
(0.9 mL, 6.4 mmol). The reaction mixture was cooled to 5.degree. C.
and then pyrrolidine (0.32 mL, 3.9 mmol), was added drop wise.
After addition the reaction was stirred at RT for 1 hr, and then
the reaction mixture was washed with saturated sodium hydrogen
carbonate solution (2.times.50 mL), brine (50 ml), dried
(Na.sub.2SO.sub.4) and concentrated in vacuo to afford
3-chloro-2,2-dimethyl-1-pyrrolidin-1-yl-propan-1-one as a yellow
solid, 0.576 g, 94%.
[1056] To this intermediate,
3-chloro-2,2-dimethyl-1-pyrrolidin-1-yl-propan-1-one (0.57 g, 3
mmol) in anhydrous THF (20 mL) was slowly added a 1M anhydrous THF
solution of lithium aluminium hydride (7.5 mL, 7.5 mmol) at room
temperature. The resulting clear solution was stirred overnight at
room temperature under nitrogen to give a cloudy suspension. Water
(0.3 mL) was carefully added to the reaction mixture followed by
15% w/v aqueous sodium hydroxyde solution (0.3 mL) and water (0.9
mL). The reaction was filtered and the filtrate evaporated to
dryness to give the title compound which was used without further
purification.
[1057] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 104 mg, 54%.
[1058] LC/MS: RT=1.77 Min (270 nm), m/z=565 [M+H]. Total run time
3.75 min (short pos).
[1059] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.98 (s, 6H), 1.63 (m,
4H), 2.45 (s, 2H), 2.53 (m, 4H), 3.68 (s, 2H), 5.40 (s, 2H), 6.72
(dd, 1H), 6.92 (s, 1H), 7.01 (d, 1H), 7.28-7.40 (m, 6H), 7.84 (d,
1H), 8.03 (s, 1H), 8.14 (d, 1H), 8.41 (s, 1H), 9.79 (s, 1H), 11.44
(s, 1H), 11.98 (br s, 1H).
Example 181: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
(5-{5-[3-(3,3-difluoro-pyrrolidin-1-yl)-2,2-dimethyl-propoxy]-1H-indol-2--
yl}-6-oxo-1,6-dihydro-pyridin-3-yl)-amide
##STR00207##
[1061] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115. In this instance the relevant chloroalkyl
intermediate, required for Step 6, was not commercially available
and was synthesised according to the protocol given for Example
180.
[1062] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 20 mg, 10%.
[1063] LC/MS: RT=2.11 Min (270 nm), m/z=601 [M+H]. Total run time
3.75 min (short pos).
[1064] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.98 (s, 6H), 2.18 (m,
2H), 2.47 (s, 2H), 2.78 (t, 2H), 2.94 (t, 2H), 3.67 (s, 2H), 5.41
(s, 2H), 6.72 (dd, 1H), 6.92 (s. 1H), 7.02 (d, 1H), 7.28-7.41 (m,
6H), 7.84 (d, 1H), 8.03 (s, 1H), 8.14 (d, 1H), 8.41 (s, 1H), 9.79
(s, 1H), 11.44 (s, 1H), 12.0 (br s, 1H).
Example 182: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
(5-{5-[3-((R)-3-fluoro-pyrrolidin-1-yl)-2,2-dimethyl-propoxy]-1H-indol-2--
yl}-6-oxo-1,6-dihydro-pyridin-3-yl)-amide
##STR00208##
[1066] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115. In this instance the relevant chloroalkyl
intermediate, required for Step 6, was not commercially available
and was synthesised according to the protocol given for Example
180.
[1067] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 30 mg, 17%.
[1068] LC/MS: RT=1.56 Min (270 nm), m/z=583 [M+H]. Total run time
3.75 min (short pos).
[1069] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.98 (s, 6H), 1.75-2.11
(m, 2H), 2.45 (m, 3H), 2.73-2.86 (m, 3H), 3.68 (s, 2H), 5.05-5.17
(m, 1H), 5.41 (s, 2H), 6.72 (dd, 1H), 6.92 (s, 1H), 7.02 (d, 1H),
7.28-7.41 (m, 6H), 7.84 (d, 1H), 8.03 (s, 1H), 8.14 (d, 1H), 8.41
(s, 1H), 9.79 (s, 1H), 11.44 (s, 1H), 11.99 (br s, 1H)
Example 183: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
(5-{5-[3-((S)-3-fluoro-pyrrolidin-1-yl)-2,2-dimethyl-propoxy]-1H-indol-2--
yl}-6-oxo-1,6-dihydro-pyridin-3-yl)-amide
##STR00209##
[1071] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115. In this instance the relevant chloroalkyl
intermediate, required for Step 6, was not commercially available
and was synthesised according to the protocol given for Example
180.
[1072] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 31 mg, 18%.
[1073] LC/MS: RT=1.57 Min (270 nm), m/z=583 [M+H]. Total run time
3.75 min (short pos).
[1074] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.98 (s, 6H), 1.77-2.11
(m, 2H), 2.45 (m, 3H), 2.71-2.86 (m, 3H), 3.68 (s, 2H), 5.06-5.17
(m, 1H), 5.41 (s, 2H), 6.72 (dd, 1H), 6.92 (s, 1H), 7.02 (d, 1H),
7.28-7.41 (m, 6H), 7.84 (d, 1H), 8.03 (s, 1H), 8.14 (d, 1H), 8.41
(s, 1H), 9.79 (s, 1H), 11.44 (s, 1H), 11.99 (br s, 1H)
Example 184: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(2,2-dimethyl-3-morpholin-4-yl-propoxy)-1H-indol-2-yl]-6-oxo-1,6-di-
hydro-pyridin-3-yl}-amide
##STR00210##
[1076] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115. In this instance the relevant chloroalkyl
intermediate, required for Step 6, was not commercially available
and was synthesised according to the protocol given for Example
180.
[1077] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 16 mg, 18%.
[1078] LC/MS: RT=1.74 Min (270 nm), m/z=581 [M+H]. Total run time
3.75 min (short pos).
[1079] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.98 (s, 6H), 2.27 (s,
2H), 2.43 (m, 4H), 3.50 (m, 4H), 3.67 (s, 2H), 5.41 (s, 2H), 6.72
(dd, 1H), 6.91 (s, 1H), 7.01 (d, 1H), 7.28-7.40 (m, 6H), 7.84 (d,
1H), 8.03 (s, 1H), 8.14 (d, 1H), 8.41 (s, 1H), 9.79 (s, 1H), 11.43
(s, 1H), 11.99 (br s, 1H).
Example 185: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(2,2-dimethyl-3-piperidin-1-yl-propoxy)-1H-indol-2-yl]-6-oxo-1,6-di-
hydro-pyridin-3-yl}-amide
##STR00211##
[1081] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115. In this instance the relevant chloroalkyl intermediate
required for Step 6 was not commercially available and was
synthesised according to the protocol given for Example 180.
[1082] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 123 mg, 64%.
[1083] LC/MS: RT=1.79 Min (270 nm), m/z=579 [M+H]. Total run time
3.75 min (short pos).
[1084] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.94 (s, 6H), 1.30 (m,
2H), 1.42 (m, 4H), 2.22 (s, 2H), 2.40 (m, 4H), 3.65 (s, 2H), 5.41
(s, 2H), 6.71 (dd, 1H), 6.92 (s, 1H), 7.00 (d, 1H), 7.28-7.40 (m,
6H), 7.83 (d, 1H), 8.03 (s, 1H), 8.14 (d, 1H), 8.41 (s, 1H), 9.79
(s, 1H), 11.43 (s, 1H), 11.97 (br s, 1H).
Example 186: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(1-diethylaminomethyl-cyclopropylmethoxy)-1H-indol-2-yl]-6-oxo-1,6--
dihydro-pyridin-3-yl}-amide
##STR00212##
[1086] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115. In this instance the chloroalkyl intermediate,
1-(1-chloromethyl-cyclopropylmethyl)-pyrrolidine hydrochloride,
required for Step 6, was not commercially available and was
synthesised according to the following methodology.
Preparation of 1-(1-chloromethyl-cyclopropylmethyl)-pyrrolidine
hydrochloride
[1087] Oxalyl chloride (12.5 mL, 2M) in dichloromethane was added
to a solution of cyclopropane-1,1-dicarboxylic acid methyl ester
(2.90 g, 20 mmol) in dichloromethane (50 mL) at 0.degree. C.
(ice/water) and the solution stirred. DMF (100 .mu.L) was added and
the solution stirred for 2 hrs. at room temperature, to give a pale
yellow solution. The solution was concentrated to a yellow
semi-solid.
[1088] The semi-solid was taken up in THF (20 ml) and the solution
cooled, 0.degree. C. (ice/water), and pyrrolidine (6 mL, 71 mmol)
was added slowly and the resulting suspension stirred for 60 mins.
Ethyl acetate (150 mL) was added and the mixture washed with water
(2.times.75 mL) and saturated aqueous sodium chloride solution (75
mL). The solution was dried over anhydrous magnesium sulphate and
concentrated to yield
1-(pyrrolidine-1-carbonyl)-cyclopropanecarboxylic acid methyl ester
as a yellow/brown oil 2.20 g, 55%.
[1089] Lithium aluminium hydride solution (20 mL, 1M) in THF was
added slowly to a solution of
1-(pyrrolidine-1-carbonyl)-cyclopropanecarboxylic acid methyl ester
(2.2 g, 11 mmol) in THF at 0.degree. C. (ice/water), under a
nitrogen atmosphere, and the resulting solution stirred for 3 hrs
at room temperature. The solution was cooled, 0.degree. C.
(ice/water), and sodium sulphate decahydrate (4.9 g, 15 mmol) was
added portion-wise to give a white suspension. Diethyl ether (25
mL) was added and the suspension stirred for 18 hrs. at room
temperature. The resulting suspension was filtered, through celite,
and the solids washed with diethyl ether (2.times.50 mL). The
combined filtrates were concentrated to give
(1-pyrrolidin-1-ylmethyl-cyclopropyl)-methanol as a pale yellow oil
1.45 g, 84%.
[1090] Thionyl chloride (1 mL, 13.7 mmol) was added to a solution
of (1-pyrrolidin-1-ylmethyl-cyclopropyl)-methanol (1.45 g, 9.3
mmol) in toluene (20 mL) to give a pale brown suspension. The
suspension was heated, 110.degree. C., for 3 hrs. to give a dark
brown suspension. The resulting suspension was allowed to cool and
concentrated to a brown solid. Tritruation with diethyl ether (40
mL) gave the desired intermediate,
1-(1-chloromethyl-cyclopropylmethyl)-pyrrolidine hydrochloride as a
brown powder 1.6 g, 82%.
[1091] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 145 mg, 58%.
[1092] LC/MS: RT=1.76 Min (270 nm), m/z=565.3 [M+H]. Total run time
3.75 min (short pos).
[1093] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.40 (t, 2H), 0.60 (t,
2H), 0.95 (t, 6H), 2.45 (s, 2H), 2.50 (q, 4H), 3.85 (s, 2H), 5.40
(s, 2H), 6.70 (dd, 1H), 6.90 (d, 1H), 7.00 (d, 1H), 7.25-7.45 (m,
6H), 7.85 (d, 1H), 8.00 (s, 1H), 8.15 (d, 1H), 8.40 (s, 1H), 9.80
(s, 1H), 11.40 (s, 1H), 11.95 (br s, 1H).
Example 187: 1-Benzyl-1H-pyrazole-4-carboxylic Acid {6-oxo
5-[5-(1-pyrrolidin-1-ylmethyl-cyclopropylmethoxy)-1H-indol-2-yl]-1,6-dihy-
dro-pyridin-3-yl}-amide
##STR00213##
[1095] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115. In this instance the relevant chloroalkyl
intermediate, required for Step 6, was not commercially available
and was synthesised according to the protocol given for Example
186.
[1096] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 175 mg, 62%.
[1097] LC/MS: RT=1.73 Min (270 nm), m/z=563.3 [M+H]. Total run time
3.75 min (short pos).
[1098] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.40 (t, 2H), 0.50 (t,
2H), 1.65 (br s, 4H), 2.45 (s, 2H), 2.50 (br s, 4H), 3.85 (s, 2H),
5.40 (s, 2H), 6.75 (dd, 1H), 6.90 (d, 1H), 7.00 (d, 1H), 7.25-7.40
(m, 6H), 7.85 (d, 1H), 8.05 (s, 1H), 8.15 (d, 1H), 8.40 (s, 1H),
9.80 (s, 1H), 11.40 (s, 1H), 11.95 (br s, 1H).
Example 188: 1-Benzyl-1H-pyrazole-4-carboxylic Acid
{5-[5-(1-dimethylaminomethyl-cyclopropylmethoxy)-1H-indol-2-yl]-6-oxo-1,6-
-dihydro-pyridin-3-yl}-amide
##STR00214##
[1100] The title compound was prepared by the route outlined in
Scheme 11, following the same experimental procedures as for
Example 115. In this instance the relevant chloroalkyl
intermediate, required for Step 6, was not commercially available
and was synthesised according to the protocol given for Example
186.
[1101] The title compound was purified by trituration with
acetonitrile, and isolated as a yellow solid, 190 mg, 66%.
[1102] LC/MS: RT=1.71 Min (270 nm), m/z=537.3 [M+H]. Total run time
3.75 min (short pos).
[1103] .sup.1H NMR (d.sub.6 DMSO): .delta. 0.40 (q, 2H), 0.60 (q,
2H), 2.21 (s, 6H), 2.25 (s, 2H), 3.85 (s, 2H), 5.40 (s, 2H), 6.70
(dd, 1H), 6.90 (d, 1H), 7.00 (d, 1H), 7.25-7.45 (m, 6H), 7.85 (d,
1H), 8.05 (s, 1H), 8.15 (d, 1H), 8.45 (s, 1H), 9.80 (s, 1H), 11.40
(s, 1H), 11.95 (br s, 1H).
[1104] General Procedures
[1105] All reagents obtained from commercial sources were used
without further purification.
[1106] Anhydrous solvents were obtained from commercial sources and
used without further drying.
[1107] Flash chromatography was performed with pre-packed
silica-gel cartridges (Strata Si-1, 61 .ANG., Phenomenex, Cheshire,
UK or IST Flash II, 54 .ANG., Argonaut, Hengoed, UK). Thin layer
chromatography was conducted with 5.times.10 cm plates coated with
Merck Type 60 F.sub.254 silica-gel. Microwave heating was performed
with a Biotage Initiator.TM. 2.0 instrument.
[1108] The compounds of the present invention were characterized by
high performance liquid chromatography-mass spectroscopy (HPLC-MS)
on either an Agilent HP1200 Rapid Resolution Mass detector 6140
multi mode source M/z range 150 to 1000 amu or an Agilent HP1100
Mass detector 1946D ESI source M/z range 150 to 1000 amu. The
conditions and methods listed below are identical for both
machines.
[1109] Column for 3.75 min run: Gemini 5 .mu.m, C18, 30
mm.times.4.6 mm (Phenomenex).
[1110] Temperature: 35 C.
[1111] Column for 1.9 min run: LunaHST 2.5 .mu.m, C18, 50.times.2
mm (Phenomenex).
[1112] Temperature: 55 C.
[1113] Mobile Phase: A--Water+10 mMol/ammonium formate+0.08% (v/v)
formic acid at pH ca 3.5.
[1114] B--95% Acetonitrile+5% A+0.08% (v/v) formic acid
[1115] Injection Volume: 2 .mu.L
[1116] "Short" Method Gradient Table, Either Positive (Pos) or
Positive and Negative (Pos/Neg) Ionisation
TABLE-US-00019 Time Solvent Solvent Flow (min) A (%) B (%) (mL/min)
0 95 5 2 0.25 95 5 2 2.50 95 5 2 2.55 5 95 3 3.60 5 95 3 3.65 5 95
2 3.70 95 5 2 3.75 95 5 2
[1117] "Super Short" Method Gradient Table, Either Positive (Pos)
or Positive and Negative (Pos/Neg) Ionisation
TABLE-US-00020 Time Solvent Solvent Flow (min) A (%) B (%) (mL/min)
0 95 5 1.1 0.12 95 5 1.1 1.30 5 95 1.1 1.35 5 95 1.7 1.85 5 95 1.7
1.90 5 95 1.1 1.95 95 5 1.1
[1118] Detection: UV detection at 230, 254 and 270 nm.
[1119] The compounds of the present invention were also
characterized by Nuclear Magnetic Resonance (NMR). Analysis was
performed with a Bruker DPX400 spectrometer and proton NMR spectra
were measured at 400 MHz. The spectral reference was the known
chemical shift of the solvent. Proton NMR data is reported as
follows: chemical shift (6) in ppm, followed by the multiplicity,
where s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet,
dd=doublet of doublets, dt=doublet of triplets, dm=doublet of
multiplets, ddd=doublet of double doublets, td=triplet of doublets,
qd=quartet of doublets and br=broad, and finally the
integration.
[1120] Some compounds of the invention were purified by preparative
HPLC. These were performed on a Waters FractionLynx MS
autopurification system, with a Gemini.RTM. 5 .mu.m C.sub.18(2),
100 mm.times.20 mm i.d. column from Phenomenex, running at a flow
rate of 20 cm.sup.3 min with UV diode array detection (210-400 nm)
and mass-directed collection. Gradients used for each compound are
shown in Table 1.
[1121] At pH 4: solvent A=10 mM ammonium acetate in HPLC grade
water+0.08% v/v formic acid. Solvent B=95% v/v HPLC grade
acetonitrile+5% v/v solvent A+0.08% v/v formic acid.
[1122] At pH 9: solvent A=10 mM ammonium acetate in HPLC grade
water+0.08% v/v ammonia solution. Solvent B=95% v/v HPLC grade
acetonitrile+5% v/v solvent A+0.08% v/v ammonia solution.
[1123] The mass spectrometer was a Waters Micromass ZQ2000
spectrometer, operating in positive or negative ion electrospray
ionisation modes, with a molecular weight scan range of 150 to
1000.
[1124] IUPAC chemical names were generated using AutoNom
Standard.
[1125] Assay Protocols
[1126] (i) CHK1 Enzyme Assay
[1127] Assays for the CHK1 kinase activity were carried out by
monitoring the phosphorylation of a synthetic peptide Chktide with
the amino acid sequence, KKKVSRSGLYRSPSMPENLNRPR. The assay mixture
containing the inhibitor and CHK1 enzyme was mixed together in a
microtiter plate in a final volume of 50 .mu.l and incubated for 40
minutes at 30.degree. C.
[1128] The assay mixture contained 0.01 mM unlabeled ATP, 0.5
.mu.Ci .sup.33P-.gamma.-ATP, 14.8 .mu.M Chktide, 0.1 mg/mL BSA, 50
mM Hepes-NaOH pH 7.5 and 12.5 nM His-CHK1 (Invitrogen) enzyme. The
reaction was stopped by adding 50 .mu.L of 50 mM phosphoric acid.
90 .mu.L of the mixture was transferred to a pre-wetted 96-well
multi-screen MAPHNOB filtration plate (Millipore) and filtered on a
vacuum manifold. The filter plate was washed with 3 successive
additions of 200 .mu.l 150 mM phosphoric acid and then with 100
.mu.L methanol. The filtration plate was dried for 10 min at 6500,
scintillant added and phosphorylated peptide quantified in a
scintillation counter (Trilux, PerkinElmer).
[1129] The compounds tested in the above assay were assigned to one
of three activity ranges, namely A=IC.sub.50<100 nM,
B=IC.sub.50>100 nM and <500 nM or C=IC.sub.50>500 nM and
<1500 nM as indicated in the table below.
TABLE-US-00021 Table of CHK1 Enzyme Activities Example Activity 1 A
2 B 3 C 4 A 5 B 6 B 7 C 8 B 9 A 10 A 11 A 12 B 13 A 14 B 15 A 16 A
17 C 18 C 19 B 20 A 21 A 22 A 23 A 24 A 25 B 26 A 27 A 28 A 29 A 30
B 31 A 32 B 33 B 34 C 35 A 36 B 37 A 38 A 39 A 40 A 41 A 42 A 43 A
44 A 45 A 46 A 47 A 48 A 49 A 50 A 51 A 52 A 53 A 54 A 55 A 56 A 57
A 58 A 59 A 60 A 61 A 62 A 63 A 64 A 65 A 66 A 67 A 68 A 69 A 70 A
71 A 72 A 73 A 74 A 75 A 76 A 77 A 78 A 79 A 80 A 81 A 82 A 83 A 84
A 85 A 86 A 87 A 88 A 89 A 90 A 91 A 92 A 93 A 94 A 95 A 96 A 97 A
98 A 99 A 100 A 101 A 102 A 103 A 104 A 105 A 106 A 107 A 108 A 109
A 110 B 111 A 112 A 113 A 114 A 115 A 116 A 117 A 118 A 119 A 120 A
121 A 122 A 123 A 124 A 125 A 126 A 127 A 128 A 129 A 130 A 131 A
132 A 133 A 134 A 135 A 136 A 137 A 138 A 139 A 140 A 141 A 142 A
143 A 144 A 145 A 146 A 147 A 148 A 149 A 150 A 151 A 152 A 153 A
154 C 155 A 156 A 157 A 158 A 159 A 160 B 161 A 162 A 163 A 164 A
165 A 166 A 167 A 168 A 169 A 170 A 171 A 172 A 173 A 174 A 175 A
176 A 177 A 178 A 179 A 180 A 181 A 182 A 183 A 184 A 185 A 186 A
187 A 188 A
[1130] (ii) CHK1 Cellular Assay--Gemcitabine EC.sub.50 Assay
[1131] The gemcitabine EC.sub.50 assay was developed as a rapid
method for screening CHK1 inhibitors to determine their relative
cell activity. This assay utilises a feature of the effect of CHK1
inhibitors on gemcitabine toxicity. In the absence of a CHK1
inhibitor, gemcitabine acts predominantly as an anti-metbolite and
therefore induces very little cell death, even at high
concentrations. This can be as high as 70-80% survival at
concentrations in excess of 1 .mu.M. However, in the presence of a
CHK1 inhibitor, the mechanism of action of gemcitabine switches to
a more classical cytotoxic mode of action. For example, the
fraction of cells surviving can be reduced to around 30% and
below.
[1132] Concentrations of gemcitabine can be selected that in the
absence of a CHK1 inhibitor, have no effect on cell survival but in
the presence of a CHK1 inhibitor are highly cytotoxic. 10000 HT29
cells were plated per well of a 96 well plate and allowed to attach
at 37.degree. C. in a 5% CO2 humidified incubator for 18 hours.
CHK1 inhibitors were then titrated in the presence of 10, 15 and 20
nM gemcitabine for 72 hours and the EC.sub.50 determined by
staining with sulforhodamine B (SRB) and determining the absorbance
at 540 nm.
[1133] The compounds were tested in the above assay in the presence
of gemcitabine at 10 nM, and assigned to one of two activity
ranges, namely A=EC.sub.50<100 nM or B=EC.sub.50>100 nM and
<500 nM as indicated in the table below.
TABLE-US-00022 Table of CHK1 Cellular Activities Example Activity
Example Activity 20 B 171 A 38 B 173 A 49 A 176 B 52 A 177 A 71 A
178 A 78 A 179 A 87 A 180 A 120 A 185 A 166 A 186 A
[1134] (iii) HT 29 Xenograft in Nude Mouse
[1135] 5.times.10.sup.6 HT29 cells were subcutaneously implanted
into the flanks of Balb-c nude mice. Upon reaching approximately
100 mm.sup.3, animals were randomised into control and treatment
groups. Animals were dosed twice per week with low dose gemcitabine
(10 mg/kg) ie on days 1, 4, 8, and 11, and where indicated with
compound at its maximum tolerated dose (MTD) 24 and 30 hours post
the gemcitabine dose. Tumour volume was determined three times per
week by caliper measurement. Vehicle was dosed instead of active
ingredient in control animals.
[1136] FIG. 1 shows the In vivo potentiation results of the
compound of Example 20 in combination with gemcitabine. Dosing
Schedule: Gemcitabine 10 mg/kg i.p. days 1, 4, 8 and 11 (squares)
or gemcitabine 10 mg/kg i.p. plus Example 20 at 30 mg/kg i.v. 24
and 30 hours post gemcitabine (triangles). Vehicle (circles) was
dosed instead of active ingredient in control animals. Tumour
volumes were determined by caliper measurement 3 times per
week.
* * * * *